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Abstract
Traumatic brain injury (TBI) causes significant morbidity and mortality. Modern 
neurocritical care management utilises several monitoring techniques to identify 
or predict secondary insults but many of these techniques have significant 
limitations. The ideal cerebral monitor would be a non-invasive system able to 
provide realtime quantitative haemodynamic and metabolic information at 
multiple sites with high temporal and spatial resolution.
Near infrared spectroscopy (NIRS) fulfils many of these requirements and has 
great potential as a cerebral monitoring tool. In addition to measurements of 
oxy- and deoxy-haemoglobin concentration, NIRS can monitor changes in 
mitochondrial redox state by measuring changes in oxidised cytochrome c 
oxidase (oxCCO) concentration. This is an attractive monitoring target as it is 
intimately involved in adenosine triphosphate synthesis and cellular 
homeostasis, yet few studies exist which investigate oxCCO concentration 
changes in either the normal or injured adult human brain.
This thesis explores the use of NIRS, and in particular measurement of oxCCO 
concentration changes, for monitoring patients with TBI. Cerebral metabolism in 
both health and TBI is described and current monitoring tools and treatment 
strategies used in TBI are discussed. Studies investigating NIRS measurements 
in the brains of healthy volunteers during changes in arterial oxygen and carbon 
dioxide tension are described in order to determine the ability of NIRS to detect 
these physiological perturbations and to characterise the resulting metabolic 
changes. Spectroscopic data are analysed to investigate the methodology used 
to calculate oxCCO concentration changes. NIRS is used to monitor patients 
with TBI during normobaric hyperoxygenation and non-invasively measured 
NIRS variables are compared with those acquired using invasive cerebral 
monitoring devices. Correlations are shown between non-invasive measures of 
mitochondrial redox state and invasive measures of cellular redox state.
NIRS can monitor changes in cerebral physiology after TBI and has the 
potential to guide neuroprotective strategies on the neurocritical care unit.
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Motivations and Objectives
TBI remains a significant cause of morbidity and mortality and as it 
predominantly affects young people, carries a huge cost to society. The last 
three decades have seen great advances in the care of patients with TBI but 
despite several promising animal studies, no pharmacological agents have 
been identified which improve outcome in human studies: a process which has 
been hampered by the lack of validated surrogate markers for outcome after 
TBI. Current management strategies generally make use of strictly protocolised 
management guidelines which are directed towards providing an optimal 
physiological environment in order to minimise secondary insults and maximise 
the body’s own regenerative processes.
There is however, a potential flaw in the use of strictly protocolised 
management guidelines. There exists a wide heterogeneity in TBI, both 
between patients, and within patients across time and space. Minimising 
secondary injury to the brain after TBI requires the tailoring of metabolite supply 
to demand, but an ‘adequate supply’ may vary substantially between periods of 
hypermetabolism and periods of deep sedation or extensive mitochondrial 
dysfunction. Strictly protocolised management strategies attempt to address 
adequate metabolite demand for an average TBI patient but make no allowance 
for individual variation.
Most current protocols for the management of patients with TBI are based on 
avoiding raised ICP and maintaining adequate CPP. Gross changes in these 
variables are however likely to be preceded by biochemical changes within the 
injured brain. Identification of these biochemical changes might allow early 
intervention and potentially reduce secondary insults and improve patient 
outcome.
The ideal cerebral monitor for use after TBI would be a non-invasive system 
able to provide realtime quantitative haemodynamic and metabolic information 
at multiple sites with high temporal and spatial resolution. The development of 
cerebral monitoring tools able to detect biochemical changes in the injured brain 
has the potential to contribute to the treatment of TBI in three ways. Firstly
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monitoring of cerebral biochemistry might allow tailoring of treatment strategies 
to the individual. Secondly identification of biochemical changes which precede 
changes in ICP and CPP might allow for earlier treatment intervention and 
hence reduction of secondary injury. Thirdly the discovery of surrogate markers 
of TBI pathobiology might aid the identification of effective pharmacological 
treatments.
NIRS fulfils almost all of the requirements of the ideal cerebral monitor. In 
addition to measurements of haemoglobin oxygenation, NIRS is able to monitor 
changes in mitochondrial redox state by measuring changes in the 
concentration of oxCCO: an attractive monitoring target as it is intimately 
involved in driving ATP synthesis and thus the maintenance of cellular 
homeostasis. Measurement of oxCCO concentration changes might allow 
assessment of the adequacy of mitochondrial oxygen delivery and therefore 
facilitate the identification of ischaemic thresholds specific to a given individual 
at a given time.
However despite early enthusiasm, NIRS measurements of changes in the 
concentration of oxCCO have proved to be technically difficult and the 
relationship between mitochondrial oxygen delivery and oxCCO concentration 
changes continues to be debated. These points have contributed to a relative 
paucity of studies investigating changes in oxCCO concentrations in the adult 
human brain. Recently, the use of broadband spectroscopy systems in animals 
has addressed some of these issues and has laid the foundation to readdress 
this technique in the context of the human brain.
This thesis aims to assess the use of NIRS measurements of cerebral 
oxygenation and oxCCO concentration to monitor the injured human brain. 
Responses of NIRS variables to physiological perturbations in the healthy brain 
are not well established and so it is important to measure initially changes in 
NIRS variables that occur during well controlled changes in cerebral 
oxygenation and blood flow in healthy volunteers. This allows identification of 
normal values and determination of the sensitivity of the NIRS variable 
responses. Studies are then carried out on patients suffering from TBI on the
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neurocritical care unit. Non-invasive NIRS variables are compared with those 
acquired using invasive cerebral monitoring devices and in particular 
comparisons are made between non-invasively measured oxCCO concentration 
changes, a marker of mitochondrial redox state, and invasively measured brain 
extracellular fluid lactate pyruvate ratio, a marker of cellular redox state.
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Thesis Overview
Chapter 1 provides an overview of the primary mechanisms of ATP production 
essential for maintaining cerebral cellular integrity. This chapter concentrates on 
the physiology of the healthy brain. This is an essential prequel to 
understanding the alterations in cerebral metabolism which occur after TBI.
Chapter 2 describes the epidemiology and pathophysiology of TBI. The 
available range of neurocritical care monitoring modalities is introduced and 
their strengths and limitations are discussed. Finally the need for novel 
monitoring techniques able to overcome these limitations is discussed.
Chapter 3 provide an introduction to NIRS. Specifically the theoretical bases of 
NIRS and the various techniques used in this thesis are discussed. Particular 
mention is made of the main chromophores and optical properties of biological 
tissue. Continuous wave spectroscopy is introduced first and then followed by a 
description of spatially resolved and frequency domain spectroscopy, and 
techniques for measuring optical pathlength.
Chapter 4 describes an experimental study using NIRS to measure changes in 
TOI and CBV in the brains of healthy adult volunteers during alterations in the 
composition of inspired gases. The physiological challenges consist of 
isocapnoeic hypoxia and hyperoxia, and normoxic hypocapnoea and 
hypercapnoea. Responses to these four challenges are described individually 
and the results are then combined in order to relate changes in TOI to changes 
in Sa02, EtC02, CBV, CBF, heart rate and MAP.
Chapter 5 describes an experimental study using the same physiological 
challenges as chapter 4 but using BBS to measure changes in Hb02, HHb and 
oxCCO concentrations in the brains of healthy adult volunteers. A five hour 
phantom study to test the stability of the BBS system is presented.
Chapter 6 describes two analytical approaches to investigate the relationship 
between the haemoglobin and CCO signals measured during the healthy 
volunteer studies. It has been previously suggested that NIRS measured
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changes in oxCCO concentration might be merely an artefact of the 
measurement algorithm but the analyses described in this chapter suggest that 
this is not the case.
Chapter 7 describes a study to investigate changes in cerebral metabolism 
during normobaric hyperoxia in patients with TBI. Data from a wide range of 
invasive and non-invasive monitoring modalities including BBS, brain tissue 
oxygen tension measurement and cerebral microdialysis are presented and 
compared.
Chapter 8 provides a summary of the thesis and details promising future 
avenues of investigation.
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Chapter 1
Physiology of Normal Cerebral Cellular Metabolism
This thesis describes the use of NIRS to monitor cerebral haemodynamic and 
metabolic variables in both healthy adult volunteers and patients with TBI. 
Metabolic data from invasive cerebral microdialysis monitoring will also be 
presented. In order to interpret these data it is essential to understand the 
cellular metabolic pathways in which the monitored variables are involved. This 
chapter provides an overview of the primary mechanisms of ATP synthesis 
essential for maintaining cerebral cellular integrity. This initial chapter 
concentrates mainly on the situation found in the healthy brain.
1.1 Cellular Metabolism
Cell survival relies on the ability to maintain ionic gradients across membranes, 
and this is primarily achieved through the action of the Na/K/ATPase pump[1]. 
Neuronal depolarisation depletes these gradients and increased ATP synthesis 
is then required in order to provide the substrate required to replenish them[2]. 
This accounts, in part, for the high metabolic requirements of the brain, as 
demonstrated by the fact that it constitutes only 2% of total body mass, but has 
a normal blood flow of 45-60 ml/100g/min (15% of total cardiac output) and 
uses 3.5 ml/100g/min of oxygen (20% of total basal body oxygen 
consumption)[3]. In health, cerebral ATP requirements are traditionally thought 
to be met by the aerobic metabolism of glucose.
The overall cellular metabolism of glucose is shown in equation 1.1. This 
process consists of two parts: an anaerobic part termed glycolysis which takes 
place in the cell cytoplasm and derives pyruvate from glucose, and a second 
aerobic step which takes place in the mitochondria, and produces a proton 
gradient across the inner mitochondrial membrane which consequently drives 
the bulk of ATP synthesis.
CqH^206 + 60 2 + 38ADP + 38Pi => 6C02 + 6H20  + 38ATP Eqn 1.1
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Oxygen is transported from the lungs to the mitochondria via the circulatory 
system facilitated by cardiac pumping of blood, and diffusion gradients which 
exist between the alveoli and the pulmonary vasculature, and capillaries and 
mitochondria. The vast majority of O2 transport in blood occurs through the 
reversible binding of oxygen to hemoglobin. In addition, a small amount of 
oxygen is carried dissolved in plasma. Under normal atmospheric conditions, 
arterial blood carries approximately 20.1 ml of CVIOOml of blood bound to 
hemoglobin and 0.3 ml O2/IOO ml of blood (1.5% of the total) in solution. 
However when Fi02 is increased to 100% at atmospheric pressure the 
dissolved oxygen quantity can increase to 1.5 ml O2/IOO ml blood[4].
The cerebral metabolism of glucose commences with the transport of glucose 
from the capillary into the cell. Glucose is first transferred across the blood brain 
barrier into the brain extracellular fluid by the action of the glucose transporter 
GLUT-1. Uptake into cells is then facilitated by the action of GLUT-1 in 
astrocytes and GLUT-3 in neurones[3].
1.2 Glycolysis
Glycolysis is a multistep process in which one molecule of glucose is converted 
into two molecules of pyruvate: simultaneously a net two molecules of ATP and 
two molecules of NADH are synthesised. The first step in the glycolytic pathway 
requires the breakdown of two ATP molecules and derives two phosphorylated 
3-carbon intermediates from glucose[1]. Further reactions occur to convert 
these intermediates to two pyruvate molecules and synthesise four ATP 
molecules and two NADH molecules (figure 1.1). The net process of glycolysis 
can therefore be written as in equation 1.2.
C6H120 6 + 2ADP + 2 Pi + 2NAD+ => 2CH3COCOOH + 2 ATP + 2NADH + 2 H +
Eqn 1.2
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Figure 1.1: Classical model of Glycolysis.
The rate of glycolysis is tightly coupled to the ATP requirements of the cell and 
this is primarily achieved through modulation of the enzyme 
phosphofructokinase-1 which catalyses the conversion of fructose-6-phosphate 
to fructose-1,6-bisphosphate[3]. This is an irreversible process and ATP acts as 
an allosteric inhibitor thus reducing the rate of glycolysis when ATP levels in the 
cell are high.
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Conventional wisdom states that the pyruvate produced by glycolysis can then 
be metabolised through three routes. It can enter the citric acid cycle, through 
conversion to either acetyl coenzyme A or oxaloacetate, and thereby undergo 
aerobic metabolism, be converted to lactate by the action of lactate 
dehydrogenase or be converted into the amino acid alanine. In the presence of 
adequate mitochondrial oxygen tension, and given the tight coupling of 
glycolysis to cellular ATP requirements, the majority of pyruvate will enter the 
citric acid cycle to take part in highly efficient aerobic synthesis of ATP[2]. 
However, during cellular ischaemia when there is inadequate oxygen for 
aerobic metabolism, pyruvate will be converted to lactate and lactate levels will 
rise. In the resting human 5-10% of consumed glucose is released as lactate 
into the blood[2].
Lactate was traditionally thought to be a waste product of anaerobic metabolism 
and by inducing tissue acidosis was implicated in muscle fatigue and 
exacerbation of cerebral ischaemia. However recent work has challenged these 
assumptions[5,6]. An increasing body of evidence suggests that lactate, far 
from being harmful, is instead a source of neuronal fuel. The traditional role of 
lactate as a deleterious compound has been questioned by work suggesting 
that lactate accumulation does not cause muscle fatigue[7]. Research involving 
the cerebral utilisation of lactate has shown that astrocytes can convert 
glycogen to lactate[8] and that lactate can be used as a neuronal fuel[9,10]. 
Contrary to the traditional view, in vitro experimentation has shown that not only 
is lactate neuroprotective after hypoxic insult[9] but that it may be an essential 
fuel for neurones and preferred to glucose[11]. Studies in humans have also 
shown that lactate produced through muscle exercise is metabolised by the 
brain[12]. In response to some of these findings, Magistretti proposed the 
hypothesis of the astrocyte-neurone lactate shuttle (ANLSH), which suggests 
that astrocytes produce lactate from glucose anaerobically through glycolysis, 
and that lactate can then be shuttled, via monocarboxylase transporters found 
in both astrocytic and neuronal membranes, to the neuronal cytoplasm where it 
undergoes aerobic metabolism through the citric acid cycle (figure 1.2).
30
Figure 1.2: Schematic showing the Magistretti model of coupled lactate-pyruvate 
metabolism (taken from[3]).
A more radical hypothesis has been suggested by Schurr, who proposes that, 
as the conversion of pyruvate to lactate releases free energy, it makes 
thermodynamic and chemical sense for glycolysis to proceed naturally to lactate 
production, and that the step from pyruvate to lactate in the cytoplasm would 
occur in preference to pyruvate entering the mitochondria, even during aerobic 
conditions. Lactate would then be transported across the mitochondrial 
membrane facilitated by monocarboxylase inhibitors where it would be 
converted back to pyruvate through the action of lactate dehydrogenase. This 
theory is supported by the facts that LDH occurs within mitochondria and that 
lactate is an efficient substrate for the citric acid cycle[5]. The proposed 
chemical steps are shown in figure 1.3. This theory does not exclude that of the 
ANLSH and is able to explain the accumulation of lactate during ischaemia by a 
build up of electrons, and hence reduced substrate, restricting the ability of 
lactate to be converted to pyruvate and enter the citric acid cycle. This is in 
contrast to conventional theory which proposes an accumulation of pyruvate 
driving a pathophysiological conversion of pyruvate to lactate. These theories 
may force us to readdress the role of lactate in cerebral metabolism. However it 
is generally agreed that glucose metabolism subsequently proceeds through the 
incorporation of intramitochondrial pyruvate into the citric acid cycle.
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Figure 1.3: Schematic depiction of Schurr’s hypothetical glycolytic pathway. LDH1 and 
LDH5 are isoforms of lactate dehydrogenase. Taken from [5].
1.3 The Citric Acid Cycle
Pyruvate enters the citric acid cycle through conversion to either acetyl 
coenzyme A (equation 1.3) or oxaloacetate.
CH3 COCOOH + CoASH + NAD+ => AcetylCoA + C02  + NADH + H+ Eqn 1.3
The citric acid cycle then proceeds as depicted in figure 1.4. The net reaction 
for one turn of the citric acid cycle is shown in equation 1.3. The rate of the citric 
acid cycle is tightly coupled to cellular energy requirements, primarily through 
regulation of the enzyme isocitrate dehydrogenase which catalyses the 
conversion of isocitrate to a-ketoglutarate, and this enzyme is activated by 
increased ADP levels and inhibited by increased NADH levels[3].
AcetylCoA + GDP + Pi + FAD + 3NAD+ + 3 H20  Eqn 1 4
=> CoASH + 3C02  + GTP + FADH2 + 3NADH + 3H +
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Metabolism of glucose thus far has synthesised relatively little ATP. However, 
the NADH and FADH2 which have been produced are potent electron donors 
and are able to give up high energy electrons which are fed into the electron 
transfer chain. The passage of these electrons along the electron transfer chain 
drives the generation of a protonmotive force which is then used to synthesise 
the majority of cellular ATP.
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1.4 The Electron Transfer Chain
Thus far in the metabolism of glucose, carbon atoms have been removed in the 
form of carbon dioxide, and a series of oxidative reactions has removed 
electrons and stored them in the form of NADH and FADH2 . The remainder of 
the glucose metabolic pathway transfers these electrons to oxygen. NADH and 
FADH2 are potent electron donors, meaning that they have a low electron 
affinity, whereas oxygen is a potent electron acceptor. The reaction between 
NADH and oxygen is therefore highly energenetically favourable and occurs 
with a very large decrease in free energy (equation 1.5). The complete oxidation 
of one molecule of NADH can drive the synthesis of three molecules of ATP[2].
NADH + /20 2 +/-T =>NAD +H 20  Eqn 1.5
If this reaction were to occur directly, then a huge amount of energy would be 
lost as heat. The electron transfer chain allows this reaction to occur in many 
small steps and therefore facilitates the incremental transfer of the released 
energy[1]. This process requires complex control. Although oxygen is a highly 
reactive molecule, it has a low affinity for picking up its first electron and thus 
forming the superoxide radical O2'. Once this step is completed however it 
becomes highly reactive and has an extremely high affinity for a further three 
electrons. The electron transfer chain is able to stabilise the highly reactive 
oxygen free radical intermediates until they can be safely released as water.
The first description of the various components of the electron transfer chain 
was made by Keilin in 1925[13]. He described the existence of components 
present in a wide range of bacteria, yeasts and insects, which altered their 
absorbance of visible light as they changed between the oxidised and reduced 
forms. These coloured proteins were named cytochromes and three types, each 
with a distinctive optical absorption spectra, were discovered and designated as 
cytochrome a, b and c. The cytochromes are related by the presence of a haem 
group consisting of a porphyrin ring with a tightly bound iron atom. Since then 
further components of the electron transfer chain have been discovered and the 
nomenclature has been altered accordingly.
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Modern biochemical theory depicts the electron transfer chain as consisting of 4 
complexes embedded in the mitochondrial inner membrane. As electrons pass 
along the chain their energy state gradually reduces. Simultaneously, protons 
are pumped out of the mitochondrial matrix and into the intermembrane space 
against their concentration gradient by a mechanism known as 
chemiosmosis[14]. This proton gradient is the driving force for ATP synthesis 
which is subsequently carried out by complex V. The pathway involves more 
than 60 proteins, six different haem complexes, seven iron-sulphur groups and 
two copper atoms.
Complex I, which is also know as NADH dehydrogenase, is the largest of the 
electron transfer complexes and consists of more than 40 polypeptide chains[1]. 
NADH donates electrons to complex I, which are then passed to ubiquinone, or 
complex II, a small hydrophobic molecule which is freely mobile in the lipid 
bilayer. Electrons are then passed on to complex III, the cytochrome b-ci 
complex, which exists as a dimer, with each monomer containing three haem 
units and an iron-sulphur protein. Electrons then pass to cytochrome c, another 
small electron carrier that diffuses freely on the intermembrane side of the inner 
mitochondrial membrane and transports electrons to the cytochrome c oxidase 
(CCO) complex (complex IV). CCO functions as a dimer, with each monomer 
containing two haem complexes and two copper complexes. It is only at this 
terminal stage of glucose metabolism that the reduction of oxygen takes place 
with CCO accepting one electron at a time from cytochrome c and passing four 
at a time to oxygen. This is achieved through CCO clamping the oxygen 
molecule between a haem complex and a copper atom until it is reduced to 
water and can then be safely released. CCO will be described in greater detail 
in the next section.
As electrons pass along the electron transfer chain complexes I, III and IV pump 
protons across the mitochondrial membrane though a process which is as yet 
poorly understood[15]. The electrochemical gradient achieved through this 
process is then utilised to drive ATP synthesis. Complex V (ATP synthase) 
contains a hydrophilic pathway across the mitochondrial inner membrane. 
Protons flow through this pathway down their gradient and drive a rotating
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movement which is able to synthesise more than 100 molecules of ATP per 
second[1]. Control of the rate of ATP synthesis is primarily achieved through the 
inhibitory influence of the electrochemical proton gradient which is in turn linked 
to the ATP:ADP ratio. Increased ATP use increases the concentration of the 
ATP synthase substrates ADP and Pi. This drives ATP synthesis and thereby 
dissipates the proton electrochemical gradient, hence promoting electron 
transfer along the electron transfer chain. A depiction of the mitochondrial 
electron transfer chain is shown in figure 1.5.
Figure 1.5: The electron transfer chain. Modified from [3].
1.5 Cytochrome C Oxidase
CCO is the terminal member of the electron transfer chain. It reduces dioxygen 
to water and is responsible for consuming more than 95% of the oxygen 
metabolised by higher organisms[16]. It is able to harness the free energy 
released by the reduction of dioxygen to pump protons across the mitochondrial 
inner membrane and generate an electrochemical gradient which can then be 
used to drive the synthesis of ATP.
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X ray crystallography and spectroscopy studies have allowed the structure of 
both bacterial and bovine heart CCO to be identified, and the core subunits 
(subunits l-lll) of these two types show remarkable similarities[16-20]. Subunit I 
consists of multiple membrane spanning segments and contains two a type 
haem complexes (haem a and haem a3) and a copper ion (termed CuB). Haem 
a3 and CuB form a binuclear centre where the binding and subsequent reduction 
of oxygen takes place[15,21-23]. Subunit II contains two copper ions in a mixed 
valence state and this copper dimer is termed the Cua centre. In addition to 
these two redox active subunits, bovine CCO contains a further 11 subunits and 
functions as a dimer with a molecular weight of over 400 kDa. The 
concentration of CCO in the rat brain has been reported as ~1 pM at birth rising 
to 5.5 pM by maturity[24].
The general scheme of electron transfer through CCO is well established. 
Electrons are donated to CCO from cytochrome c, and the initial electron 
acceptor is the Cua centre. Electrons pass from CuA to haem a and then to the 
haem a3-CuB complex where they are eventually passed to oxygen. This 
process is accompanied by the transfer two protons per electron. One of these 
protons is involved in the reduction of oxygen and the other is pumped across 
the mitochondrial membrane. Many intermediate states have been proposed as 
mediating this process and the mechanisms of the proton pumping have not 
been fully characterised. However, it appears that two electrons pass to the 
haem a3-CuB complex before oxygen binding occurs. The haem a3-CuB oxygen 
complex then proceeds through a peroxy form and then, with the addition of a 
further electron, to a ferryl form before the addition of a fourth electron 
completes the reaction process[15,25,26]. The four main redox centres 
involved in electron transfer within the CCO enzyme each exhibit changes in 
optical absorption related to their redox state. A simplified schematic of the 
electron transfer is shown in figure 1.6 together with the wavelengths at which 
the main changes in optical absorption occur for each centre.
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Figure 1.6: A simplified scheme of the flow of electrons through CCO and the relevant 
absorbing wavelengths for each centre.
The activity of CCO is regulated by a diverse set of mechanisms, nucleotides 
and hormones, and ten nucleotide-binding sites of CCO have been 
identified[16]. ATP/ADP ratio appears to be an important regulatory factor and is 
capable of altering H+/e' stoichiometry, thereby reducing the electrochemical 
gradient produced by electron transfer when the ATP/ADP ratio is high[27]. The 
proton gradient across the mitochondrial membrane inhibits electron transfer 
between Cua and haem a thereby reducing CCO activity when the requirement 
for ATP synthesis is reduced: conversely, collapsing the proton gradient has the 
opposite effect [28]. Increases in pH inhibit the passage of electrons to the 
haem a3-CuB complex through an effect on the rate of protonation and therefore 
inhibit CCO[29]. Reduction in the rate of electron exit from the haem a3-CuA 
complex will reduce the activity of CCO leading to further reduction of the CuA 
and haem a centres[30]. This can occur through the presence of inhibitors such 
as cyanide or NO, both of which bind to the haem 3 3  centre. Importantly, this 
effect will also be produced when low mitochondria oxygen tension limits the 
rate of electron transfer from CCO to oxygen.
An increasing body of literature has demonstrated the ability of NO to inhibit 
CCO and this may have important implications for our understanding of the 
regulation of CCO activity. NO is a free radical gas which is involved in a 
diverse range of physiological and pathophysiological processes in the central 
nervous system. Specifically it is involved in cellular signalling mechanisms and 
the regulation of CBF. NO inhibits CCO by reversibly binding to the haem a r  
CuB complex in a manner which is competitive with oxygen[31-34]. NO 
mediated inhibition of CCO transiently increases AMP:ATP ratio, leading to 
activation of phosphofructokinase and GLUT-mediated glucose uptake, thus 
causing rapid increases in the rate of glycolysis[35-37]. Alternatively, CCO
38
inhibition may have the effect of redistributing oxygen away from the electron 
transfer chain towards non-respiratory oxygen-dependent targets when oxygen 
tension is low[38].
In the study of mitochondrial metabolism, CCO occupies an important role, as it 
is located at the terminal end of the electron transfer chain and instrumental in 
maintaining the driving force for ATP synthase. Mitochondrial mutations 
affecting CCO have been associated with several disease processes, including 
motor neuron disease, acquired sideroblastic anaemia, and epilepsia 
partialis[16] but few techniques exist with which to study CCO activity. It is 
possible to use histopathological techniques to assess CCO activity in vitro[39] 
but this requires removal of living tissue and is therefore of limited use in the 
study of the human brain. It is however possible to exploit the differences in 
optical absorption exhibited by the CCO redox couples to obtain information 
about CCO redox state. The study of this optical technique forms the major part 
of this thesis and is discussed in detail in chapter 3.
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Chapter 2
Traumatic Brain Injury
This chapter describes the epidemiology and pathophysiology of TBI. The 
rational of current management strategies is discussed and recent 
developments are presented. A key focus of modern TBI management is the 
minimisation of secondary cerebral insults and a wide range of monitoring 
modalities are used in order to detect these insults with a view to reducing their 
duration and impact. The available range of neurocritical care monitoring 
modalities is introduced and their strengths and limitations are discussed. 
Finally the need for novel monitoring techniques able to overcome these 
limitations is discussed.
2.1 Epidemiology of Traumatic Brain injury
TBI is a major cause of morbidity and mortality. Recent data collected in a 
district general hospital in Southern England show TBI cases making up 3.4% 
of accident and emergency attendances with an overall incidence of 453 per 
100 000 per year. 10.9 % of these were classified as moderate or severe TBI as 
defined by GCS 9-12 and 3-8 respectively[1] on admission to hospital[2], and 
these are associated with a mortality rate of between 22 and 46%[3-5].
Many victims of TBI survive, but the incidence of severe disability in survivors of 
severe TBI is between 27 and 29%[3-5]. As trauma is predominantly a disease 
of the young[6,7], disability after TBI results in a considerable loss of productive 
years and income potential, with a huge estimated annual cost to society[8]. 
Despite being one of the leading causes of death and disability in the western 
world, TBI remains incompletely understood with few evidence based treatment 
strategies.
2.2 Pathophysiology of Traumatic Brain Injury
The pathophysiology of TBI is often described in terms of primary and 
secondary injury. Primary brain injury was originally defined as physical brain 
injury sustained at the moment of impact, and secondary injury as injurious 
events which occur at any later stage. Primary injury is largely caused by
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acceleration, deceleration and rotational forces to the brain[9]. Shearing forces 
cause disruption of tissue structure between areas of differing densities which 
cause immediate structural damage to neurons[10,11]. Focal injuries occur in 
the form of contusion injuries, gross tissue disruption and haemorrhage into the 
extradural, subdural, subarachnoid or intracerebral regions. These primary 
injuries were initially thought to be immediate and irreversible[9], however there 
is a growing body of evidence to suggest that a substantial component of cell 
death due to primary injury may occur hours after the injury[11,12]. This 
evolving primary injury disrupts membrane stability, and damages intra-axonal 
cytoskeleton function and axonal transport mechanisms. The resultant 
impairment of anterograde axoplasmic transport leads to local axonal swelling, 
and can eventually result in axonal disconnection and distal degeneration[13]. It 
has therefore become apparent that the primary injury will evolve over time, and 
that its time course will overlap with secondary, or additional, injury 
processes[12] (figure 2.1).
Figure 2.1: A model of primary (A) and secondary (B) injury after TBI (modified from 
[12]).
After TBI, the nervous system has an increased susceptibility to further 
damage, or secondary injury, which can include a wide range of ischaemic, 
ionic, neurochemical and immunological processes. Many of these injury 
mechanisms are common to several cerebral disease processes, such as
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TBI[14], stroke[15] and subarachnoid haemorrhage[16], and have common 
metabolic pathways leading to failing cellular energy production, inability to 
maintain ionic gradients and eventual cell death. The aetiology of secondary 
injury is not fully understood but appears to be related in part to the presence of 
events which impair cellular metabolite delivery known as secondary insults. 
Secondary insults can be systemic, for example hypotension, hypoxaemia, 
anaemia, and acid-base or glucose disturbances, or intracranial, for example 
intracranial hypertension, cerebral oedema, seizures and regional cerebral 
blood flow disturbance^, 17-22].
The vast array, and interactions, of secondary brain injury mechanisms are 
outside the scope of this thesis, however some of the major processes are 
discussed below.
The detrimental effects of systemically induced secondary insults were first 
demonstrated by Miller, in the late 1970’s and early 1980’s, who demonstrated 
a doubling of mortality in severely head injured patients presenting to hospital 
with hypotension (systolic blood pressure <95 mmHg) or hypoxaemia (arterial 
oxygen tension<8 kPa)[23-25], and these findings have been confirmed by 
others[17,26]. Adequate arterial blood pressure is required to maintain CBF, 
Bouma et al demonstrated global CBF reduced below a level associated with 
cerebral ischaemia in animals (<18 ml/100g.min[27,28]), in the first six hours 
post TBI, in 13% of patients with severe head injury. Although TBI may alter the 
ischaemic threshold, this sub-group had poorer outcome and increased 
mortality when compared to those with a CBF >18 ml/100g/min[29]. These 
studies highlight the importance of an adequate supply of oxygen and glucose. 
In health, aerobic glucose metabolism is the major source of energy metabolism 
in the brain, as has already been noted. However, in the face of inadequate 
oxygen delivery, ATP production proceeds anaerobically. Anaerobic metabolism 
is relatively inefficient and if ATP production is inadequate to meet cellular 
requirements then the ionic homeostasis of the cell will fail[30], heralding 
intracellular changes in the concentrations of sodium, potassium and calcium, 
an increased concentration of lactate and corresponding drop in pH[30]. High
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concentrations of lactate have been associated with poor outcome after TBI in 
both animal and human models[31-33].
2.2.1 Excitotoxicity
Elevated glutamate release and resultant excessive cellular depolarisation 
occur after cerebral ischaemia[34,35]. The neurotoxic effects of glutamate were 
first reported in mouse retina[36], and it was originally believed that this toxic 
effect was a direct consequence of an extended period of depolarisation caused 
by the high glutamate levels[37]. This mechanism was thus termed 
excitotoxicity. More recent work has suggested that glutamate has detrimental 
effects through two main pathways: an early phase characterised by neuronal 
swelling and dependent on cellular influx of extracellular sodium and chloride 
ions (consistent with the original concept of excitotoxicity), and a delayed phase 
characterised by neuronal disintegration and dependent on cellular calcium 
influx through both glutamate, and voltage, gated calcium channels[20,21]. 
NMDA[20] and AMPA[38] glutamate receptors have been implicated in these 
processes.
2.2.2 Calcium Influx
Calcium is involved in many facets of cell signalling and homeostasis. It is an 
important cellular messenger involved in the regulation of many enzymatic and 
synthetic pathways. However TBI is associated with dysregulation of
intracellular calcium ion homeostasis and this is thought to be one of the most 
important underlying common pathophysiological pathways in neuronal 
injury[39]. The stimulus for this initial calcium influx is poorly understood but it 
appears to be both related to, and able to promote, the release of
glutamate[40]. Uncontrolled calcium influx into the cell and release of
intracellular calcium stores will activate phospholipases, disrupt mitochondrial 
electron transport, and release free radicals[41], while initiating a complex chain 
reaction leading to cytokine, and potassium release which results in
depolarisation and calcium entry into neighbouring cells[14,41 ]. Calcium has 
long been implicated in cell death, and delayed neuronal degeneration after 
cellular ischaemia has been shown to be dependent on the presence of 
extracellular calcium [20]. However it has also been suggested that calcium
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may have a neuroprotective role. The breakdown of neuronal cells releases 
phosphate and phosphatides into the extracellular space which bind calcium 
and thus lower extracellular calcium concentration. The calcium gradient for 
entry into neighbouring cells is reduced, and this process may therefore have 
the effect of inducing cell death in damaged cells while protecting those that are 
potentially viable[41].
2.2.3 Free Radical Mediated Damage
Increased levels of free radicals are found in the brains of animals post TBI and 
have been implicated in the pathophysiology of secondary brain injury [42-45]. 
Oxygen free radicals are formed during both ischaemia and reperfusion and 
cause damage through increased lipid peroxidation, protein oxidation and 
deoxy-ribonucleic acid damage[46]. An increasingly important role in cerebral 
homeostasis and pathophysiology has been postulated for the free radical gas 
NO. In the context of TBI, recent data suggest that NO may have both 
protective[47,48] and damaging effects[49,49]. In particular, NO has a role in 
the regulation of CBF after TBI[48] with low cerebral concentrations of NO found 
in the early post TBI period when CBF is reduced[42]. Conversely, NO has 
complex pathological roles. It has been implicated in the induction of 
macrophage apoptosis post TBI[49] and is able to react with superoxide to form 
the highly toxic free radical peroxynitrite[50]. The multiple interactions of these 
secondary injury processes are again highlighted by the discovery that NO may 
mediate glutamate mediated excitotoxicity, as it is generated endogenously by 
NMDA receptor stimulation[51], and induces mitochondrial calcium release[52].
2.2.4 Mitochondrial dysfunction
Adequately functioning mitochondria are essential to aerobic energy 
metabolism. It has been demonstrated in both animals[53] and humans[54] that 
TBI causes mitochondrial dysfunction and subsequent decreased ATP 
production. Severe oxidative stress and high mitochondrial calcium 
concentrations cause opening of the mitochondrial permeability transition pore 
which dissipates the mitochondrial transmembrane protonmotive force for ATP 
production, releases prop-apoptotic factors and contributes to free radical 
production^ 5,22,55,56]. As has been discussed above, calcium influx, NO and
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glutamate are all implicated in this process. Cerebral microdialysis studies in 
humans after TBI show increased lactate:pyruvate ratio (LPR), demonstrating 
predominantly anaerobic metabolism, even when adequate regional cerebral 
blood flow and tissue oxygen tension is maintained indicating that cellular 
energy disturbances can be caused not only by a failure of metabolite delivery 
but also by a failure of metabolite utilisation[57]. Hovda et al studied a rat model 
of TBI using a lateral fluid percussion injury and demonstrated an injury-induced 
reduction in cytochrome c oxidase (CCO) activity which began on day 1 post 
injury and lasted for up to 10 days[58]. This finding suggests the intriguing 
possibility that the mitochondrial dysfunction which is observed following TBI in 
humans, and appears to be the common final pathway of secondary injury 
processes, may be related to changes in CCO activity.
A simplified schematic of pathophysiological processes involved in the evolution 
of TBI is shown in figure 2.2. All these pathological processes provide potential 
avenues for the development of pharmacological neuroprotective agents. 
However, despite several promising pre-clinical trials, no pharmacological 
neuroprotectants have shown efficacy in human trials thus far[59]. Current 
treatment of TBI is therefore based on physiological neuroprotection: minimising 
secondary insults, and thus secondary injury through optimisation of 
physiological parameters.
49
Figure 2.2: Schematic showing interaction of secondary injury processes in TBI (taken 
from [30]). Na+ Sodium, K+ Potassium, CBF Cerebral Blood Flow, OH* Hydroxyl Free 
Radical.
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2.3 Treatment of Traumatic Brain Injury
The last four decades have seen significant advances in the management of 
TBI. This process has been greatly aided by detailed data collection from large 
series of TBI patients, the introduction of cranial CT scanning in 1972 and the 
development in, 1974, of the Glasgow Coma Score[1], which has gained 
widespread acceptance as an objective measure of level of consciousness and 
head injury severity. Despite this, many controversies remain and although a 
huge amount of observational and case series data has been collected, there 
exists relatively little data from well conducted randomised controlled trials. 
Following an extensive review of the scientific literature, the American 
Association of Neurologic Surgeons published guidelines for the treatment of 
severe head injury in 1996 with subsequent revisions in 2000 and 2007. At this 
time they concluded that of the 14 topics analysed, only 3 were based on class I 
evidence and therefore deemed worthy of designation as standards of care[60]. 
Similar guidelines have also been published by the European Brain Injury 
Consortium[61].
Extensive investigation has been directed towards discovering effective drug 
therapies to protect the injured brain and most have attempted to disrupt the 
putative pathobiology of TBI. Despite several encouraging animal studies, 
human TBI trials assessing glutamate antagonists, steroids, free radial 
scavengers, calcium channel antagonists, bradykinin antagonists and growth 
factors have all failed to show efficacy[59]. Therefore current management 
strategies are directed towards providing an optimal physiological environment 
in order to minimise secondary insults and maximise the body’s own 
regenerative processes.
The concept of directing management to minimise secondary cerebral insults 
first gained credence in the 1970s. Secondary insults are common after TBI and 
have been reported to occur, at some point, in as many as 91% of patients 
requiring treatment in the NCU[26]. Hypotension and hypoxaemia were initially 
identified by Miller et a/[23-25] and then by Chesnut et a/[ 17,62] as being 
associated with worse outcome after TBI. Jones et al assessed the incidence of 
eight potential secondary insults in 124 patients with TBI and found that the
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durations of hypotension, pyrexia and hypoxaemia were significant predictors of 
mortality[26]. As early as 1977 it was suggested that aggressive goal directed 
treatment of patients with TBI was able to improve outcome, and important 
areas of management such as the evacuation of mass lesions, control of ICP, 
mechanical ventilation, and medical therapy using sedatives and osmotic 
agents were identified[63}. Raised ICP has been noted by several studies to be 
associated with increased morbidity and mortality[64-68]; however identification 
of the optimum threshold for the treatment of raised ICP has proved more 
difficult. There is some class II evidence to suggest that the threshold is in the 
region of 20-25 mm Hg[66,67] and strategies designed to maintain ICP below 
this level have been termed ICP directed therapy.
Rosner et al introduced the concept of CPP (defined as MAP -  ICP) directed 
therapy in the 1990s. Rosner studied plateau waves of raised ICP in cats using 
a fluid-percussion model of TBI and postulated that the trigger for this event was 
a decrease in CPP, leading to compensatory cerebral vasodilatation. A vicious 
cycle is set up, consisting of raised cerebral blood volume leading to raised ICP 
and consequently a further decrease in CPP[69]. Rosner postulated that 
maintaining a CPP greater than 70 mm Hg, by manipulation of MAP, would 
minimise periods of raised ICP and ensure an adequate CBF with which to 
supply oxygen and glucose to the injured brain in the face of an altered 
autoregulatory threshold[70]. In health, the brain is able to maintain a constant 
CBF across a wide range of CPP (approximately 50-150 mm Hg) and this 
process is termed cerebral autoregulation (figure 2.3). However, after TBI these 
processes are damaged and CBF declines at CPP levels above the normal 
lower limits of autoregulation[71-73]. Rosner studied 158 patients who were 
treated using this strategy and provided class II evidence that CPP directed 
therapy lowered mortality and improved outcome when compared to traditional 
ICP directed therapy[70,74]. In contrast, Robertson et al randomised TBI 
patients to ICP or CPP directed therapy, and although they found a lower 
incidence of secondary insults, defined using jugular venous oximetry criteria, in 
the group treated using CPP directed therapy, there was no significant 
difference in outcome between the two groups[75]. They also discovered a five 
fold risk of ARDS in the CPP directed therapy group and concluded that the
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vasopressor load required to maintain a CPP >70 mm Hg might induce 
systemic complications in some patients. Additional studies have shown that 
patients who develop acute lung injury after TBI have a significantly raised 
incidence of raised ICP and poorer outcome[76]. Analysis of physiological data 
from 427 patients in the Selfotel trial, carried out in 2000, showed poorer 
outcomes for those with a CPP persistently below 60 mm Hg[77], and in 2003, 
based primarily on these studies, the Brain Trauma Foundation amended its 
guidelines for the management of severe traumatic brain injury to suggest that 
CPP be maintained at a minimum of 60 mm Hg.
E 100
0JQ-
ec
©o
£o
-aoJO
-Q
2-Q0>I_V
u
80 -
E 60
40 -
20  -
0
Physiological autoregulation 
Pathophysiological autoregulation
i
50 100 150
Mean blood pressure, mm Hg
200
Figure 2.3: Idealised depiction of physiological and pathophysiological cerebral 
autoregulation.
The Lund Concept has been suggested as an alternative approach to the 
treatment of TBI. This focuses on avoiding brain oedema given that the blood 
brain barrier is impaired and is based upon prevention of raised ICP and 
improvement of pericontusional perfusion and oxygenation. The treatment 
protocol has been reviewed in depth[78], and specifically includes the
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antagonisation of vasoconstriction through reduction of plasma catecholamine 
concentration and minimising the use of vasopressors. There is some evidence 
to suggest that the use of the Lund Concept might improve patient outcome 
after TBI when compared to historical controls[79], but to date no randomised 
controlled trial has been undertaken comparing the Lund Concept based 
treatment with CPP directed therapy.
Most consensus guidelines combine aspects of ICP and CPP directed 
therapy[60,61] and treatment strategies have moved from approaches simply 
designed to reduce ICP, toward a multifaceted approach aiming to maintain 
cerebral oxygen and glucose delivery. Comparison with historical controls has 
provided some evidence that the use of these protocolised intensive care 
management strategies in the care of TBI patients can reduce mortality and 
improve outcome[8,80,81].
There is however, a potential flaw in the use of strictly protocolised 
management guidelines. There exists a wide heterogeneity in TBI, both 
between patients, and within patients across time and space[82-84]. Minimising 
secondary injury to the brain after TBI requires the tailoring of metabolite supply 
to demand, but an ‘adequate supply’ may vary substantially between periods of 
hypermetabolism and periods of deep sedation or extensive mitochondrial 
dysfunction. Strictly protocolised management strategies attempt to address 
adequate metabolite demand for an average TBI patient but make no allowance 
for individual variation. The concept of individualised TBI therapy was first 
introduced by Miller et al in 1993 who noted that the empirical treatment of 
raised ICP was not efficacious, and suggested that treatment should be directed 
toward the specific cause of the raised ICP[85]. The concept that minimising 
cerebral ischaemia after TBI may require individual optimisation of CPP has 
been expounded by others[86-88].
Individualised patient management is intuitively attractive. It does, however, 
require clinical monitoring systems able to assess the adequacy of metabolite 
delivery to the brain with high temporal and spatial resolution.
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2.4 Monitoring the Injured Brain
The goal of monitoring the injured brain is to facilitate the minimisation of 
secondary injury by detecting harmful physiological events before they cause 
irreversible damage. This then allows diagnosis and effective treatment of 
harmful pathophysiological processes and provides ‘on-line’ feedback to guide 
therapy[89].
As already noted secondary insults to the injured brain can be either systemic 
or cerebral in origin. Monitoring to detect these insults must also, therefore, 
consist of both systemic and cerebral components. Systemic variables routinely 
monitored on the NCU include electrocardiogram morphology, arterial blood 
pressure, arterial oxyhaemoglobin saturation, arterial blood analysis, central 
venous pressure and systemic temperature. These monitoring modalities will 
not be discussed further, but instead this section will concentrate on cerebral 
monitoring.
2.4.1 Invasive Cerebral Monitoring
2.4.1.1 Intracranial Pressure
Measurement of ICP is central to the application of both ICP and CPP directed 
therapy. ICP monitoring has become integral to the management of TBI in most 
centres and indications for its use are well established[90]. Despite this, the use 
of ICP monitoring is not universal[91,92] and there exists no class I evidence 
supporting its efficacy. Additionally some data exist to suggest that ICP directed 
therapy may result in increased levels of therapy intensity and prolonged 
mechanical ventilation compared to clinically guided therapy, without evidence 
for improved outcome after severe head injury[93].
Two main methods exist for the invasive measurement of ICP. The ‘gold 
standard’ technique remains a pressure transducer connected to a catheter with 
its tip positioned in the lateral ventricle. This method ensures that a global 
pressure measurement is recorded and has the additional advantages of 
allowing periodic external calibration and therapeutic CSF drainage. However, 
placement of the ventricular catheter may be difficult in cases of severely raised 
ICP and there is a significant risk of developing ventriculitis with its attendant
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increased morbidity and mortality[94]. Transducer tipped systems can be placed 
in the brain parenchyma or subdural space, either through a skull bolt on the 
NCU or by an open technique during a neurosurgical procedure, with minimal 
infection and complication rates[95]. Measured pressure, however, may not be 
representative of true CSF pressure as interhemispheric supratentorial 
intracranial pressure gradients in TBI patients have been demonstrated and 
whilst these systems have been shown to perform well during bench testing[96], 
drift will still occur during long term monitoring. In addition to absolute ICP 
levels, information can also be gained from analysis of ICP waveform[97].
2.4.1.2 Jugular Venous Oximetry
Jugular venous oximetry is a technique which can be used to estimate the 
balance between global cerebral oxygen delivery and utilisation. A catheter is 
inserted into the dominant internal jugular vein and advanced to the jugular 
bulb, therefore minimising contamination from extracerebral venous return. 
Once catheter positioning has been checked on a lateral cervical spine 
radiograph, then measurement of Sjv02 can be made either continuously using 
a spectroscopic technique, or directly by aspirating blood samples and using a 
co-oximeter. Reduced Sjv02 indicates that cerebral oxygen delivery is 
inadequate to meet demand. In the context of TBI this is most often related to 
reduced CBF, secondary to decreased CPP or hyperventilation associated 
vasoconstriction. Conversely raised Sjv02 indicates luxury perfusion caused by 
either raised CBF or reduced oxygen demand secondary to mitochondrial 
dysfunction or cell death. Reduction in Sjv02 below 50% after TBI is associated 
with poor outcome[98], and Sjv02 is responsive to changes in CPP[99]. 
However the use of jugular venous oximetry has never been shown to improve 
outcome after TBI. A major limitation of jugular venous oximetry is its lack of 
sensitivity to regional changes and PET data exist suggesting that low Sjv02 
values only occur after TBI when a significant volume of the brain becomes 
ischaemic[100]. Sjv02 is a flow weighted average of cerebral venous oxygen 
saturation and has been shown to correlate poorly with regional tissue 
oxygenation in areas of focal pathology[101]. It is also possible that significant 
arteriovenous shunting, after TBI, might interfere with this measurement. In
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addition, current monitors suffer severely from artefacts and require frequent 
recalibration.
2.4.1.3 Tissue Oxygen Tension
Invasive probes have been developed to monitor focal Pbr02. Currently only 
one Pbr02 monitor is commercially available for use in humans, (Licox, GMS, 
Kiel-Mielkendorf, Germany). This Pbr02 probe utilises a closed polarographic 
(Clark-type) cell with electrochemical electrodes. Oxygen, which has diffused 
from the brain tissue across a semi-permeable membrane, is reduced by a gold 
polarographic cathode. This reaction produces a flow of electrical current 
directly proportional to the oxygen concentration and related to the brain 
temperature[102]. Measured Pbr02 represents the balance between oxygen 
delivery and cellular oxygen consumption. However it requires oxygen diffusion 
to the probe and will therefore be affected by changes in diffusion distance from 
capillary to probe as well as the proportion of arterioles and venules in the 
region of interest, and it has been suggested that this may determine whether 
measured Pbr02 more closely relates to CBF or oxygen extraction fraction[103]. 
Pbr0 2  probes provide a highly focal measurement and whilst this offers the 
potential of selectively monitoring critically perfused tissue, it means that probe 
positioning is crucial and that global changes may be missed.
Studies in human subjects with uncompromised cerebral circulation undergoing 
elective cerebrovascular surgery suggest that normal PbrC>2 values are in the 
region of 4.7 to 6.7 kPa[104,105]. Studies in patients following TBI have shown 
that PbrC>2 increases with CPP and importantly that the ceiling of this effect is 
higher in areas of focal ischaemia[106,107]. Comparative studies have also 
shown correlation between Pbr02 and regional CBF, and between changes in 
Pbr02 and changes in regional venous oxygen saturation measured using PET. 
It has been demonstrated that reduced PbrC>2 is associated with poor outcome 
after TBI, yet the threshold for hypoxia has proved more difficult to identify and 
is likely to be related to both the duration and level of hypoxia. Ischaemic 
thresholds of between 0.7 and 2.7 kPa have been suggested[108-111]. It is 
clear that Pbr0 2  can be altered using clinical intervention, and that measured 
levels relate to outcome. What is less clear is whether manipulation of this
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variable can affect outcome. Recent evidence, however, suggests that Pbr02 
directed therapy can improve outcome and this possibility merits further 
investigation^ 12].
2A .1.4 Cerebral Microdialysis
Cerebral MD is a well established laboratory tool and is being increasingly used 
as a bedside monitor to provide on-line analysis of brain tissue biochemistry 
during neurointensive care. A MD catheter consists of a fine double lumen 
probe, lined at its tip with a semi-permeable dialysis membrane. The probe tip is 
placed into biological tissue and perfused via an inlet tube with fluid isotonic to 
the tissue interstitium. The perfusate passes along the membrane before exiting 
via outlet tubing into a collecting chamber (figure 2.4).
Figure 2.4: Components of clinical MD catheter. 1, pump connector; 2, inlet tube; 3, 
MD catheter; 4, MD membrane; 5, outlet tube; 6, microvial holder; 7, microvial for 
collection of microdialysate (taken from [113].
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Diffusion drives the passage of molecules across the membrane along their 
concentration gradient. The MD catheter therefore acts as an artificial blood 
capillary and the concentration of substrate in the collected fluid 
(microdialysate) depends in part on the balance between substrate delivery to, 
and uptake/excretion from, the ECF[113](figure 2.5).
Figure 2.5: Schematic representation of relationship between blood capillary and MD 
catheter in brain tissue (taken from [113].
Placement of the MD catheter in ‘at risk’ tissue, such as the area surrounding a 
mass lesion after traumatic brain injury allows biochemical changes to be 
measured in the area of brain most vulnerable to secondary damage (figure 
2.6). Guidance has been issued on catheter placement for monitoring patients 
after TBI and positioning should be checked by subsequent computed 
tomography scan[114].
Commercial assays are available to measure dialysate concentrations of 
glucose, lactate, pyruvate, glycerol and glutatate, and tentative normal values 
for these variables have been described (table 2.1 )[115,116].
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Figure 2.6: Changes in LPR in ‘at-risk’ (A) and normal appearing (B) brain during a 
period of low and normal CPP. The normal range for LPR is shown by the shaded 
area. Note the increase in LPR in the ‘at-risk’ tissue during a period of cerebral 
hypoperfusion with normal values measured by the catheter in normally appearing 
brain (taken from [113].
Table 2.1: Suggested normal concentrations of commonly measured biochemical 
markers in microdialysate samples from the uninjured human brain, collected at a 
perfusate flow rate of 0.3 pL min'1 (taken from [113].
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The pathophysiological changes associated with commonly monitored cerebral 
MD biomarkers have been reviewed recently [113,117] and are summarised in 
table 2.2.
The measurement of MD lactate and pyruvate concentrations provides 
information on the extent of anaerobic glycolysis, and the extracellular LPR 
reflects the intracellular redox state - a marker of mitochondrial 
function[118,119]. LPR is a more robust and reliable biomarker of tissue 
ischaemia than lactate concentration alone[120] and, because lactate and 
pyruvate have very similar molecular weights, the LPR is independent of 
catheter recovery in v/Vo[121]. LPR is therefore the most widely monitored MD 
variable after TBI.
In the human brain, severe hypoxia/ischaemia is typically associated with 
marked increases in the LPR[122] which correlates with PET measured oxygen 
extraction fraction[123]. An increase in LPR above established thresholds (20- 
25) is associated with poor outcome in TBI[32,33], and has traditionally been 
assumed to indicate tissue ischaemia. However, it has proved difficult to 
establish the tissue hypoxic threshold for a raised LPR[57] and it is increasingly 
apparent that anaerobic glycolysis may occur due to failure of effective 
utilisation of delivered oxygen because of mitochondrial failure as well as 
because of hypoxia/ischaemia[124].
The use of cerebral MD may be able to assist in clinical decision making, such 
as management of cerebral perfusion pressure[88], guidance of 
hyperventilation[125] and the appropriateness of extensive surgical 
procedures[126].
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Table 2.2: Biochemical markers of secondary brain injury (taken from [113].
2.4.2 Non-invasive Cerebral Monitoring
2.4.2.1 Cerebral Blood Flow Velocity
Transcranial Doppler ultrasonography (TCD) is a non-invasive technique which 
uses ultrasound waves to derive cerebral blood flow velocity from the Doppler 
shift caused by red blood cells moving through the field of view. TCD is not 
able to provide absolute measurements of CBF, but if the angle of insonation 
and the diameter of the insonated vessel remain constant then changes in TCD 
measured cerebral blood flow velocity correlate with changes in CBF. Several 
studies have shown minimal changes in the diameter of basal cerebral arteries 
during various physiological challenges[127,128]. The TCD signal is directed 
through areas of thin cranium and can then insonate several vessels arising 
from the circle of Willis. The transtemporal route is most commonly employed
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although measurements can also be made through the suboccipital or 
transorbital routes. TCD has been used to test autoregulatory reserve by 
monitoring changes in cerebral blood flow velocity in response to changes in 
MAP and this technique may have a role in providing an individual-specific CPP 
target[129]. Typical TCD instrumentation for continuous monitoring is shown in 
figure 2.7.
Figure 2.7: TCD instrumentation with probes fixed in place for continuous monitoring
2.4.2.2 Imaging Techniques
Cerebral imaging techniques such CT, SPECT, MRI, MRS, and PET can 
provide detailed haemodynamic and metabolic information over multiple regions 
of interest. Many of these techniques are powerful research tools, yet they are 
all limited by two disadvantages.
Firstly they are only able to provide snapshot images of the brain and therefore 
cannot be used to track the course of brain injury over time and are therefore 
restricted in their ability to guide neuroprotective treatments strategies.
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Secondly they require the transfer of critically ill patients to specialised imaging 
facilities: a process which can be detrimental to the patient’s condition, 
especially in the context of raised ICP, and may preclude investigation of the 
sickest amongst them, who may be most at need of the investigation.
Xenon enhanced CT is a technique which uses CT scanning during inhalation 
of 30% xenon gas in oxygen to measure regional cerebral blood flow across 
multiple regions of interest. [130]. This technique has been used to successfully 
predict outcome after TBI[131 ]. Absolute CBF can also be determined using CT 
scanning and intravenous administration of contrast agent. This technique, 
which is known as CT perfusion is able to provide maps of CBF and CBV using 
similar methodology to Xenon enhanced CT.
SPECT is a technique which uses gamma radiation emitting nuclear isotopes 
and multiple detectors to generate tomographic images[132]. Several tracers 
have been investigated for the purposes of producing maps of CBF. However 
the production of quantitative information is difficult and image quality is 
generally of poor resolution[130].
MRI studies can be used to obtain information on CBF, CBV and the presence 
of acute ischaemia. The introduction of gadolinium based intravascular contrast 
agents causes changes in intravascular magnetic susceptibility[130] and 
perfusion-weighted MRI techniques can be used to derive information regarding 
CBF and CBV. However the generation of absolute values has proved difficult 
and most studies therefore present relative CBF and CBV[132]. MRS uses 
similar technology to MRI and is able to assess the metabolic state of the brain, 
non-invasively and without using exogenous tracers. It detects magnetic 
resonance signals from individual tissue solutes rather than just water and lipids 
as in the case in standard MRI[133]. Signals relating to either hydrogen or 
phosphorous nuclei are most commonly obtained and can provide information 
relating to adenosine triphosphate, lactate and phosphocreatine concentrations. 
Data can either be obtained for a single region of interest, or, given longer 
acquisition times, metabolite maps can be produced. Many studies have been
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published using MRS to investigate TBI in animal models and human studies 
are now forthcoming[133].
PET remains the gold standard technique for the imaging of cerebral blood flow 
and metabolite concentrations in the injured brain. It is, however, hampered by 
the requirement for radioactive tracers and it is not widely available. PET uses 
photon detectors to detect electromagnetic radiation produced from the collision 
of electrons and positrons and is thus able to monitor the accumulation of 
positron-emitting radioisotopes within the brain. The tracer 15-oxygen is used to 
measure CBF, CBV, CMRO2 and oxygen extraction fraction, while 18- 
fluorodeoxyglucose is used to measure cerebral glucose metabolism[132]. PET 
studies in humans have demonstrated the wide inter-patient heterogeneity 
present after TBI[83] and have tried to define ischaemic thresholds after head 
injury[134]. Due to the practicalities of its use, and its availability, PET is 
primarily a research tool and is unlikely to become part of routine clinical care.
2.5 Summary
Invasive cerebral monitoring techniques are able to provide continuous 
information at the bedside, but can only provide information on a single and 
hyperfocal area of the brain and carry an attendant risk of complications. 
Imaging techniques are the gold standard for providing structural, 
haemodynamic and metabolic information with high spatial resolution over 
multiple sites. However they have greatly reduced temporal resolution and 
require the transfer of critically ill patients.
There is a need for a non-invasive bedside monitoring technique which is able 
to provide realtime quantitative haemodynamic and metabolic information at 
multiple sites with high temporal and spatial resolution. Several techniques 
which meet some or all of these criteria are being investigated such as 
electrocorticography[135], fluorescence spectroscopy[136] and photoacoustic 
spectroscopy[137].
NIRS involves the measurement of changes in the attenuation of near infrared 
light due to absorption and scatter by tissue. This technique has the potential to
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fulfil all of the criteria detailed above, with the exception of the high spatial 
resolution, and thus is an attractive option as a system for monitoring the injured 
brain. NIRS will be described in detail in chapter 3.
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Chapter 3
Near Infrared Spectroscopy
In this chapter the theoretical bases of near infrared spectroscopy and the 
various NIRS techniques used in this thesis are discussed. Particular mention is 
made of the main chromophores and optical properties of biological tissue. 
Continuous wave spectroscopy is introduced first and then followed by a 
description of spatially resolved (SRS) and frequency domain spectroscopy 
(FDS), and techniques for measuring optical pathlength.
3.1 Principles of Light Transport in Tissue
The simplest form of spectroscopy described in this thesis is known as 
continuous wave spectroscopy and is based on observing the attenuation of 
light of fixed incident intensity, by tissue at a single constant distance c/from the 
incident light. The interpretation of the attenuation data is based upon a series 
of observations which together from the basis of the modified Beer-Lambert 
Law (MBLL).
Bouguer observed in 1729 that successive layers of a homogenous material of 
equal thickness 6d absorb the same fraction, dl/l of light of initial intensity I 
which is incident upon them. This relationship, which is known as the Lambert- 
Bouguer law, can be stated mathematically as:
dl Eqn 3.1
- j  = - f t a sd
pa is a constant defined as absorption coefficient (cm'1).
Integration of equation 3.1 gives:
/  =  l0e~Ma d E Qn 3  2
I = the transmitted intensity of light of initial intensity l0 after it has passed a distance d 
through a homogenous absorber with absorption coefficient pa-
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This can also be expressed in base 10 as:
l = l010“ 't c/ Eqn 3.3
k = the extinction coefficient (cm'1).
Therefore (
/4 = log10
v h
= k d
Eqn 3.4
A = attenuation and has units of optical density (OD) when defined in log base 10.
In 1852 Beer determined a relationship between absorption coefficient and 
absorber concentration.[1]. He found that that for an absorber dissolved in a 
non-absorbing solution, the attenuation is directly proportional to the 
concentration of the solution, or
H a =  a  c Eqn 3.5
c=concentration of solute (molar) and a=specific absorption coefficient (molar'1 cm'1).
This is known as the Beer law. Combining equations 3.2 and 3.5 gives the 
Beer-Lambert law:
I = l0e~acd Hgn 3.6
A further important principle is that, for a solution containing a mixture of 
absorbing compounds, the extinction coefficients are additive and the total 
attenuation is given by the sum of the attenuations attributable to each of the 
absorbers. Therefore for a mixture of n absorbers dissolved in a non-absorbing 
solution:
A = (/c-| + k2 +... + kn )d Eqn 3.7
These terms can all be defined in both natural logs and log base 10 but 
consistency of the log base used is essential.
The Beer-Lambert law assumes that all light incident on the interrogated 
material is either absorbed or transmitted. It assumes therefore no reflection at 
tissue interfaces and no light scattering. The situation in biological tissue is 
more complex and does not satisfy these assumptions. In biological tissue there 
exist multiple boundaries between different media. Refractive index mismatches
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occur at these boundaries and these will deflect photons from their initial path. 
This photon deflection away from a single detector gives rise to attenuation and 
is known as light scatter (figure 3.1). If we assume no absorption then by 
analogy with absorption:
I = l0e~Msd Eqn 3 8
ps = the scattering coefficient (cm'1).
The contribution of various tissue components to total scatter is determined by 
both their relative scattering efficiency and the number of scattering particles. 
Types of scatter interactions can be classified by the diameter of the scattering 
particles with respect to wavelength. Scattering caused by intracellular 
structures such as organelles and mitochondria with diameter less than A /tt is 
described by the theory of Rayleigh scattering. This describes scatter occurring 
when an incoming photon excites an atom into a transiently elevated state. This 
produces an oscillating electric dipole moment. The induced oscillating electric 
dipole moment then re-radiates a photon at the same frequency as the 
incoming photon but in a random direction travelling radially away from the 
centre of the interaction: this is an example of isotropic scatter. Rayleigh Ganz 
Debye theory describes scattering events caused by structures with diameter 
greater than A /tt. In this situation the large particle is considered as a collection 
of smaller Rayleigh scatterers with additional refraction and reflection effects 
taking place at boundaries. Constructive and destructive interference effects 
between the refracted and reflected components produce an angular 
dependence of the scattered intensity and thus anisotropic scatter. Biological 
tissue contains a large number of small Rayleigh scatterers, each with a 
relatively low scattering efficiency due to the low refractive mismatches with 
surrounding media, and a smaller number of Rayleigh Ganz Debye scatterers 
with a higher relative scattering efficiency.
The anisotropy (direction of scatter) is commonly characterised by the mean 
cosine of the scattering angle which is defined as the anisotropy factor g. When 
scattering is isotropic, g=0 and for tissue, which is predominantly forward 
scattering, g=0.7-0.97. In tissue multiple scattering occurs and light rapidly loses 
directionality. The situation can be simplified by considering a case of isotropic
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scatter when the scatter coefficient has been reduced by a factor (1 -g). This 
modified scattering coefficient is called the transport scattering coefficient pst 
and:
Mst =^s(1 —9 ) Eqw 3.9
Light scattering has two important implications. Firstly light that is scattered may 
not reach the detector and so measured light attenuation will be caused by both 
scattering and absorption. Secondly, as photons undergo multiple scattering 
interactions they will travel further than the direct distance between source and 
detector and the chance of further scatter or absorption will relate to this optical 
pathlength rather than the direct distance (figure 3.1).
A B
Detector Detector
Figure 3.1: Schematic of light transport under (A) absorbing, non-scattering conditions 
and (B) scattering and absorbing conditions. In B the pathlength travelled is increased 
and a proportion of photons are scattered in such a way as to miss the detector.
The MBLL takes account of light attenuation due to scattering and the increase 
in optical pathlength[2]. In log base 10 it is stated as:
A  =  log-io
v ' /
= £-c-d- DPF + G
Eqn 3.10
G = light attenuation due to scattering, e = the specific extinction coefficient and 
DPF=the differential pathlength factor, a multiplier which accounts for the increased 
optical pathlength due to scattering.
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The majority of near infrared light absorption and scatter in biological tissue is 
caused by constituents whose concentration we can assume to be fixed. We 
can therefore make the assumption that, although attenuation due to light 
scatter is wavelength dependent, its magnitude at a given wavelength is fixed. 
This assumption allows the use of the MBLL to relate changes in light 
attenuation to changes in chromophore concentration which can be stated:
AA = AC-ed-  DPF Eqn 3.11
DPF is highly dependent on the degree of light scattering, but is also dependent 
on pa and this makes intuitive sense as in the limit pa »  ps we would revert to 
the Beer-Lambert Law implying that ln(l0/l) is a non-linear function of pa. 
Diffusion theory can be used to generate theoretical relationships between 
ln(l0/l) and pa at different values of ps and the local slope of the of the curve will 
then be the optical pathlength. When ps=0 the relationship between ln(l0/IJ and 
pa is a straight line, corresponding to the Beer-Lambert Law, and has gradient 
equal to the geometric pathlength and but as ps increases the relationship 
becomes progressively non-linear (figure 3.2) and the DPF is therefore a 
function of both pa and ps. In general however we are measuring relatively small 
changes in attenuation superimposed on a large background attenuation and so 
the optical pathlength over the range of measurement is assumed to be 
constant and equation 3.11 can be employed[3]. It is possible to measure the 
differential pathlength factor DPF by a variety of methods and this topic will be 
discussed separately. Experimentally measured values of DPF for brain and 
muscle of children, adults and animals have been published[2,4-6].
With these assumptions and given the knowledge of e, the source detector 
distance d and the differential pathlength factor DPF we are able to convert 
measured change in attenuation into change in chromophore concentration. At 
this stage it is useful to discuss the chromophores present in biological tissue.
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Figure 3.2: Theoretical form of relationship between ln(l0/l) and pa calculated for an 
infinite slab of thickness 1cm. The linear relationship corresponds to zero scattering 
and has slope equal to the geometric pathlength d, whereas the non-linear curves 
correspond to non-zero scattering and have local gradient equal to the optical 
pathlength d.DPF (modified from [6]).
3.2 Optical Chromophores in Biological Tissue
The main chromophores present in biological tissue are water, lipids, melanin, 
haemoglobin and cytochrome c oxidase.
3.2.1 Water
Water accounts for 60-90% of total body mass but its concentration varies 
greatly between tissue types[7]. Due to its high concentration, water is one of 
the main absorbers in tissue. Its extinction spectrum is shown in figure 3.3 and 
demonstrates that photon absorption due to water becomes extremely high 
above about 1700 nm. In this range photons will travel a very short distance
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before being absorbed and this will limit the volume of tissue that can be 
interrogated.
Figure 3.3: The extinction spectra of pure water (taken from [8]).
3.2.2 Lipids
Lipids are present in the subcutaneous tissue and are the principle component 
of the myelin sheaths of nerves. The extinction spectrum of lipid is relatively flat 
with some broad peaks in the region of 650-1000 nm, but these peaks have 
much lower magnitude than those of water and thus have a much smaller effect 
on the light attenuation across cranial tissue.
3.2.3 Melanin
Melanin is present in the epidermis and is arranged in a structure which 
produces effective light scattering. Melanin is a significant attenuator of light 
especially in the ultraviolet region (200-400 nm). It serves to protect the body 
mainly by scattering incident photons and thus reducing the photon density.
The concentrations of each of these chromophores in tissue will not change 
rapidly. Over the time course of the studies described in this thesis, one can 
assume that their concentrations will remain stable and they can therefore be 
termed fixed absorbers. The chromophores of interest are those whose 
concentrations would be expected to change in relationship to changes in tissue 
physiology.
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3.2.4 Haemoglobin
Haemoglobin binds to oxygen in a reversible manner to form oxy-haemoglobin 
and this binding of oxygen induces a conformational change in the haemoglobin 
molecule. HbC>2 and HHb both exhibit high absorption at wavelengths less than 
-600 nm (figure 3.4). There exists a so-called ‘window of transparency’ between 
the large absorption peaks of the haemoglobin and water at wavelengths 
between 600-100 nm. This region is known as the near infrared (NIR) and due 
to the relatively low tissue absorption at these wavelengths, light incident on the 
skin surface can travel a sufficient distance to allow interrogation of structures 
beneath the tissue surface[9]. Hb02 and HHb both have distinctive spectra 
within this wavelength range (figure 3.5).
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Figure 3.4: Specific extinction spectra of oxy- and deoxy-haemoglobin (from [10-12]).
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Figure 3.5: Specific extinction spectra of oxy- and deoxy-haemoglobin (from[10-12].
3.2.5 Cytochrome C Oxidase
The biochemistry of CCO has been discussed in chapter 1. The optical 
absorption difference spectrum between oxidised (oxCCO) and reduced CCO 
(redCCO) has features at various wavelengths and these can be attributed to 
the four main redox centres involved in electron transfer within the CCO 
enzyme (figure 1.6). The ox-redCCO spectrum has a distinct band in the NIR 
(figure 3.6) and the oxidation state of the Cua subunit is responsible for this 
differential light absorption[9,13]. Assuming the total concentration of CCO 
remains constant during an experiment then changes in the NIRS CCO signal 
represent changes in the CCO redox state. This signal has the potential to 
provide a non-invasive marker of changes in mitochondrial oxygen delivery and 
utilisation.
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Figure 3.6: Specific extinction spectra of oxidised and reduced CCO and the oxidised - 
reduced difference spectra (ox-red CCO) (data from Dr. J Moody, Plymouth University).
Using knowledge of the spectra of these chromophores, Jobsis published the 
first description of in vivo NIRS in 1977[9]. When using MBLL to measure 
A[Hb0 2 ], A[HHb] and A[oxCCO] there are clearly three unknowns. Solving for 
these requires at least three simultaneous equations and these can be provided 
by measuring light attentuation at a minimum of 3 wavelengths.
However, although the specific extinction coefficients of the ox-redCCO 
difference spectrum in the near infrared region are similar in magnitude to those 
of HbC>2 and HHb[14], the concentration of CCO in the brain is approximately 
one order of magnitude less than these other two chromophores[15]. This 
complicates its detection and raises the possibility that NIRS measured 
changes in A[oxCCO] might be subject to artefacts resulting from measurement 
algorithm errors[16,17]. Modelling studies have demonstrated that these errors 
can be reduced by measuring light attenuation at multiple wavelengths[1 0 ].
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This technique is called broadband spectroscopy (BBS) and in this thesis BBS 
data are analysed using a generalised algorithm termed the UCLn algorithm 
with the form:
a  [HHb\ = — -—
' d ■DPF  
vA[oxCCO])
A[Hb02] £H b 0 M i )  £ HHb(Ai) ^o xC C o W  f  AA(A,)
£Hb02(Aj) sHHbW £oxCCO(Ay ) J  [AA(Aj), Eqn 3.12V
e = the specific extinction coefficient of the subsequent chromophore and AA = the 
change in attenuation, at n wavelengths Ai to Aj.
For the studies described in this thesis we use two MBLL based NIRS systems. 
The Hamamatsu NIRO 300 (Hamamatsu Photonics, KK) is able to measure 
light attenuation at 4 wavelengths (775nm, 813 nm, 853 nm, and 910 nm) and 
uses the UCL4 algorithm which has the same form as equation 3.10 with n=4. 
Additionally in order to overcome some of the difficulties of making 
measurements of A[oxCCO] we use a BBS system which measures attenuation 
at 120 wavelengths between 780 and 900 nm and uses a least square fitting 
procedure to determine the changes in chromophore concentrations. This 
system is described in detail in chapter 5.
3.3 Spatially Resolved Spectroscopy
The use of the MBBL allows calculation of absolute changes in chromophore 
concentration, but can only therefore measure change from an arbitrary 
baseline and cannot derive absolute concentrations. SRS is a technique which 
allows calculation of absolute tissue oxyhaemoglobin saturation. The spatially 
resolved spectroscopy system used for the studies described in this thesis is 
the Hamamatsu NIRO 300 and the measured tissue oxyhaemoglobin saturation 
is known as tissue oxygenation index (TOI).
In order to calculate absolute concentrations of chromophores we need to 
further investigate the issue of light scattering.
Eqn 3.13
90
Photon transport through tissue can be described by the diffusion approximation 
to the transport equation [18]. Assuming a semi-infinite homogenous half-space 
geometry:
R(p,r) = (4 nDv)
-3
2 1
-5
2
Pst
t exp(-//a v r ) e x p
f  2 -2  ^  
P + Pst
ADvr
Eqn 3.14
R= reflected light intensity at a distance p and time f from an impulse input. pa and pst = 
the absorption and transport scattering coefficients respectively, D = the diffusion 
coefficient (D=1/3(pa+Mst) and v = the velocity of light in the medium.
In the case of continuous wave light input, the intensity I at distance p from the 
input can be expressed as the integral of R(p,t) over time and so the attenuation 
is defined as:
00
A(p) = -logio |R(p,r)rt Eqn 3.15
0
Differentiation of equation 3.15 with respect to p gives:
1d A = ____
dP In10 V3Pa ' Pst P.
Eqn 3.16
The SRS technique measures attenuation at several wavelengths using multiple 
closely spaced detectors. This allows calculation of dA/dp which can then be 
used to derive a wavelength specific value of pa pst- Mst is almost constant 
across wavelength in the NIR but more formally it is found that based on a 
homogenous model:
Mst(;l) = /f(1- /7'0  Eqn 3.17
h = the normalised slope of pst against A which is approximately constant across tissue 
types and subjects with a value of 6.3><1 O'4 mm'1 nm[19] and k is a constant.
Knowledge of dA/dp and equations 3.16 and 3.17 then allows the calculation of 
scaled wavelength specific absorption coefficients k-pa. The NIRO 300 
measures dA/dp using 3 closely separated photodiodes at 3 wavelengths (775, 
813 and 850 nm) (figure 3.7) and uses a least square error method to calculate 
scaled absolute concentrations of Hb0 2  and HHb.
91
In matrix form this is shown as:
-1
k[Hb02] 
k [HHb
£ Hb02 (A1)
£Hb02 (A 1) (^2 )
EHb02 ) )
k ' Ma (^1 ) 
k-MaU 2 )
k - M a ( h )
Eqn 3.18
A1 , A2, A3 represent the 3 wavelengths.
If we assume that k is constant then the calculation of TOI is possible:
/c[HbQ>]TOI = x100 Eqn 3.19
3 photodiodeEmitter detector
dp
Figure 3.7: The NIRO 300 optode with a schematic of spatially resolved spectroscopy.
The NIRO 300 is a 2 channel NIRS system which allows simultaneous 
measurement at two sites and has a maximum acquisition rate of 6  Hz. In 
addition to its SRS capability it uses change in light attenuation measured at 
four wavelengths (775, 813, 850 and 910 nm) by the central photodiode to 
calculate A[Hb02], A[HHb] and A[oxCCO] using the MBLL. The NIRO 300 
spectrometer is shown in figure 3.8.
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When applying non-invasive NIRS to the adult head, our goal is to make 
measurements of chromophore concentrations in the brain. Using the 
interoptode spacings described in this thesis (35-50mm), near infrared light will 
pass through the cerebral cortex and thus light attenuation will be affected by 
changes in cerebral chromophore concentrations[20]. However, some light will 
pass through only the skin and scalp before reaching the detector and will also 
contribute to the measured signal. The extra- and intracranial contributions to 
the measured signal may vary between individuals and disease states, but 
studies investigating cranial SRS measurements during selective clamping of 
the internal and external carotid circulation suggest that SRS is less prone to 
extracerebral contamination and has increased sensitivity and specificity to 
intracerebral layers than NIRS using the MBBL[21].
Figure 3.8: NIRO 300 spectrometer and source detector optode configuration.
3.4 Frequency Domain Spectroscopy
In order to calculate absolute concentrations of chromophore concentrations it 
is necessary to calculate values for pst. One technique through which this can 
be achieved is frequency domain spectroscopy (FDS). This entails using a light 
source with the intensity modulated at high frequency. The frequency domain 
NIRS system we are currently using produces light at 4 wavelengths (690, 750, 
790, 850 nm) intensity modulated at 110 MHz allowing detection of the average 
value (dc), amplitude (ac) and phase (O) of the detected light at two source 
detector separations (figure 3.9) (ISS, Inc., Champaign, IL). Following the work
Source Optode Probe Holder
Detector Optode
Connecting Optic Fibres
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of Fantini et al [22,23] if r is the detector source separation, Sac is the slope of In 
(i^ac) as a function of r and S<j> is the slope of cp as a function of r, then it has 
been shown for a semi-infinite medium, that the diffusion approximation yields:
Ms =
Mst =
0)
2v
V
’ac
Q 2  _ Q  ^^ac j)
Eqn 3.20 
Eqn 3.21
3 He Ma
where cj = the angular modulation frequency of the light source and v = the speed of 
light in the tissue.
The conditions under which these equations are valid (pa «  Pst, u ) /2 tt «  vpst) 
are well satisfied by most biological tissues in the NIR for modulation 
frequencies up to 1 GHz.
FDS also allows the continuous measurement of DPF. In the semi-infinite 
geometry it can be shown that if pa0 is the absorption coefficient at time 0  and 
A p a/p ao « 1  then:
DPF =
2-yjMaO Mst ) ■*" 1 Eqn 3.22
sam ple
ac
dc I dc I
Figure 3.9: FDS demonstrating changes in dc intensity (dc I), ac intensity (ac I) and 
phase (O) when intensity modulated light passes across tissue.
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3.5 Calculation of Optical Pathlength
The main NIRS techniques which exist for the calculation of optical pathlength 
are FDS, time resolved spectroscopy (TRS) and 2nd differential spectroscopy. 
The FDS technique has proved to be easily applicable to clinical situations and 
has been used to measure DPF in both neonates and adult volunteers[4,5]. The 
results suggest an effect of age on DPF with the relationship:
DPFjqq = 5.13 + 0 .0 7  ■ y0,81 Eqn 3 23
DPF78o = DPF at 780 nm and Y is the age of the subject in years.
3.5.1 TRS
Using TRS, a tunable laser is used to send an ultrashort picosecond laser pulse 
across the tissue sample. A streak camera then detects the transmitted light 
pulse and thus measures the time of flight of the light across the tissue (figure 
3.10). If t is the mean time taken for the light to cross the tissue then the DPF 
can be calculated from:
D P F Eqn 3 24 
d n
c= the speed of light in a vacuum, d is the refractive index of tissue and d is the 
interoptode spacing.
The equipment required for this technique requires a laser capable of delivering 
pico second light pulses and tends to be confined to optical laboratories, but 
measurements have been made on both animals and humans[2,24-26].
sample reference pulse
Area=l
time=t
Figure 3.10: Time domain spectroscopy.
95
3.5.2 2nd Differential Spectroscopy
We have already noted that the water absorption spectrum has several weak 
features in the NIR (figure 3.3). The water content of tissue is known with 
reasonable accuracy[7], and therefore if we could calculate the apparent water 
concentration from the amplitude of the spectral features and divide it by the 
known water concentration we would obtain an estimate of the optical 
pathlength[6 ]. Mathematically from equations 3.7 and 3.8:
A H o  Eqn 3 2 5
d.DPF  = -------^ -----
£ h 2o  c h 2o
AH2o = the attenuation attributable to water, eH2o and cH2o = the specific extinction 
coefficient and assumed concentration of water respectively.
When illuminating tissue this calculation is not trivial: measurement of the 
amplitude of the water feature is complicated by the presence of an arbitrary dc 
baseline, relating to scattering losses and the absolute photometry of the 
system, and the wavelength dependence of these scattering losses. However, 
the wavelength dependence of scatter is approximately linear in the NIR. Thus if 
we take a second differential of the attenuation spectrum with respect to 
wavelength, and perform a least squares fit with the corresponding second 
differential spectra of relevant tissue chromophores including water, we can 
determine the amplitude of the tissue water feature relative to the amplitude of 
the pure water reference irrespective of any dc or linear background [6 ,1 1 ].
In order for this technique to be of use the second differential NIR absorption 
spectrum of water must be sufficiently featured so as to constrain the fitting 
procedure and suitable features exist at 710-760 nm and 820 nm (figure 3.11). 
This technique has been validated in wfro[6 ] and has been used in vivo to 
measure DPF in animals and humans[11,27-30].
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Figure 3.11: Second differential spectra of 20 pM HHb, 40 pM Hb02 (which are an 
approximation to their in vivo concentrations) and 100% H20  (taken from [6]).
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Chapter 4
Response of cerebral tissue oxygenation index to changes in inspired 
concentrations of oxygen and end tidal carbon dioxide tension in healthy 
adult volunteers
This chapter describes an experimental study using NIRS to measure changes 
in TOI and CBV in the brains of healthy adult volunteers during alterations in the 
composition of inspired gases. Specifically a two channel NIRO 300 
spectrometer is used to measure TOI, A[Hb0 2 ] and A[HHb] using SRS and the 
MBLL. The physiological challenges consist of isocapnoeic hypoxia and 
hyperoxia, and normoxic hypocapnoea and hypercapnoea. Responses to these 
four challenges are described individually and the results are then combined in 
order to relate changes in TOI to changes in Sa0 2 , EtC0 2 , CBV, CBF, HR and 
MBP.
4.1 Introduction
TOI provides a measure of tissue oxyhaemoglobin saturation and has been 
discussed in chapter 3. Measurement of TOI using the NIRO 300 has been 
studied using tissue phantoms filled with intralipid, water and human blood 
during studies where the oxygenation is varied using yeast and oxygen bubbling 
and has been found to correlate well with co-oximeter analysis of the phantom 
contents[1]. NIRO 300 measurement of TOI also correlates well with TRS 
measurement of tissue oxygen saturation in the human arm during arterial and 
venous occlusion[1]. The development of TOI has been motivated, in part, by 
the desire to provide clinicians with an easily accessible measure of the balance 
of tissue oxygen delivery and utilisation and hence the adequacy of tissue 
oxygen delivery. Cerebral TOI has been evaluated during selective internal and 
external carotid artery clamping and shows high sensitivity and specificity to 
intracranial changes[2]. Cerebral TOI appears less affected by changes in the 
extracranial vasculature than NIRS measurements made using the MBLL. 
However the interpretation of clinical TOI data remains complex. TOI 
measurement has been compared to jugular venous oximetry in both adults[3,4] 
and children[5] and has shown considerable variation in terms of baseline
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values and the rate and magnitude of recorded changes. A recent study by 
Rasmussen et al estimated capillary oxyhaemoglobin saturation as a mean of 
arterial and jugular bulb oxyhaemoglobin saturation and compared this derived 
value with TOI changes in Fi0 2  and FiC0 2 . They demonstrated a correlation 
between the two measures, but the comparison between TOI and the modelled 
capillary saturation showed wide variation[6 ] and this variation may limit the use 
of absolute TOI values to define ischaemic thresholds or guide targeted therapy 
in the clinical environment.
There may be several reasons for these findings. Comparisons between TOI 
and jugular venous oximetry are hindered by technical issues relating to the 
regions interrogated: jugular oximetry provides a flow weighted global measure 
of the adequacy of cerebral oxygen delivery and is therefore insensitive to 
regional heterogeneity, whereas NIRS is a regional technique. There are also 
methodological issues specific to NIRS: cranial NIRS interrogates a multi- 
compartmental system of arteries, arterioles, capillaries, venules and veins and 
each compartment has different volumes and oxyhaemoglobin saturations: 
conversely the theory behind SRS is based on a the interrogated medium being 
flat and homogenous. The typical cerebral arteriakvenous volume ratio is 1:3[7] 
(25% arterial and 75% venous) yet this will depend on individual anatomy, local 
physiology and/or the presence of disease[8 ]. It is intuitively obvious that 
baseline arteriakvenous volume ratio (AVR) will affect baseline TOI and 
furthermore that changes in AVR will cause changes in TOI.
By derivation from equation 3.13 it can be shown theoretically that:
TOI = Sa02 - ( v  }Vv f  c m r o 2 )
W a + V v ) k.CBF.[Hb\)
x i o o  Eqn 4 -1
Sa02 = arterial oxyhaemoglobin saturation, Vv and Va = venous and arterial blood 
volume respectively, CMR02 = cerebral metabolic rate for oxygen, k = oxygen carrying 
ability of haemoglobin, CBF = cerebral blood flow and [Hb] = blood haemoglobin 
concentration.
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This equation helpfully demonstrates the factors which might affect cerebral TOI 
measurements. Most of these factors will affect either cerebral oxygen delivery 
or utilisation and one would therefore expect TOI to be sensitive to the balance 
between these two and hence reflect the adequacy of cerebral oxygen delivery. 
AVR however will have no direct effect (if one ignores the indirect effects on 
vascular resistance and hence CBF) on either oxygen delivery or utilisation and 
yet from equation 4.1 one would expect it to affect TOI. Changes in AVR might 
therefore induce changes which precipitate erroneous interpretation of TOI 
data. Baseline variability in absolute TOI might be addressed by using change 
in TOI as a measure of change in the adequacy of oxygen delivery, but this 
might also be confounded by changes in AVR.
CBF responses to changes in PaC02 and Pa02 are well documented and are 
mediated by changes in the calibre of arterioles[9] (figure 4.1). Ito et al used 
PET to investigate CBV changes in the various cerebral vascular compartments 
during hypo- and hypercapnoea[10]. They observed increases in arterial CBV 
during hypercapnoea and decreases during hypocapnoea yet found no 
associated changes in capillary or venous volume and concluded that changes 
in CBV during hypo and hypercapnoea are caused only by changes in arterial 
blood volume. Changes in PaC02 and, by extension, Pa02 will therefore induce 
changes in cerebral AVR and we can use these paradigms to investigate the 
importance of changes in AVR on TOI.
Figure 4.1: Cerebral blood flow response to changes arterial carbon dioxide and 
oxygen tension (taken from [9]).
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In this study we use alterations in Fi0 2  and EtC0 2  (a surrogate of PaC0 2 ) to 
induce changes in cerebral oxygen delivery, CBF and CBV and investigate the 
resulting TOI response. We use TCD to measure mean blood flow velocity in 
the basal middle cerebral artery (VMCA) and use this as a surrogate measure 
of CBF. This technique relies on there being no change in the diameter of the 
insonated vessel and no change in the insonation angle. MRI studies suggest 
that basal middle cerebral arterial diameter does not change during the types of 
challenge described in this study[1 1 ] and the use of a head fixation system 
ensures a stable insonation angle. Experimental studies have shown that 
changes in VMCA correlate reliably with 133Xenon measured changes in 
CBF[12]. Additionally we calculate changes in CBV from the MBLL NIRS data in 
order to assess its effect on TOI.
4.2 Methods
This study was approved by the Joint Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery and the Institute of 
Neurology. We studied 15 healthy subjects (5 female and 10 male) with median 
age 31 years (range 27-39).
4.2.1 Instrumentation
The source-detector optode pair for each channel of the NIRO 300 was placed 
in a black plastic holder with a source-detector separation of 5cm. One channel 
was fixed to the right hand side of the forehead and the other to the left hand 
side of the forehead in the midpupillary line with the channel laterality allocated 
randomly. Within each pair the source fibres were positioned medially and the 
detector optodes laterally in order to minimise the transmission of light from the 
channel 1 source to the channel 2 detector and vice versa. A bandage and a 
light absorbing cloth were placed over the optode holders to eliminate stray light 
and prevent optode movement. SRS and MBBL data was collected at 6  Hz.
A modified oximeter probe (Novametrix Medical Systems Inc., Wallingford, CT, 
USA) measured beat-to-beat Sa0 2 , and a Portapres finger cuff (Biomedical 
Instrumentation, TNO Institute of Applied Physics, Belgium) measured MBP and 
HR non-invasively. VMCA was collected at 50 Hz using a 2 MHz transcranial
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Doppler ultrasonography (Pioneer TC2020, Nicolet, UK) fixed in place over the 
right temporal region. A modified anesthetic machine delivered gas to the 
subject via a Mapelson E breathing system connected to a mouthpiece with the 
expiratory limb having length 50 cm (figure 4.2). FiC>2 and EtC02 were 
measured using an inline gas analyser (Hewlett Packard, UK) and a C0 2 SM0 
optical sensor (Novametrix Medical Systems Inc.) respectively. The monitoring 
configuration is shown in figure 4.3.
Fresh . 50cm .
Gas  1 |-------------------
Flow ' '
Mouthpiece
Figure 4.2: Mapelson E breathing system.
PC 1
T
Systemic
Monitoring
Systemic
Monitoring
NIRO
Transcranial
Doppler
Figure 4.3: Monitoring configuration showing positioning of two channel NIRO 300 
NIRS system and TCD.
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4.2.2 Study Protocol
The study was divided into four sections with a rest period between each. Each 
challenge period was preceded by five minutes data collection at normoxia and 
normocapnea.
4.2.2.1 Hypoxaemia
Nitrogen was added to the inspired gases, to induce a gradual fall in Sa0 2  to 
80%, and immediately after this was achieved, the Fi0 2  was returned to 
normoxia for five minutes. This cycle was repeated three times. EtC0 2  was 
continuously fed back to subjects and they adjusted their minute ventilation to 
maintain normocapnea throughout the study.
4.2.2.2 Hyperoxia
Fi0 2  was increased to 1 0 0 % for five minutes and then returned to normoxia for 
five minutes. Similar to the hypoxaemia phase of the study, the cycle was 
repeated three times and the subjects adjusted their minute ventilation to 
maintain normocapnea throughout the study.
4.2.2.3 Hyperventilation
The subjects hyperventilated and aimed to reduce their EtC0 2  by 1.5 kPa. They 
maintained a stable EtC0 2  at this reduced level for five minutes and then 
returned to a normal ventilatory rate allowing EtC02 to return to baseline values 
over approximately five minutes.
4.2.2.4 Hypercapnoea
Approximately 6 % CO2 was added to the inspired gases and was titrated to 
induce an increase in EtC0 2  of 1 .5 kPa. The elevated EtCC>2 was maintained for 
ten minutes and the inspired carbon dioxide fraction was then returned to zero 
for a further five minutes. At the end of the study a venous blood sample was 
obtained and the haemoglobin concentration was measured immediately using 
a blood gas analyser (ABL 700, Radiometer Copenhagen, Denmark).
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4.2.3 Data Analysis
Absolute A[Hb0 2 ] and A[HHb] for each channel were calculated from changes 
in light attenuation using the UCL4 algorithm assuming a DPF of 6.26[13]. 
Change in total hemoglobin concentration (A[HbT]) was defined as 
A[Hb02]+A[HHb]. VMCA was calculated from the CBF velocity envelope using a 
trapezoidal integration function (MatLab, Mathworks Inc., USA).
The start and end of each period of hypoxaemia, hyperoxia or C02 manipulation 
was identified from the Sa02 data, the Fi02 data or the EtC02 data respectively. 
To enable comparison between subjects and across paradigms, within each 
individual period of alteration of Fi02 or EtC02 (the challenge period) eight time 
points were selected so that the period between adjacent points represented an 
eighth of the total time course of the challenge period. This produced nine time 
points with point 1 representing the point just prior to the start, and point 9 the 
end of the challenge period. The same technique was applied separately to the 
recovery period, producing points 9 (just prior to start of recovery) to 17 (end of 
recovery period). At each time point, the mean of the preceding ten seconds of 
data was calculated (figure 4.4). For the hypoxaemia and hyperoxia challenges, 
data from the three experimental cycles were averaged to give a single course 
for each subject and, for each of the paradigms, a mean of the two NIRS 
channels was calculated. Group median changes from baseline at each time 
point were produced.
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data window
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Figure 4.4: Schematic of data analysis for hypoxaemia paradigms using Sa02 data to 
define data windows for summary analysis.
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Changes in CBV were calculated using the formula:
ACBV = A[HbT] MWHbx 100 Eqn 4.2
[Hb]CSLVH ■ pBrain
ACBV = change in cerebral blood volume (ml/100g of brain), A[HbT] =change in total 
haemoglobin concentration (mol/l), M W Hb = molecular weight of haemoglobin (64 500 
g/mole), [Hb] = the large vessel haemoglobin concentration (g/l), CSLVH = the cerebral 
small vessel to large systemic vessel haematocrit[14] and p = the brain density (1.05 
g/ml)[15].
Statistical analysis was carried out using SAS software (v9.1, SAS Institute, 
USA). Percentage changes from baseline for VMCA, and absolute changes 
from baseline for other measured variables were compared using non- 
parametric analysis of variance (ANOVA) with post hoc pairwise 
comparisons[16] and p values less than 0.05 were considered significant.
Multiple regression analysis was carried out using ATOI as the dependent 
variable and changes in other systemic variables as regression variables. 
Regression variables which were not significant were then removed and the 
regression analysis repeated.
4.3 Results
4.3.1 Hypoxaemia
Baseline values for measured variables are shown in table 4.1. There was no 
significant difference between the baseline TOI measured on the left and right 
sides of the forehead (p=0.49). All subjects reached an Sa0 2  of 80% at the 
nadir of each cycle of the hypoxaemia. The median time of hypoxia required to 
achieve arterial oxygen saturation of 80% was 4.5 minutes (interquartile range 
3.9 -5.9 minutes) and the length of each recovery period was fixed at 5 minutes 
for all subjects.
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Median IQR
Fi02 (%) 2 1 . 0 2 1 . 0  to 2 1 . 0
S a02 (%) 99.2 98.2 to 99.2
EtC02 (kPa) 5.4 5.2 to 5.7
HR (m in1) 62.5 60.0 to 71.5
MBP (mmHg) 77.6 70.3 to 8 8 . 8
VMCA (cms'1) 43.2 37.9 to 51.1
Hb (g/l) 147 137.5 to 149.5
TOI R (%) 68.3 65.2 to 71.9
TOI L (%) 67.4 65.9 to 69.2
TOI R- TOI L (%) 0.5 -2.2 to 2.3
Table 4.1: Median and interquartile range for baseline values of measured variables 
prior to the start of hypoxaemia (n=15). TOI R is TOI measured over the right side of 
the forehead, TOI L is TOI measured over the left side of the forehead and TOI R-TOI 
L is the difference in TOI between the two sides.
Data from the hypoxaemic protocol for a single subject is shown in figure 4.5 in 
order to demonstrate the experimental time course. Group data showing 
median and interquartile range for measured variable values is shown in figure 
4.6.
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Figure 4.5: Data for individual subject during three cycles of hypoxaemia.
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Figure 4.6: Median and interquartile range (n=15) for variable values during 
hypoxaemia ( *  p<0.05, t  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
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Hypoxaemia Recovery
Median IQR Median IQR
F i02 (%) 9.3§ 6.7 to 11.3 2 1 . 0 2 1 . 0  to 2 1 . 0
A Sa02 (%) -15.8§ -18.4 to -14.1 0 . 0 -0.3 to 0.0
AEtC02 (kPa) -0 .2 § -0.4 to -0.1 0 . 0 0 . 0  to 0 . 1
AHR (m in1) 15.2§ 1 0 . 0  to 16.6 -1.5 -2 . 6  to 1 . 2
AMBP (mmHg) 0 . 2 -0.5 to 1.3 2 .6 * -2 . 6  to 1 . 2
AvMCA (%) 7.9§ 4.8 to 13.4 1.3 -1.4 to 4.8
ACBV (ml/100g) 0.08§ 0.07 to 0.13 0 . 0 2 0.01 to 0.04
ATOI (%) -7.6§ -9.4 to -6.2 -0.3* -0.7 to -0.2
Table 4.2: Median and interquartile range (IQR) (n=15) for changes from baseline to 
nadir of hypoxaemia, and end of recovery period for measured variable values 
( f  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
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4.3.2 Hyperoxia
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Figure 4.7: Median and interquartile range (n=15) for variable values during hyperoxia 
( *  p<0.05, f  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
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Hyperoxia Recovery
Median IQR Median IQR
F i02 (%) 72.4§ 69.0 to 76.8 2 1 . 0 2 1 . 0  to 2 1 . 0
ASa02 (%) 0.7s 0.5 to 0.9 0 . 0 -0 . 1  to 0 . 1
AEtC02 (kPa) -0.3§ -0.4 to -0.1 -0 . 1 -0 . 2  to 0 . 0
AHR (min*1) -3.3§ -5.8 to -0.6 0 . 0 -0.9 to 1.8
AMBP (mmHg) 2.4* 0.5 to 4.0 2.7* 0.6 to 4.7
AvMCA (%) -7.3+ -10.5 to -0.8 -0 .6 * -2.3 to 2.1
ACBV (ml/100g) -0.06§ -0.06 to -0.03 -0 . 0 2 -0.02 to 0.04
ATOI (%) 2 .0 s 1.9 to 2.6 0.3 -0.2 to 0.5
Table 4.3: Median and interquartile range (IQR) (n=15) for changes from baseline to 
end of hyperoxia, and end of recovery period for measured variable values 
( *  p<0.05, f  p<0.01, § p<0.0001 for change from baseline).
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4.3.3 Hyperventilation
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Figure 4.8: Median and interquartile range (n=15) for variable values during 
hyperventilation ( *  p<0.05, t  P<0.01, $ p<0.001, § p<0.0001 for change from 
baseline).
115
Hyperventilation Recovery
Median IQR Median IQR
F i02 (%) 2 1 . 0 2 1 . 0  to 2 1 . 0 2 1 . 0 2 1 . 0  to 2 1 . 0
ASaOz (%) 0.3§ 0.0 to 0.9 -0.5 -1.9 to 0.2
AEtC02 (kPa) -1.5§ -1.7 to -1.4 0 . 0 -0 . 2  to 0 . 0
AHR (min*1) 3.9 -1.9 to 6.2 -0.4 -5.2 to 1.6
AMBP (mmHg) -3.9 -7.0 to 5.6 -5.6 -4.0 to 11.0
AvMCA (%) -32.1§ -34.1 to -24.0 5.2 0.3 to 11.2
ACBV (ml/1 OOg) -0.16§ -0.20 to -0.09 -0.05 -0.08 to -0 . 0 2
ATOI (%) -2.4§ -3.6 to -1.7 -1.5 -2 . 1  to -0 . 8
Table 4.4: Median and interquartile range (IQR) (n=15) for changes from baseline to 
end of hyperventilation, and end of recovery period for measured variable values 
(§ p<0.0001 for change from baseline).
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4.3.4 Hypercapnoea
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Figure 4.9: Median and interquartile range (n=15) for variable values during 
hypercapnoea ( *  p<0.05, f  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
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Hypercapnoea Recovery
Median IQR Median IQR
F i02 (%) 21.0 21.0 to 21.0 21.0 21.0 to 21.0
ASa02(%) 0.7* 0.2 to 1.7 0.5* 0.0 to 1.3
AEtC02 (kPa) 1.7§ 1.5 to 1.9 0.0 -0.2 to 0.1
AHR (m in1) 0.3 -1.6 to 2.1 -0.5 -3.8 to 0.6
AMBP (mmHg) 3.6 -5.9 to 9.2 -0.2 -7.0 to 9.2
AvMCA (%) 4.9* -1.8 to 27.7 -11.5§ -14.9 to -3.0
ACBV (ml/100g) 0.09* 0.04 to 0.10 0.05* -0.02 to 0.11
ATOI (%) 2.6§ 2.0 to 3.2 1.0+ 0.6 to 2.2
Table 4.5: Median and interquartile range (IQR) (n=15) for changes from baseline to 
end of hypercapnoea, and end of recovery period for measured variable values 
( *  p<0.05, f  p<0.01, $ p<0.001, § p<0.0001 for change from baseline).
4.3.5 Combined Analysis
Multiple regression was initially carried out using ATOI as the independent 
variable and the other systemic variables as the regression variables.
The significant variables were ASa02 (p<0.0001), AEtC02 (p<0.0001), ACBV 
(p=0.0003) and AMBP (p=0.03), whereas AVMCA (p=0.7) and AHR (p=0.2) 
were not significant factors.
The regression analysis was repeated using only the significant regression 
variables to determine the regression beta values.
The regression analysis revealed:
A TOI = 0.53 x ASa02 +1.13 x A EtC02 + 2.35 x ACBV + 0.01 x AMBP
Eqn 4.3
with overall adjusted rvalue 0.82 (p<0.0001).
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The standardised beta coefficients, p values and variance inflation factors for 
each variable are shown in table 4.6.
Variable ASa02 AEtC02 ACBV AMBP
standard p 0.71 0.37 0.09 0.04
p value <0.0001 <0.0001 0.0005 0.03
VIF 1.1 1.7 1.9 1.1
Table 4.6: Standardised regression estimates (standard (3), p values and variance 
inflation factors (VIF) for multiple regression analysis variables shown in equation 4.3.
4.4 Discussion
In this study four paradigms were used in order to measure the response of TOI 
to changes in cerebral oxygen delivery. Hypoxaemia and hyperoxia were used 
to alter arterial oxygen content and changes in arterial C02 tension were used 
to alter cerebral blood flow. TOI increased significantly in response to hyperoxia 
and hypercapnoea and significantly decreased in response to hypoxaemia and 
hyperventilation. PET studies suggest that changes in CBV occurring during 
experimental protocols of this type only occur in the arterial compartment[10] 
and will therefore alter the AVR. Analysis of the combined datasets revealed 
that changes in TOI are significantly affected by changes in Sa02, EtC02, CBV 
and MBP. However analysis of the standardised beta estimates of the multiple 
regression analysis indicated that changes in Sa02 and EtC02 are far stronger 
predictors of ATOI whereas the other two variables are only weak predictors. 
We can therefore conclude that the confounding affect of CBV changes on 
ATOI is minimal and that ATOI has the potential to provide a clinically useful 
marker of changes in the balance of cerebral oxygen delivery and utilisation.
Table 4.1 shows a large variation in baseline TOI values across this group of 
healthy volunteers: the IQR for baseline TOI recorded over the right frontal lobe 
was 6.7%. The magnitude of this interindividual variation will limit the clinical
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usefulness of absolute TOI: the IQR of the absolute right sided TOI is similar in 
magnitude to the median ATOI of 7.6% recorded during hypoxaemia to Sa02 of 
80% and only half the ATOI value of 13% which has recently been suggested 
as a threshold for cerebral ischaemia[17].
As one would expect there was no significant difference in TOI between the 
right and left sided measurements, with a median difference of 0.5%, and 
similarly the median values for left and right sided baseline TOI were similar 
(67.4 vs. 68.3) yet the interquartile range of 4.5% demonstrates the degree of 
intra-individual variation. This is particularly important when assessing the use 
of SRS as a clinical monitor with the aim of being able to make clinical 
inferences about a single individual and again suggests that this variation may 
limit the use of absolute TOI as a clinical monitoring tool. Several investigators 
have compared cerebral oxygenation measured using SRS, with jugular venous 
oximetry in children and adults in healthy and pathological states. The 
predominant finding is one of strong individual correlations but less marked 
group correlations between the two measures[4,18-21]. This may be explained 
to some extent by the baseline variation. Each section of the results will now be 
discussed individually.
4.4.1 Hypoxaemia
This protocol was successful in desaturating all subjects to an Sa02 of 80%. 
There was a significant increase in heart rate and minimal change in MBP 
during the study in agreement with previous investigations[22]. An EtC02 
feedback loop was used to minimise changes in EtC02. Despite this, a small 
but significant median reduction in EtC02 of 0.2 kPa was found at the nadir of 
hypoxemia due to the hypoxaemic stimulus to hyperventilate. The multiple 
regression analysis suggests that this magnitude of AEtC02 would induce a 
ATOI o f-0.2%.
The threshold for hypoxaemic vasodilatation in healthy volunteers has been 
investigated using NIRS and TCD and has been reported to be in the region of 
an Sa02 of 90%[22]. We also show an increase in VMCA and CBV during
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hypoxaemia and this was associated with a median decrease in TOI of 7.6%. 
Al-Rawi et al attempted to define the ATOI associated with cerebral ischaemia 
by studying patients undergoing carotid artery clamping during surgery. They 
used EEG to define the presence of ischaemia and no patients with a 
ATOM 3% met their ischaemic criteria. The paradigm used here is therefore 
unlikely to be causing EEG changes in our study cohort.
4.3.2 Hyperoxia
During the hyperoxic phase of the study, the Fi02 at the anaesthetic machine 
was increased to 100% with a FGF of 8l/min. This FGF is less than the peak 
inspiratory flow of a healthy subject and with the Mapelson E system employed 
there will be a degree of mixing between the FGF and room air entrained via the 
expiratory limb. The Fi02 presented in these results is measured at the mouth 
and due to this gaseous mixing the median Fi02 attained during hyperoxia was 
72.4%.
A significant reduction in HR was observed and similar findings have been 
found in the conscious dog[23]. A significant decrease in EtC02 of 0.3 kPa was 
observed and this occurred despite subjects attempting to maintain isocapnoea. 
This is most likely to be related to the Haldane effect which describes how 
increasing oxyhaemoglobin saturation decreases the affinity of haemoglobin for 
carbon dioxide[24,25]. This would reduce carbon dioxide uptake from tissue and 
might therefore translate to a reduction in PaC02 and hence EtC02. It has also 
been suggested that Haldane effect mediated carbon dioxide retention in the 
respiratory centres of the brain might induce a hyperventilatory response[26].
We demonstrate a reduction in VMCA and CBV in response to hyperoxia. This 
may be in part due to the reduction in arterial carbon dioxide tension however 
arterial-spin-labelled MRI investigations suggest that normobaric hyperoxia has 
a direct vasoconstrictive effect as well as an indirect effect mediated via the 
reduced PaC02[26].
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Despite this reduction in CBV and VMCA which might tend to reduce TOI, we 
show an increase in TOI which is of a greater magnitude (median 2.0%) than 
the increase in Sa02 (median 0.7%). This implies that the increase in dissolved 
blood oxygen is contributing to the increase in TOI. An important corollary of 
this finding is that, assuming a constant cerebral metabolic rate for oxygen, our 
data suggest that the combined effect of the increased arterial oxygen content 
and reduced cerebral blood flow is an overall increase in cerebral oxygen 
delivery.
4.3.3 Hyperventilation
During the hyperventilation phase of the study a median reduction in EtC02 of
1.5 kPa was achieved with an interquartile range of 0.3 kPa indicating that the 
experimental challenge was well controlled. Hyperventilation was associated 
with an increase in Sa02 and HR reflecting the increased physical work 
involved. The reduction in PaC02 caused a reduction in CBV, presumably 
related to arteriolar vasoconstriction, and a reduction in VMCA was also 
observed. These findings are in agreement with many studies investigating 
cerebrovascular responses to changes in arterial C02 tension[27-29].
It is interesting to note that the CBV and VMCA responses have different 
timescales. VMCA returns to baseline during the recovery period whereas the 
CBV returns towards but does not reach baseline by the end of the study. This 
suggests that the autoregulatory processes which attempt to maintain a stable 
CBF entail further mechanisms beyond changes in arteriolar calibre. TOI 
reduced during hyperventilation despite the small increase in Sa02 suggesting 
that the effect of the arteriolar vasoconstriction and hence reduction in arterial 
volume and CBF is the predominant driver of TOI during this paradigm.
4.3.4 Hypercapnoea
During the hypercapnoea phase of the study a median increase in EtC02 of 1.7 
kPa was recorded. This was associated with an increase in Sa02 which is likely 
to be caused by hyperventilation induced by the increase in PaC02. During the 
early part of the hypercapnoeic phase there was an increase in VMCA, however 
this returned towards baseline before the end of the hypercapnoeic period,
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again demonstrating that further autoregulatory mechanism are occurring. CBV 
increased during hypercapnoea and returned towards but did not reach 
baseline values during the recovery period. TOI increased during hypercapnoea 
and the time course of the response suggests that this effect is related more 
closely to the increase in CBV rather than the increase in VMCA. Similar to the 
CBV response TOI returned towards but did not reach baseline values by the 
end of the recovery period. A similar increase in Pbr02 in response to 
hypercapnoea which outlasts the CO2 changes has been demonstrated in a rat 
model[30].
4.3.5 Combined Analysis
The multiple regression analysis revealed the factors which significantly affect 
ATOI. From equation 4.3 and assuming constant CMR02 and intravascular 
haemoglobin concentration, one would expect ATOI to be affected by changes 
in Sa02, CBF and CBV. We find that changes in Sa02 and CBV are significant 
factors, yet change in VMCA is not. The dominant factor likely to cause change 
in VMCA is change EtC02 and the multiple regression results describe the 
significance of various factors while controlling for the effects of all the other 
regression variables. These results indicate that changes in EtC02 can account 
for the changes in VMCA and this leads to changes in VMCA not being a 
significant factor in the prediction of ATOI. This is confirmed by running the 
regression analysis with changes in EtC0 2  omitted, in which case changes in 
VMCA becomes a significant factor (analysis not shown). Change in MBP is 
also a significant regression variable but changes in HR is not. The y intercept 
produced by our regression analysis was not significantly different from zero 
and so can be ignored.
The standardised beta values demonstrate the relative importance of each of 
the significant regression variables. Change in Sa02 is the most important 
factor with a standardised beta value of 0.71 and change in EtC02 is the 
second most important factor. The remaining two factors, change in CBV and 
change in MBP have standardised beta values an order of magnitude lower and 
therefore, although they are significant factors they have relatively little effect on
123
the magnitude of ATOI. The variable inflation factors (VIF) demonstrate the 
degree of colinearity between the regression variables and a value of >10 is 
usually considered unacceptable. In this analysis all the VIF are <2.
For ATOI to be clinically useful it should represent changes in the balance of 
cerebral oxygen delivery and utilisation. Change in arterial CBV has no direct 
effect on cerebral oxygen delivery or utilisation and yet it has a small but 
significant effect on ATOI. It is possible to use the results from our multiple 
regression analysis to derive a modification to TOI (TOIm) which is insensitive 
to changes in cerebral blood volume by simply subtracting a factor of ACBV 
scaled by the regression constant. Based on the data presented here this would 
result in equation 4.4.
ATOIm = ATOI -  2.35 x A CBV Eqn 4.4
This modification merits further evaluation in clinical studies to assess if it has 
greater sensitivity and specificity to changes in the adequacy of cerebral oxygen 
delivery than ATOI. Clearly however our data from healthy volunteers may not 
reflect the cerebrovascular responses in disease states and clinical studies are 
required.
Multiple linear regression is one of many ways in which it is possible to model 
the relationship between TOI and the variables recorded during this study. 
Whilst the overall adjusted r value 0.82 (p<0.0001) suggests that the linear 
model fits the data with reasonable accuracy, there may be other models which 
provide better fits. One potential source of error relates to the measurement of 
TOI. The multiple linear regression model assumes no error in the TOI 
measurement and this assumption may not be valid. Regression techniques 
exist which are able to account for errors in the dependent variable. These 
techniques, which are known as errors-in-variables, or major axis, regression, 
are based on minimising the orthogonal distance between the data points and 
the regression line. This can be contrasted with standard linear regression 
which minimises the distance along the y axis between the data points and the
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regression line. Employing these techniques in the context of multiple 
independent variables is complex and will not be discussed further.
This study could be improved by direct measurement of Pa02 and PaC02, 
however this would entail the placement of invasive arterial catheters into 
healthy volunteers with its attendant risks. We have therefore used Sa02 as a 
measure of arterial oxygen content, which therefore does not account for 
arterial oxygen carriage in solution and EtC02 as a surrogate for PaC02. The 
quantity of dissolved oxygen is likely to be negligible under conditions of 
normoxia and hypoxia, but it may become significant during the hyperoxic 
phase of the study and this might lead to errors in our regression results. 
Conversely change in EtC02 is an accurate surrogate of change in PaC02 and 
is therefore unlikely to affect our results[31].
4.5 Conclusion
Absolute TOI shows considerable variability in healthy volunteers and this may 
limit its clinical usefulness as an absolute measure of the adequacy of oxygen 
delivery. ATOI also has theoretical limitations as one would expect it to be 
sensitive to arterial CBV changes which do not directly affect cerebral 
oxygenation or utilisation. We confirm the influence of changes in CBV on ATOI 
in healthy volunteers, yet multiple regression analysis suggests that the effects 
of ACBV and AMBP are small and that the predominant factors affecting ATOI 
are changes in Sa02 and AEtC02. One would also expect ATOI to be sensitive 
to changes in CMR02 but this study protocol does not allow for altering CMR02 
and it is hard to envisage a protocol able to achieve this in healthy volunteers. 
ATOI may therefore be clinically useful as a monitor of trends in the balance 
between cerebral oxygen delivery and utilisation. Clinical studies are required in 
order to establish the magnitude of ATOI associated with inadequate cerebral 
oxygen delivery. Studies are required in patients groups at risk of cerebral 
ischaemia such as those suffering from TBI, subarachnoid haemorrhage or 
undergoing complex cardiac surgery. In particular useful comparisons could be 
made between ATOI and invasive cerebral monitors such as cerebral
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microdialysis and brain tissue oxygen tension in the context of TBI. The 
comparison between ATOI and EEG changes also shows particular promise. 
Ultimately large well controlled studies will be required to determine whether the 
use of TOI trend monitoring in patient groups at high risk of cerebral ischaemic 
events can lead to improved clinical outcomes.
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Chapter 5
Changes in cerebral mitochondrial redox state during alterations in 
inspired oxygen fraction and end tidal carbon dioxide tension in healthy 
adult volunteers.
This chapter describes an experimental study using BBS to measure changes 
in CCO redox state, and Hb02 and HHb concentrations in the brains of healthy 
adult volunteers during alterations in the composition of inspired gases. The 
physiological challenges are identical to those used in the studies in chapter 4. 
Additionally, a moderate graded hyperventilation study is used to investigate 
change in oxidised cytochrome c oxidase concentration in response to small 
changes in end tidal C02 tension such as those which occur coincidentally 
during our hypoxaemia protocol. The stability of the BBS system is investigated 
by conducting a five hour phantom study and measuring changes in attenuation 
over this time period.
5.1 Introduction
CCO is the terminal electron acceptor of the mitochondrial electron transfer 
chain and catalyses over 95% of oxygen metabolism, thereby driving ATP 
synthesis[1]. CCO redox state reflects the balance between electron donation 
from cytochrome c, and oxygen reduction to water. Although many factors can 
influence CCO redox state[2], the most significant is the availability of molecular 
oxygen[3].
In chapter 3 the spectroscopic features of the difference spectrum between 
oxidised and reduced CCO were discussed and the distinct feature at -830 nm 
which allows measurement A[oxCCO] using NIRS was noted [4,5]. Assuming 
the total concentration of CCO remains constant during an experiment then 
changes in the NIRS CCO signal represent changes in the CCO redox state.
The CCO signal therefore has the potential to provide a non-invasive marker of 
changes in mitochondrial oxygen delivery and utilisation, and might allow 
detection of ischaemic thresholds and guidance of subsequent clinical
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interventions. The potential to make non-invasive measurements of 
mitochondrial metabolism has proved an exciting prospect to biochemists, 
clinicians and physicists alike. NIRS modelling studies suggest that detection of 
the CCO signal is improved by using BBS, thus increasing the number of 
wavelengths at which NIR light intensity is measured and using a least squares 
regression technique to convert changes in NIR light attenuation to changes in 
chromophore concentrations^].
NIRS measured A[oxCCO] has been validated, in animals, as a marker of 
cellular energy status against magnetic resonance spectroscopy measured 
reduction in phosphocreatine and nucleoside triphosphate levels[7,8] 
suggesting that A[oxCCO] measurement may be able to provide clinically useful 
information at the bedside. Cerebral A[oxCCO] has been measured in humans 
in clinical situations associated with reduced cerebral oxygen delivery, namely 
cardiac surgery[9] and obstructive sleep apnea[10], but these studies are hard 
to standardise. Controversy remains regarding the relationship between 
A[oxCCO] and oxygen delivery and specifically the reduction in cerebral oxygen 
delivery required to produce A[oxCCO].
This study aims to quantify BBS measured cerebral A[oxCCO] during changes 
in arterial oxyhaemoglobin saturation and cerebral haemodynamics induced by 
changes in Fi02 and EtCC>2 in healthy human volunteers and examine its 
relationship to cerebral oxygen delivery and NIRS haemoglobin measurements.
5.2 Methods
This study was approved by the Joint Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery and the Institute of 
Neurology. We studied 8 healthy volunteers (7 male, 1 female, median age 31.5 
years, range 30-36). A second cohort of twelve subjects underwent an identical 
hypercapnoea protocol as part of a separate study but with identical 
instrumentation. For analysis of the hypercapnoea protocol these data sets 
were combined to give a final subject number of 20 (14 male, 4 female, median 
age 31 years, range 24-36).
131
A further 9 subjects underwent the moderate graded hyperventilation study (5 
male, 4 female, median age 29 years, range 27-31).
5.2.1 Instrumentation
The BBS utilises light from a stabilised tungsten halogen light source which is 
filtered with 610nm long-pass and heat absorbing filters, and transmitted to the 
tissue sample via a 3.3mm diameter glass optic fibre bundle. Light incident on 
the detector optode is then focused via an identical fibre bundle onto the 400 
pm entrance slit of a 0.27m spectrograph (270M, Instruments SA, France) with 
a 300g/mm grating. NIR spectra between 650 and 980 nm are collected at 1Hz 
on a cooled charge coupled device detector (Wright Instruments, UK) giving a 
spectral resolution of ~5nm.
Prior to the commencement of each study a reference spectrum was recorded 
onto the spectrometer by measuring absolute light intensity across a hollow box 
lined with light absorbing material. BBS optodes were then placed 3.5 cm apart 
in a black plastic holder, and fixed to the right side of the subject’s forehead in 
the midpupilary line. A modified pulse oximeter probe (Novametrix Medical 
Systems Inc., USA) measured Sa02, and a Portapres finger cuff (Biomedical 
Instrumentation, TNO Institute of Applied Physics, Belgium) measured MBP and 
HR non-invasively. Blood flow velocity in the basal right middle cerebral artery 
was collected at 50 Hz using 2 MHz transcranial Doppler ultrasonography 
(Pioneer TC2020, Nicolet, UK) fixed in place over the right temporal region. A 
modified anesthetic machine delivered gas to the subject via a Mapelson E 
breathing system connected to a mouthpiece with the expiratory limb having 
length 50 cm. Fi02 and EtC02 were measured using an inline gas analyser 
(Hewlett Packard, UK) and a CO2SMO optical sensor (Novametrix Medical 
Systems Inc.) respectively.
5.2.2 BBS Stability Protocol
The BBS optodes were placed on an epoxy phantom with optical properties 
similar to biological tissue, fixed firmly with an adhesive bandage and then 
covered with a light absorbing cloth. Intensity data were collected onto the BBS 
for a period of three hours. A study length of three hours was chosen because,
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although the studies in this chapter had a maximum duration of approximately 
40 minutes, the studies described in chapter 7 lasted approximately three 
hours.
5.2.3 Human Subject Study Protocols
Study protocols were identical to those described in section 4.2.2 and consisted 
of phases of hypoxaemia, hyperoxia, hyperventilation and hypercapnoea. When 
analysing the hypoxaemia and hyperoxia study data it became apparent that 
small changes in EtC02 were occurring despite our efforts to avoid them. In 
order to address this, an additional moderate graded hyperventilation study with 
a reduced set of measured variables consisting of Fi02, Sa02, EtC02 and BBS 
was carried out. The aim of this study was to determine the effect of the small 
changes in EtC02 we observed during the hypoxaemia and hyperoxia studies. 
This moderate hyperventilation study commenced with five minutes baseline 
monitoring at normoxia and normocapnoea. Subjects then hyperventilated and 
aimed to reduce their EtC02 by 0.1 kPa every minute for five minutes resulting 
in a final EtC02 0.5 kPa below baseline. They then returned to a normal 
ventilatory rate allowing EtC02 to return to baseline values over approximately 
five minutes.
5.2.4 Data Analysis
In order to assess the stability of the BBS system, five minute means of 
intensity data between 780 and 900 nm were calculated at the beginning and 
end of the three hour phantom test. Change in attenuation over the three hour 
period of study was then calculated using equation 3.4.
For the human subject study protocols, absolute A[oxCCO], A[Hb02] and 
A[HHb] were calculated from changes in light attenuation with a multiple 
regression technique termed the UCLn algorithm using 120 wavelengths 
between 780 and 900 nm[6]. This wavelength range has been suggested as 
optimal for measuring A[oxCCO] as it minimises absorption induced changes in 
light scattering during deoxygenation which might occur if the HHb absorbance 
peak between 740 and 780 nm were included in the spectral fit[11 ].
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Chromophore spectra used were those available on the UCL Medical Physics 
website[12] with correction factors for the wavelength dependence of the optical 
pathlength applied to the chromophore absorption coefficients[13].
Individual baseline optical pathlength (PL) was calculated using second 
differential analysis of the 740 nm water feature[14] of the initial 60 seconds of 
spectral data. NIR light attenuation due to the illuminated tissue was calculated 
using equation 3.4 with the reference spectrum assumed to be lo. The 
attenuation spectrum attained has an arbitrary dc baseline, but the second 
differential pathlength measurement is insensitive to this offset. For the 
pathlength calculation, the tissue water concentration was calculated as an 
average of skin, bone and cerebral grey matter water content[15] giving a value 
of 60.7%.
Change in total hemoglobin concentration (A[HbT]) was defined as 
A[Hb02]+A[HHb] and change in haemoglobin difference concentration 
(A[Hbdiff]) as A[Hb02]-A[HHb][16]. VMCA was calculated from the cerebral 
blood flow velocity envelope using a trapezoidal integration function (MatLab, 
Mathworks Inc., USA). Data analysis was identical to that described in section
4.2.3 and figure 4.4.
Cerebral oxygen delivery (cD02) in ml O2/100g tissue/min is defined as:
CDO2 = CBF(1.39xHbxSa02 + 0.003x Pa02) Eqn 5.1
CBF=cerebral blood flow (ml/100g tissue/min), 1.39 = the oxygen carrying capacity of 
haemoglobin (ml/g Hb), Hb=arterial haemoglobin saturation (g/dL), 0.003=solubility of 
oxygen in blood (ml/mmHg Pa02/dL) and Pa02=arterial partial pressure of oxygen (mm 
Hg).
Assuming that TCD insonation angle and basal middle cerebral artery diameter 
remain unchanged during a study, then mean VMCA correlates with cerebral 
blood flow[17].
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Ignoring the small dissolved oxygen component, we can define an estimated 
cerebral oxygen delivery (ecDCb) as:
ecD02 =kxVMCA(1.39xHbxSa02) Eqn 5.2
k = individual specific constant.
Assuming constant arterial haemoglobin concentration during the study, 
percentage change in AecDC>2 is calculated as percentage change from 
baseline of Sa02 x VMCA. This analysis technique was not applied to data from 
the hyperoxia phase of the study as one would expect this to be associated with 
significant changes in the quantity of dissolved oxygen present in arterial 
blood[18].
Statistical analysis was carried out using SAS software (v9.1, SAS Institute, 
USA) and p values <0.05 were considered significant. Group changes were 
compared with baseline using non-parametric ANOVA and post hoc pairwise 
comparisons.
Correlations between variables were assessed by applying Spearman rank 
correlation to data from the 17 time points, with Bonferoni corrected two tailed 
tests of significance.
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5.3 Results
5.3.1 BBS Stability
Change in attenuation over the three hour period of the phantom study is shown 
in figure 5.1. The mean change in attenuation across the wavelength range was 
0.004 OD. The group mean change in attenuation between baseline and the 
nadir of hypoxaemia also shown for comparison on figure 5.1.
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Figure 5.1: Change in attenuation during three hour phantom study compared to group 
mean change in attenuation from baseline to nadir of hypoxaemia.
5.3.2 Human Studies
Table 5.1 shows baseline data for the subject group. There were no significant 
changes in PL during any of the phases of the study (p>0.05).
5.3.2.1 Hypoxaemia
The median time of hypoxia required to achieve arterial oxygen saturation of 
80% was 4.7 minutes (range 3 - 1 2  minutes). The length of each recovery 
period was fixed at 5 minutes for all subjects.
Figure 5.2 shows data for a single subject, demonstrating the experimental time 
course. Assessment of the data during both hypoxaemia and recovery revealed 
a significant correlation between AecD02 and A[oxCCO] (r=0.78 p<0.001), but
Hypoxaemia 
3 Hour Phantom Study
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no correlation between AecD02 and A[Hbdiff] (r=0.49 p=0.145) or between 
AecD02 and A[HbT] (r=-0.33 p=0.584).
Median IQR
F i02 (%) 21.0 21.0 to 21.0
S a02 (%) 98.6 98.2 to 99.2
EtC02 (kPa) 5.7 4.9 to 5.8
HR (min*1) 61.1 56.7 to 70.4
MBP (mmHg) 74.4 67.7 to 79.8
VMCA (cms*1) 43.2 37.9 to 49.7
PL (cm) 12.5 11.9 to 12.7
Table 5.1: Median and interquartile range (IQR) (n=8) for baseline Fi02) Sa02, EtC02, 
HR, MBP, VMCA and PL.
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Figure 5.2: Sa02, AecD02) A[Hbdiff], A[HbT] and A[oxCCO] for single subject during 
three cycles of hypoxaemia.
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Figure 5.3: Median and interquartile range (n=8) for variable values during 
hypoxaemia ( *  p<0.05, t  p<0.001, § p<0.0001 for change from baseline).
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Hypoxaemia Recovery
Median IQR Median IQR
Fi02 (%) 8.0^ 4.9 to 10.2 21.0 21.0 to 21.0
ASa02 (%) -15.4§ -14.3 to -17.5 0 -0.2 to 0
AEtC02 (kPa) -0.1* 0 to -0.4 0 0 to 0.1
AHR (mirf1) 14.1§ 10.3 to 17.2 -1.5 -0.1 to 2.4
AMBP (mmHg) 0.5 -0.2 to 1.4 2.4* 0.9 to 5.2
AVMCA (%) 9.9* 4.1 to 13.7 0 OtoO
AecD02 (%) -9.2§ -5.4 to -12.1 0 OtoO
A[Hbdiff] (pmol/l) -12.7§ -11.4 to -16.9
*COo1 -0.1 t o -1.8
A[HbT] (pmol/l) 2.8§ 2.3 to 4.5 1.0* 0 to 1.8
A[oxCCO] (pmol/l) -0.24t -0.28 to -0.06 0.1* 0 to 0.12
APL (cm) -0.1 -0.5 to 0.1 0 0 to 0.2
Table 5.2: Median and interquartile range (IQR) (n=8) for changes from baseline to 
nadir of hypoxaemia, and end of recovery period for measured variable values ( *  
p<0.05, t  P<0.01, $ p<0.001, § p<0.0001 for change from baseline).
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5.3.2.2 Hyperoxia
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Figure 5.4: Median and interquartile range (n=8) for variable values during hyperoxia 
( *  p<0.05, f  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
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Hyperoxia Recovery
Median IQR Median IQR
F I02(%) 73.3§ 70.5 to 78.6 21.1 21.0 to 21.3
A Sa02 (%) 0.9§ 0.7 to 1.0 0.1 Oto 0.1
AEtC02 (kPa) -0.3§ -0.3 to -0.2 -0.1* -0.15 to -0.05
AHR (min'1) -3.3* -5.1 to -1.9 -0.2 -0.9 to 1.7
AMBP (mmHg) 3.1* 1.3 to 4.4 3.6t 2.1 to 4.8
A VMCA (%) -6.4t -10.3 to -1.4 -0.9 -2.0 to 0.6
A[Hbdiff] (pmol/l) 4.2§ 3.9 to 5.2 0.7 0.4 to 1.2
A[HbT] (pmol/l) -1.1s -1.7 to -0.6 -0.2 -0.5 to 1.0
A[oxCCO] (pmol/l) 0.07* 0.03 to 1.8 -0.03 -0.06 to 0.02
APL (cm) 0.2 -0.4 to 0.2 0.1 -0.2 to 0.1
Table 5.3: Median and interquartile range (IQR) (n=8) for changes from baseline to 
nadir of hyperoxia, and end of recovery period for measured variable values ( *  
p<0.05, f  p<0.01, $ p<0.001, § p<0.0001 for change from baseline).
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5.3.2.3 Hyperventilation
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Figure 5.5: Median and interquartile range (n=20) for variable values during 
hyperventilation ( *  p<0.05, f  P<0.01, £ p<0.001, § p<0.0001 for change from 
baseline).
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Hyperventilation Recovery
Median IQR Median IQR
F i02 (%) 21.0 21.0 to 21.0 21.0 21.0 to 21.2
ASa02 (%) 0.5§ 0.3 to 0.7 -0.5 -1.2 to 0.2
AEtC02 (kPa) -1.5§ -1.65 to -1.4 -0.2 -0.4 to 0
AHR (m in1) 1.7 -0.5 to 7.6 -2.4* -5.0 to 0.4
AMBP (mmHg) 0.3 -3.0 to 6.3 0.3 -3.7 to 6.8
AVMCA (%) -28.5§ -32.2 to -24.6 4.3 -4.6 to 7.5
AecD02 (%) -27.9§ -31.7 to -24.5 1.8 -5.5 to 7.8
A[Hbdiff] (Mmol/I) -3.1§ -3.8 to -1.5 -4.8§ -6.0 to -2.9
A[HbT] (pmol/l) -2.7§ -4.1 to -1.1 -1.4* -3.3 to -0.5
A[oxCCO] (pmol/l) -0.26* -0.42 to -0.03 -0.21* -0.45 to -0.02
APL (cm) 0 -0.2 to 0.2 0 -0.3 to 0.3
Table 5.4: Median and interquartile range (IQR) (n=20) for changes from baseline to 
nadir of hyperventilation, and end of recovery period for measured variable values ( *  
p<0.05, |  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
During hyperventilation there were no correlations between AecD02 and 
A[oxCCO] (r=-0.31 p=0.69) or AecD02 and A[HbT] (r=-0.25 p=0.96) but AecD02 
correlated with A[Hbdiff] (r=-0.68 p=0.008).
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5.3.2.4 Hypercapnoea
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Figure 5.6: Median and interquartile range (n=8) for variable values during 
hypercapnoea ( *  p<0.05, f  p<0.01 for change from baseline).
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Hypercapnoea Recovery
Median IQR Median IQR
F i02 (%) 21.0 21.0 to 21.0 21.0 21.0 to 21.0
ASa02 (%) 0.8* 0.1 to 1.7 0.4 0.1 to 1.3
AEtC02 (kPa) 1.7* 1.6 to 2.0 0.1 -0.2 to 0.3
AHR (m in1) -0.3 -1.4 to 2.1 -0.3 -1.7 to 1.4
AMBP (mmHg) 4.4 -7.4 to 5.9 0.1 -3.7 to 5.9
AVMCA (%) 13.7* 0.9 to 30.4 -9.3* -14.4 to -2.5
AecD02 (%) 14.7* 2.9 to 31.0 -8.9 -13.5 to -1.3
A[Hbdiff] (pmol/l) 7.3§ 5.4 to 9.2 6.6* 2.3 to 8.2
A[HbT] (pmol/l) 2.9* 1.0 to 4.2 2.7* 0.7 to 4.3
A[oxCCO] (pmol/l) 0.28§ 0.16 to 0.43 0.16 0.06 to 0.19
APL (cm) 0.2 -0.5 to 0.5 0 -0.2 to 0.5
Table 5.5: Median and interquartile range (IQR) (n=8) for changes from baseline to 
nadir of hypercapnoea, and end of recovery period for measured variable values ( *  
p<0.05, f  p<0.01, t  p<0.001, § p<0.0001 for change from baseline).
During hypercapnoea there were no correlations between AecD02 and 
A[oxCCO] (r=0.37 p=0.414), AecD02 and A[HbT] (r=-0.28 p=0.76) or AecD02 
and A[Hbdiff] (r=-0.37 p=0.42).
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5.3.2.5 Moderate Hyperventilation
Hypercapnoea Recovery
Median IQR Median IQR
F i02 (%) 21.0 21.0 to 21.0 21.0 21.0 to 21.0
A Sa02 (%) 0.3t 0.2 to 0.5 0.0 -0.4 to 0.2
AEtC02 (kPa) -0.6§ -0.6 to -0.4 0 -0.2 to 0.3
A[Hbdiff] (pmol/l) -1.4 -1.6 to -0.5 -1.2 -2.1 to -0.2
A[HbT] (pmol/l) -0.8 -1.9 to -0.2 0.8 -1.0 to 1.8
A[oxCCO] (pmol/l) 0.05 -0.06 to 0.10 -0.02 -0.06 to 0.12
APL (cm) -0.3 -0.4 to 0.6 1.0 -0.1 to 1.2
Table 5.6: Median and interquartile range (IQR) (n=9) for changes from baseline to 
nadir of hyperventilation, and end of recovery period during moderate graded 
hyperventilation study for measured variable values ( t p<0.01, § p<0.0001 for change 
from baseline).
5.4 Discussion
Changes in cerebral [oxCCO] measured using BBS in adult humans during 
changes in oxygenation and EtC02 are shown. These results demonstrate the 
potential of this instrumentation to make non-invasive measurements of 
changes in mitochondrial redox in the adult brain. Measured optical pathlength 
did not change significantly during any of these studies suggesting that large 
changes in light scattering which would invalidate the assumptions of the MBLL 
did not occur. Signal to noise ratio for the calculation of optical pathlength using 
second differential spectroscopy has been estimated using Monte Carlo 
simulation[19]. From this data we would estimate the predicted accuracy of our 
pathlength calculation to be in the region of 5.2%.
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5.4.1 Phantom Study
The results from the stability study show a small change in NIR light attenuation 
across the course of a three hour data collection period. This change in 
attenuation can be considered an instrumentation artefact as one would not 
expect any changes in the optical characteristics of the epoxy phantom over this 
time scale. However the magnitude of the attenuation change during the 
phantom study is negligible compared to that measured during hypoxaemia and 
in addition the spectrum of this artefactual attenuation change is very near to 
being flat and will have a minimal effect on the chromophore fitting procedure. 
We can therefore conclude that the stability of the BBS system is adequate for 
studies of the duration we describe and that the cerebral chromophore changes 
measured are not a product of instrumentation artefact.
5.4.2 Hypoxaemia
We describe significant changes in cerebral [oxCCO] measured during 
hypoxaemia to an Sa02 of 80%. We found distinct differences between the 
measured CCO and haemoglobin signals. Figure 5.3 shows A[HbT] rising 
during the hypoxaemic challenge before gradually returning towards, but not 
reaching, baseline values after five minutes of normoxic recovery. This infers an 
increase in cerebral blood volume during hypoxaemia probably as a result of 
hypoxaemic vasodilatation. A[Hbdiff] provides an assessment of changes in the 
balance of A[Hb02] and A[HHb] and is usually assumed to be a measure of 
changes in the balance of regional cerebral oxygen delivery and utilisation. 
Although its interpretation is complicated by volume changes within the various 
vascular compartments, A[Hbdiff] has been used to define thresholds for critical 
ischaemia in patients undergoing neurovascular procedures[16]. In this study 
we show A[Hbdiff] decreasing during hypoxaemia and then returning towards, 
but not reaching, baseline values after five minutes of normoxic recovery. 
A[oxCCO] decreases during hypoxaemia and returns to baseline before 
A[Hbdiff] with a subsequent increase above baseline during the normoxic 
recovery period. Increased cerebral A[oxCCO] during the recovery period after 
hypoxaemia has been demonstrated in animal models[20] and has not been
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fully explained but may be related to ecD02 rising above baseline during the 
recovery period.
Calculation of the correlation between AecD02 and A[Hbdiff], A[HbT] and 
A[oxCCO] was performed on the data from both the hypoxaemic and recovery 
phases of the study to assess the ability of the three measures to detect both 
decreased and increased ecD02. Both A[Hbdiff] and A[HbT] did not rise above, 
or drop below, baseline respectively in response to the increase in ecD02 
during recovery and this results in the lack of significant correlations. There was 
a significant correlation between AecD02 and A[oxCCO], inferring that this 
NIRS measurement has clinical relevance as a measure of changes in cerebral 
oxygen delivery. We therefore suggest that A[oxCCO] provides a more reliable 
assessment of changes in cerebral oxygen delivery during hypoxaemia than 
either A[Hbdiff] or A[HbT].
Hampson et al investigated changes in the CCO signal in response to 
hypoxaemia in healthy volunteers and demonstrated reduction of CCO during 
reductions of Sa02 to 70%, although they were not able to calculate 
chromophore concentration changes. However, the light attenuation conversion 
algorithm used in Hampson’s study, known as the Duke-P algorithm, has been 
criticised, because it produces a high degree of crosstalk between the Hb02 
and CCO signals and, furthermore, when applied to animal datasets, has 
produced A[oxCCO] in excess of total CCO concentration measured in brain 
homogenates[6].
Edwards et al investigated A[oxCCO] in neonates using a commercial six 
wavelength NIRO 1000 spectrometer. They found no A[oxCCO] during 
alterations in Sa02 between 85-99%[21]. Our previous work in patients with 
obstructive sleep apnoea demonstrated a reduction in A[oxCCO] during severe 
desaturation[10], but this clinical paradigm did not allow for controlled Sa02 
manipulation and cellular and cerebrovascular responses in this patient group, 
who are exposed to repeated severe hypoxic episodes, may not reflect those of 
healthy individuals.
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In an attempt to investigate the effect of an isolated hypoxaemia on A[oxCCO] 
we used an EtC02 feedback loop to minimise changes in PaC02. Despite this, 
we found a small but significant median reduction in EtC02 of 0.1 kPa at the 
nadir of hypoxemia. However the moderate graded hyperventilation protocol 
results demonstrate that a slow reduction in EtC02 of 0.5 kPa does not produce 
a significant reduction in A[oxCCO] and it is therefore unlikely that the 0.1 kPa 
reduction in EtC02 during hypoxaemia is unlikely to be of clinical relevance to 
the A[oxCCO] results.
Controversy exists over how readily CCO becomes reduced following reduced 
oxygen tension. Several different algorithms exist for the conversion of light 
attenuation to chromophore concentration changes and the choice of algorithm 
can affect the results[6]. Some animal studies suggest that CCO reduction only 
occurs during extreme reduction in cerebral oxygen delivery[20,22,23], whilst 
others have found a gradual reduction in CCO during hypoxaemia[24]. These 
variations may relate to the experimental challenges, which comprised graded 
hypoxia[24], anoxia[20,23] or induced hypotension[22]. Some investigators 
have observed a 20-25 second delay between changes in haemoglobin 
concentrations and CCO redox state following anoxia and have interpreted this 
as evidence that CCO reduction does not occur during moderate 
hypoxaemia[20,23]. Yet we also observed a temporal delay between the first 
significant drops in A[Hbdiff] and A[oxCCO] during a moderate hypoxaemia 
paradigm and the instigation of anoxia may be too swift a challenge to allow full 
investigation of the relationship between CCO redox state and oxygen delivery. 
In addition, these studies used animals initially ventilated with supra-normal 
concentrations of oxygen, resulting in baseline arterial oxygen tensions between
14.7 and 65 kPa[20,22-24]. Elevated baseline values might further delay the 
onset of changes in CCO redox during hypoxaemia leading to the conclusion 
that CCO reduction only occurs after severe reduction in oxygen delivery. 
These comparisons are further complicated by the fact that some studies have 
been performed in perfluorocarbon (PFC) exchanged animals[24] with resultant 
greatly decreased tissue oxygen delivery compared to the blooded animal for a 
given arterial oxygen tension.
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For the measurement of A[oxCCO] to be a useful clinical marker of reduced 
cerebral oxygen delivery, changes from baseline must be observed before 
irreparable cerebral hypoxic injury occurs. We show that in the healthy human 
brain, gradual CCO reduction takes place during moderate hypoxaemia in 
healthy volunteers. This result indicates that BBS measurement of CCO redox 
state has the potential to monitor the adequacy of cerebral mitochondrial 
oxygen delivery and therefore merits evaluation as a patient monitor.
5.4.3 Hyperoxia
The responses of HR, MBP, and EtC02 to hyperoxia were similar to those 
discussed in chapter 4 and are not discussed further. We observed a reduction 
in [HbT] during hyperoxia demonstrating the vasoconstrictive affect with 
subsequent reduction in cerebral blood volume and this then returned to 
baseline during the recovery period. Hyperoxia has competing effects on 
cerebral oxygen delivery consisting of increased arterial oxygen content but 
reduced cerebral blood flow. In our study [Hbdiff] increased during hyperoxia 
despite the reduction in VMCA, and hence CBF, as measured by TCD. 
Assuming no large changes in CMRO2 this implies that the combined effect of 
hyperoxia is to increase cerebral oxygen delivery. A[oxCCO] also increased 
during hyperoxia and then returned to baseline by the end of the study. This 
suggests that cerebral CCO is not fully oxidised at normoxic normocapnoea and 
that changes in mitochondrial redox state can be induced by normobaric 
hyperoxygenation. Other investigators have shown positive A[oxCCO] either in 
the recovery period after anoxia or in response to changes in PaC02 and 
oxidation of CCO has also been demonstrated in response to visual 
stimulation[25] . Evidence therefore exists to suggest that increases in baseline 
CCO oxidation state occur during physiological challenges, but, to our 
knowledge, this is the first report of positive A[oxCCO] during hyperoxia. The 
resting oxidation state of CCO has been investigated using BBS in animal 
models. Springett et al compared the drop in A[oxCCO] during anoxia at either 
normocapnoea or hypercapnoea in the piglet brain. Full reduction of CCO 
during anoxia and full oxidation of CCO in the hyperaemic period after anoxia at 
hypercapnoea were assumed and hence a baseline CCO oxidation state of
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67.3 ± 18.3% oxidised was derived[20]. Cooper et al compared the reduction in 
A[oxCCO] during anoxia with the reported total CCO concentration in the adult 
rat brain and assuming full reduction during anoxia derived a baseline oxidation 
of 82.0 ± 16.6% oxidised. Both these values are likely to be approximations: 
the assumption of complete CCO oxidation in the recovery period after 
hypercapnoeic anoxia as used by Springett et al may be erroneous and the 
comparison of NIRS data with CCO concentration measured in brain 
homogenates as carried out by Cooper et al makes no allowance for the 
multilayered anatomy of the rat brain with differing CCO concentrations in the 
various layers[26]. Both these studies suggest that CCO is not fully oxidised at 
normoxia and normocapnoea and our data are consistent with these findings. 
Conversely Inagaki and Tamura used a dual-wavelength spectrophotometer in 
the blood free isolated rat head to study A[oxCCO] and found no further 
oxidation from baseline during increased oxygen tension. They therefore 
concluded that CCO was >95% oxidised at baseline. This study used a PFC 
perfused rat head which had been isolated from the body and this has some 
advantages in that the effects on light attenuation by changes in haemoglobin 
oxygenation are negligible. However this model is far from physiological as 
oxygen transfer to the brain tissue in the PFC perfused animal differs markedly 
from that found in the blood perfused animal and, in this study, cerebral 
perfusion was maintained by a non-pulsatile pump rather than the heart. These 
findings may therefore not be indicative of physiological responses in the 
healthy brain.
Our data present the intriguing possibility that it is possible to increase oxidation 
in the mitochondrial electron transfer chain by the simple technique of 
increasing Fi02 and demonstrates the potential of BBS to measure the induced 
changes. Increased oxidation of CCO suggests an increase in aerobic 
metabolism and therefore ATP production increased Fi02 might be a 
therapeutic option in conditions associated with cell death related energy failure. 
This possibility is investigated in chapter 7.
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5.4.4 Hyperventilation
The haemodynamic and CBF responses to hyperventilation have been 
discussed in chapter 4. VMCA returned to baseline by the end of the study but 
A[HbT], which reflects arteriolar vasoconstriction, remained significantly below 
baseline at the end of the study, and a similar trend was observed in A[Hbdiff]. 
The predominant mechanism for this reduction in A[Hbdiff] is reduced CBF, 
which will tend to increase oxygen extraction and hence reduce venous 
oxyhaemoglobin saturation, and reduced arterial CBV producing a decrease in 
AVR. The reduced pCC>2 will cause a reduction in pH and this will induce a left 
shift in the oxygen-haemoglobin dissociation curve increasing the affinity for 
oxygen and tending to oppose the increased oxygen extraction. A[Hbdiff] 
remains below baseline at the end of the study and given that VMCA has 
returned to baseline by this stage, this is likely to be related to the persistence 
of reduced arterial CBV and AVR.
A[oxCCO] reduced during hyperventilation and did not return to baseline by the 
end of the study. The median drop in A[oxCCO] during hyperventilation was
0.26 pM and this compares with a median drop of 0.24 pM during hypoxaemia. 
It is interesting to note that the median estimated change in DO2 during 
hyperventilation was 27.9% and this is much greater than that observed during 
hypoxaemia (9.2%). The estimated change in DO2 during hypoxaemia will be 
an underestimate as there will also be a reduction in the quantity of dissolved 
oxygen but this effect is unlikely to be clinically significant. The A[Hbdiff] 
changes associated with the two challenges also vary markedly (-12.7 pM 
during hypoxaemia and -3.1 pM during hyperventilation) and this finding is at 
odds with the AecD0 2  response.
It may be that the reduced oxygen delivery during hyperventilation is 
responsible for the observed drop in A[oxCCO], however CCO oxidation state is 
affected by other factors other than oxygen tension for example electron flux 
through the enzyme, pH changes and changes in ADP concentration[27]. 
Changes in PaC02 will have metabolic effects beyond changes in oxygen 
delivery most notably to cause a decrease in pH and this reduction in pH will
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tend to further reduce the CCO oxidation state[28,29]. This does not fully 
explain our results as one might therefore expect hyperventilation to be 
associated with a greater drop in A[oxCCO] than hypoxaemia. It appears that 
CCO redox state might be affected by a range of metabolic processes as yet 
incompletely understood. This may explain why we found no correlation 
between AecD02 and A[oxCCO] in this part of the study.
5.4.5 Hypercapnoea
In many ways the responses we observed in the BBS variables during 
hypercapnoea appear to be a continuation of those seen during 
hyperventilation. VMCA increased during hypercapnoea and returned to 
baseline by the end of the study, whereas A[HbT] and A[Hbdiff] increased with 
hypercapnoea and remained elevated above baseline values at the end of the 
study. A[oxCCO] also increased during hyperventilation and similarly to the 
discussion in 5.4.3 this may relate to increases in CBF and hence oxygen 
delivery or the metabolic effect of decreased pH. Similar to the results of the 
hyperventilation study we found no correlation between AecD02 and A[oxCCO] 
during this paradigm.
Oxidation in CCO during hypercapnoea has been observed in human neonates 
using a commercial six wavelength NIRS system and also in piglets using a 
BBS system[21,23]. The piglet study by Quaresima et al is particular notable as 
similar A[oxCCO] were found in the blooded and bloodless PFC exchanged 
animal suggesting that this finding is not related to crosstalk artefact or changes 
in light scattering.
5.5 Conclusion
We describe quantification of cerebral A[oxCCO] during hypoxaemia in healthy 
adults and show that this measurement provides a marker of reduced cellular 
oxygen availability in healthy humans. Hyperoxia induces increases in 
A[oxCCO] and oxidation in cerebral mitochondrial redox in disease states might 
be possible by the simple and cheap intervention of increasing Fi02. Changes 
in EtC02 also induce A[oxCCO], and these changes may be related to changes
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in DO2 or metabolic effects. Further work both in vitro and in vivo is required to 
determine the relative contributions of these processes.
Although NIRS measured haemoglobin concentrations reflect intravascular 
oxygenation, the CCO signal indicates changes in mitochondrial oxygen 
delivery and utilisation. In health there is likely to be a close relationship 
between intravascular and mitochondrial oxygen delivery. However, in 
pathological situations, this relationship may be altered by tissue oedema, 
which reduces oxygen diffusion from capillary to mitochondrion. In addition, 
mitochondrial dysfunction, which reduces the ability to metabolise oxygen, may 
occur. It is anticipated that in these situations the mitochondrial CCO signal will 
yield different information to the intravascular haemoglobin signal, and will 
provide clinicians with a bedside tool with which to ensure adequate 
mitochondrial oxygen delivery and thus potentially preserve cell function.
The clinical relevance of cerebral A[oxCCO] has been demonstrated by NIRS 
measurements in adult patients undergoing cardiac surgery, where cerebral 
A[oxCCO] correlates with neurological outcome[9,30]. Other patient groups 
exist who are at risk of critically reduced cerebral oxygen delivery and one 
example of such a group is patients who have suffered TBI. The use of BBS 
monitoring in patients with TBI will be examined in chapter 7.
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Chapter 6
Investigation of the presence of crosstalk between cytochrome c oxidase 
and haemoglobin signals during hypoxaemia
It has been suggested that NIRS measured A[oxCCO] might simply be an 
artefact of light conversion algorithms which are not able to adequately separate 
the CCO and haemoglobin signals. This is a complex area, yet the data 
collected during the studies described in this thesis provide an opportunity to 
investigate this issue.
In this chapter the presence of crosstalk is addressed through the application of 
two separate analysis techniques to the data recorded during the hypoxaemia 
part of the healthy volunteer studies (chapter 5). Firstly the relationship between 
the CCO and haemoglobin signals during the hypoxaemic and recovery phases 
of the study is investigated. Secondly, algorithms which either include or 
exclude the fitting of the oxidised-reduced CCO spectrum are compared.
The aim of this analysis is to investigate whether the CCO signal we are 
recording using BBS can be explained as merely be an artefact of the Hb02 and 
HHb signals. If the CCO signal is explicable as an artefact then it is unlikely to 
provide information above that provided by the haemoglobin signals or be of 
clinical use.
6.1 Analysis of relationship between CCO and haemoglobin signals during 
hypoxaemia
6.1.1 Introduction
The specific extinction coefficients of the oxidised-reduced CCO difference 
spectrum in the near infrared region are similar in magnitude to those of oxy- 
and deoxy-haemoglobin[1], but the concentration of CCO in the brain is 
approximately one order of magnitude less than these other two 
chromophores[2]. This makes the separation of haemoglobin and CCO signals 
theoretically prone to crosstalk and raises the possibility that NIRS measured
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changes in A[oxCCO] might be subject to artefacts resulting from measurement 
algorithms[3,4].
However, data collected using BBS systems and the UCLn algorithm during 
experimental protocols utilising mitochondrial inhibitors and perfluorocarbon- 
blood exchange in animals have shown that A[oxCCO] measurements are 
stable during large contemporaneous changes in [Hb02] and [HHb][5,6]. If 
significant crosstalk were present then one might expect these changes in 
haemoglobin concentrations to produce spurious A[oxCCO]. Furthermore, data 
from human visual stimulation studies and from primary autonomic patients 
during periods of posture induced orthostatic hypotension suggest that cerebral 
A[oxCCO] is not merely crosstalk artefact[7,8].
In order to show that crosstalk is minimal it is necessary to show that Hb and 
Hb02 (or any two non-collinear combinations) can be varied without affecting 
the CCO signal[9]. When using human subjects it is difficult to devise ethical 
experimental paradigms with which to test the presence or absence of crosstalk 
as it is not clear whether a particular change in haemoglobin oxygenation will 
affect CCO redox and there does not exist an alternative ‘gold standard’ with 
which to measure CCO redox without removing cerebral tissue. The main factor 
likely to affect CCO redox state is mitochondrial oxygen tension and this in turn 
will be predominantly affected by haemoglobin oxygenation. It is therefore 
unlikely that we will be able to produce wholly independent changes in 
haemoglobin oxygenation and CCO redox. However, if A[oxCCO] was merely a 
spurious artefact of the light conversion algorithm and no significant changes in 
light scattering occur, we might expect there to be a constant relationship 
between A[oxCCO] and the haemoglobin concentration changes. Conversely, if 
we do not observe a constant relationship between A[oxCCO] and the 
haemoglobin concentration changes then it is unlikely that measured A[oxCCO] 
is merely crosstalk artefact. When analysing the data from the hypoxaemia part 
of the healthy volunteer studies described in section 5.3.2.1 it became apparent 
that the CCO and haemoglobin signals showed different responses with 
A[oxCCO] returning to baseline values early in the hyperaemic recovery period
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and subsequently rising above baseline levels whereas A[Hbdiff] and A[HbT] 
remain below and above baseline levels respectively. This suggested the there 
might be separation of the CCO and haemoglobin and signals and provided an 
ideal opportunity to investigate their inter-relationship.
6.1.2 Methods
The data used for this analysis were those collected during the hypoxaemia 
phase of the healthy volunteer studies as detailed in section 5.3.2.1. Briefly a 
BBS system was used to collect NIR spectra during alterations in Fi02 though 
optodes placed on the heads of healthy volunteers. Spectra were collected at 1 
Hz and converted into A[Hb02 ], A[HHb] and A[oxCCO] using the UCL/? 
algorithm. 10 second means of changes in chromophore concentrations were 
produced at nine equally spaced points during the hypoxaemia phase and nine 
equally spaced points during the recovery phase, thus splitting each phase into 
eight sections as shown in figure 4.4.
A multiple linear regression model was produced from the hypoxaemic period 
data (time points 1 to 9) for all subjects with A[oxCCO] as the dependent 
variable, and A[Hb02] and A[HHb] as the independent variables. This analysis 
characterises the relationship between the A[oxCCO], and A[Hb02] and A[HHb] 
during the hypoxaemic phase. A predicted A[oxCCO] (A[oxCCO]pred) for the 
recovery period was derived from the recovery period A[Hb02] and A[HHb] 
using the multiple linear regression model results and A[oxCCO]Pred and 
A[oxCCO]meas for the recovery period were compared. If A[oxCCO] was merely 
crosstalk artefact then the relationship between A[oxCCO], and A[Hb02] and 
A[HHb] should remain constant during the two phases and A[oxCCO]pred and 
A[oxCCO]meas would be identical.
Statistical analysis was carried out using SAS software (v9.1, SAS Institute, 
USA) and p values <0.05 were considered significant. A[oxCCO]pred and 
A[oxCCO]meas for the recovery period were compared using a mixed model 
analysis to account for the repeated measures within each subject.
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6.1.3 Results
There were no changes in optical pathlength during the study (p>0.05). Multiple 
linear regression of the group data from the hypoxaemic period revealed:
A[oxCCO] = 0.0422x A[Hb02] + 0.0652x A[HHb]- 0.0173 Eqn 6.1
p<0.0001 r=0.51
Equation 6.1 was used to derive A[oxCCO]Pred for the recovery period. 
A[oxCCO]Pred and A[oxCCO]meas differed significantly (p=0.01) (figure 6.1).
o  -0.2
Time point
Figure 6.1: Comparison of measured and predicted A[oxCCO] during the recovery 
phase of the healthy volunteer hypoxaemia study.
6.1.4 Discussion
The fact that there were no significant changes in mean optical pathlength 
during the study, and that A[oxCCO]pred and A[oxCCO]meas were different (figure 
6.1), suggests that A[oxCCO]meas is not merely a crosstalk artefact resulting 
from the large changes in A [Hb02] and A[HHb].
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6.2 Analysis of residuals from fitting chromophore concentrations to near 
infrared data
6.2.1 Introduction
The UCLn BBS algorithm is a multiple regression technique which produces a 
‘best fit’ between the attenuation data and the chromophore spectra. This fitting 
procedure may produce residuals due to changes in light scattering, changes in 
concentrations of chromophores not included in the algorithm or imperfect 
chromophore spectra. In order to verify the validity of the regression technique 
the residuals to the regression analysis must satisfy a number of assumptions: 
they must be normally distributed, heteroscedastic and independent with a 
mean close to zero[10]. In addition, by examining the residuals to various fitting 
procedures we can deduce the nature of optical changes which are not 
accounted for by the algorithm.
In this analysis we apply algorithms which either include or exclude the fitting of 
the oxidised-reduced CCO spectrum to the changes in attenuation measured 
during hypoxaemia as presented in section 5.3.2.1. If changes in CCO redox 
state are occurring then an algorithm which fits only A[Hb02] and A[HHb] to the 
attenuation data might result in residuals which are similar to the oxidised- 
reduced CCO spectrum. Including A[oxCCO] in the algorithm should then 
reduce the magnitude of the residuals and therefore improve the regression fit. 
Conversely if the changes in attenuation can be accounted for solely by 
A[Hb02] and A[HHb] then including A[oxCCO] in the algorithm will not improve 
the fit and might increase the magnitude of the residuals.
6.2.2 Methods
The data used for this analysis were those collected during the hypoxaemia 
phase of the healthy volunteer studies and summarised in section 6.1.2. The 
points just prior to the start of each hypoxaemia (baseline), and at the nadir of 
each hypoxaemia (hypoxaemia) were identified manually using the SaC>2 data. 
At each of the two points the mean of the preceding ten seconds of data was 
calculated. Data from the three experimental cycles were averaged to give 
mean values for Sa02 and NIR light intensity at baseline and hypoxaemia for
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each subject. Optical pathlength was calculated using second differential 
analysis of the 740nm water feature as previously discussed[11]. Change in 
NIR attenuation between baseline and hypoxaemia was then calculated from:
Eqn 6.2
where AA=change in attenuation, l b a s e = l i g h t  intensity at baseline and lhyPox=light 
intensity at hypoxaemia (OD).
The UCL/7 algorithm[12] was used to fit chromophore extinction coefficients, 
corrected for the wavelength dependence of the optical pathlength[13], to the 
group mean change in attenuation, using 120 wavelengths between 780 and 
900 nm. Chromophore specific extinction coefficients were downloaded from 
the medical physics UCL website[14]. First, only Hb02 and HHb spectra (2 
component fit -  equation 6.3) and then Hb02, HHb and the oxidised-reduced 
CCO difference spectra (3 component fit -  equation 6.4) were fitted to the group 
mean change in attenuation. After interpolation of the residuals to the spectral 
resolution of the BBS system, the sums of the squares of the residuals from 
these two analyses were calculated, and the distributions of the two sets of 
residuals were compared.
PL=pathlength (cm), £ = specific extinction coefficient of the subsequent chromophore 
(OD/pM/cm) and AA =change in attenuation, at wavelengths Kt to Aj.
rA[Hb02])_  1 
v A [HHb] ) ~ P L
£H b 02 i ) s HHb ( * i ) } \ A A ( ^ i )
K£H b 02( ^ j )  £ H H b ( ^ j ) j
"A [Hb02]^|_ 1 
, A [HHb] J ~ PL
—  1
£H b 02 ( ^ i ) £HHb ( Ai ) £oxCCO ( ^ / ) 1 (  ) !  £ q n  q  4
K£Hb02( ^ j )  £H H b ( ^ j )  £o x C C o ( ^ j ) j
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A simulated attenuation spectrum was then calculated using assumed A[HHb], 
A[Hb02] and A[oxCCO] and their respective specific extinction coefficients 
(equation 6.5): for this purpose attenuation changes due to other chromophore 
concentration changes were ignored.
AA(Aj) = PL{A[Hb02]x £Hb02 (A') + A[Hb02] x £ H H b ) + A[Hb02]x £oxc c o (^/')
Eqn 6.5
A 2 component model was fitted to this spectrum and the resultant residuals 
were compared with the residuals from the 2 component fit to the measured 
group mean change in attenuation between baseline and hypoxaemia. 2 
component fits to the experimental and simulated data for each individual were 
then compared.
Statistical analysis was carried out using SAS software (v9.1, SAS Institute, 
USA) and p values <0.05 were considered significant. Group changes between 
baseline and hypoxaemia were compared using Wilcoxon signed rank test, 
distributions of the residuals from the various fitting procedures were compared 
using a 2 sample Siegel-Tukey test[15] and normality of residuals was 
assessed using the Shapiro-Wilk test. Exact two tailed tests of significance were 
used throughout.
6.2.3 Results
Results are presented as median (interquartile range). During the study Sa02 
fell from a baseline value of 98.6% (98.2 to 99.2) to 82.9% (81.7 to 84.7) at the 
end of hypoxaemia (p=0.008). Due to the ten second averaging window this 
median Sa02 is higher than the 80% target which triggered then end of 
hypoxaemia phase. There was no change in optical pathlength between 
baseline and hypoxaemia (p=0.31) with median (IQR) of 12.6cm (11.6 to 12.8) 
at baseline and 11.9cm (11.4 to 12.3) at the end of hypoxaemia. Group mean 
change in attenuation from baseline to hypoxaemia is shown in figure 6.2.
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Figure 6.2: Group mean change in attenuation between baseline and hypoxaemia.
The residuals from the 2 and 3 component fits to the group mean experimental 
spectrum differed from each other (p<0.0001) (figure 6.3). The sum of the 
squares of the residuals was 9.6x10'b OD2 for the 2 component fit to the 
experimental spectrum and 1.2x1 O'6 OD2 for the 3 component fit to the 
experimental spectrum. The residual mean was 1.6x1 O'5 OD for the 2 
component fit and 2.6x1 O'8 OD for the 3 component fit. The residuals for both 
the 2 and 3 component fits showed no significant departure from normality (2 
component p=0.39, 3 component p=0.92). Heteroscedasticity of the residuals 
was tested by plotting predicted changes in attenuation against residuals (figure 
6.4). The 2 component fit produced residuals that were clearly heteroscedastic 
whereas those produced by the 3 component fit were more homoscedastic. 
There was no difference between the residuals from the 2 component fits to the 
experimental and simulated spectra (p=0.49) (figure 6.3).
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Figure 6.3: Residuals from 2 and 3 component fits to group mean change in near 
infrared attenuation between baseline and hypoxaemia and 2  component fit to 
simulated 3 component spectrum.
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Figure 6.4: Graphical test for heteroscedasticity plotting residuals of regression against 
change in attenuation predicted by regression results for 2 and 3 component fits.
 Residuals from 2 component fit to experimental data
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The 2 component fits to the experimental and simulated data for each subject 
are shown in figure 6.5. In six out of eight subjects, there were no differences 
between the two sets of residuals (p>0.05) whereas in the two remaining 
subjects the two sets of residuals differed (p<0.05).
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Figure 6.5: Residuals from 2 component fits to change in near infrared attenuation 
between baseline and hypoxaemia (- -) and 2 component fit to simulated spectrum (—) 
for each individual subject. Two subjects had significant differences between the two 
sets of residuals (marked with *).
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6.2.4 Discussion
The quality of a multiple regression fit can be determined by assessing the 
residuals of the fitting procedure. The better the fit the smaller will be the sum of 
the square of the residuals, with the perfect theoretical fit having residuals all 
equal to zero. Regression analysis assumes that any residuals which are 
present should be randomly distributed around zero, normally distributed and 
exhibit homogenous variance[10]. These assumptions must all be satisfied in 
order for the regression analysis to be valid and the presence of residuals which 
are not randomly distributed suggests that there is a component missing from 
the fitting analysis.
The residuals from the two fits to the experimental data are both normally 
distributed and have means close to zero. However figure 6.4 demonstrates 
that the residuals from the fit using only A[Hb02] and A[HHb] (2 component fit) 
to the group mean experimental spectrum exhibit non-constant variance 
(heteroscedasticity). The 2 component residuals show a broad peak located 
around 830 nm (figure 6.3) which is similar to the oxidised-reduced CCO 
difference spectrum (see figure 3.5). This suggests that the attenuation of NIR 
spectra by the healthy human brain during hypoxaemia cannot be accounted for 
solely by A[HHb] and A[Hb02]. When the model including A[oxCCO] (3 
component fit) is used, the sum of the squares of the residuals is reduced and 
the residuals appear random, thus improving the fit and satisfying the 
assumption of independent residuals. The simulated spectrum assumes that 
A[HHb], A[Hb02] and A[oxCCO] are occurring and that no other chromophores 
are causing a change in optical attenuation. The residuals from the 2 
component fit to this spectrum are those that would be expected from the 2 
component fit to the experimental data if A[HHb], A[Hb02] and A[oxCCO] were 
occurring in the brain during this hypoxaemic challenge. The residuals from the 
2 component fit to the experimental spectrum do not differ from those resulting 
from the 2 component fit to the simulated spectrum. This strongly suggests that 
A[oxCCO] is occurring and accounts for the distribution of the residuals from the 
2 component fit to the experimental data.
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There is no statistical difference between the individual 2 component fits to the 
experimental and simulated data in six out of eight of the individual subjects. 
This demonstrates the optical effect of A[oxCCO] at the individual as well as the 
group level. In the two subjects who exhibited differences between the residuals 
to the experimental and simulated data, the residuals to the simulated data are 
close to zero. This results in a very low dispersion in the residuals to the 
simulated data. It is possible that in these two individuals the physiological 
challenge was insufficient to produce a significant change in A[oxCCO]. In one 
case the plot of the 2 component fit to the simulated spectrum is concave 
downwards rather than concave upward as shown by all the other subjects. 
This implies that we measured an increase in A[oxCCO] in this subject. This is 
unlikely to be a physiological response to hypoxaemia. Re-examining the 
individual data during this study suggests that this finding might relate to 
artefactual changes in light attenuation which may be caused by inadequate 
optode fixation of subject movement.
This analysis adds further weight to our conclusion that real changes in cerebral 
CCO signal occur during moderate hypoxaemia by demonstrating that 
A[oxCCO] measured using our BBS system and the UCL/7 algorithm is not 
merely crosstalk artefact and that we can detect these changes using non- 
invasive BBS.
6.3 General Discussion
Many techniques including in vivo, in vitro and in silico experiments have been 
used to investigate crosstalk in the context of measurement of A[oxCCO]. 
Matcher et al applied various light conversion algorithms to a simulated data set 
consisting of a time series of absolute attenuation spectra generated using 
analytical diffusion theory[12]. They combined in vitro spectra of Hb02 and HHb 
representing concentration changes of between 0 and 40 pM for A[HHb] and 20 
and 60 pM for A[HbC>2] and excluded any change in the CCO signal so that any 
A[oxCCO] derived by the algorithms would be a spurious artefact. Six different 
published algorithms were compared and it was found that the UCLn algorithm 
produced the smallest spurious A[oxCCO] with a magnitude of 0.06 pM. This
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study highlights the fact that different instrumentation and algorithms will affect 
the presence and degree of crosstalk experienced and re-iterates that non­
broadband NIRS systems may be unsuitable for measuring A[oxCCO][5]. When 
interpreting this finding it is important to realise that the magnitude of the 
haemoglobin concentration changes used to produce the simulated spectra for 
this modelling study are at least an order of magnitude greater than those we 
measured during hypoxaemia in healthy volunteers. This study also 
demonstrates that using multiple wavelengths within the conversion algorithm 
significantly reduces the spurious A[oxCCO]. Further modelling studies have 
suggested that algorithm accuracy for A[oxCCO] significantly increases with 
number of wavelengths used up to approximately 10 wavelengths[16].
A similar study using a NIRO 300 spectrometer has been performed in vitro 
using human blood, intralipid and water in a tissue phantom with the 
oxyhaemoglobin concentration varied using oxygen bubbling and yeast and a 
spurious A[oxCCO] of 1% of the A[Hb02] was found[17]: we would expect our 
BBS system, which uses multiple wavelengths to produce a smaller artefact 
than the four wavelength NIRO 300.
Cooper et al took a different but complementary approach in a study using a 
BBS system to investigate CCO redox changes in the neonatal pig[5]. The CCO 
redox state was fixed using cyanide and then large changes in haemoglobin 
oxygenation were induced. A[oxCCO] was found to be stable during the large 
contemporaneous haemoglobin concentration changes and it was concluded 
that BBS is able to accurately measure changes in the cerebral CCO redox 
state. Quaresima et al used a similar neonatal pig model to investigate changes 
in cerebral CCO redox state during episodes of anoxia[6]. They found very 
similar A[oxCCO] responses in both the blooded animals and those who had 
80% of their haemoglobin replaced by a perfluorocarbon blood substitute. 
These findings again suggest that we are able to measure A[oxCCO] against a 
background of changing haemoglobin concentration without producing 
significant artefactual A[oxCCO].
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Conversely Sakamoto et al reported crosstalk between the CCO and HHb 
signals in the piglet brain when using a BBS system[3]. They fixed the CCO 
redox state using cyanide and then used haemodilution to reduce the 
haematocrit from 35 to 5%. A linear drop in A[oxCCO] * PL during 
haemodilution was found and it was concluded that the CCO signal is highly 
dependent on haematocrit. However in this study PL was directly measured 
using second differential spectroscopy and a linear decrease in PL with 
haemodilution was found. The results for the CCO redox state are presented as 
chromophore concentration multiplied by PL and are therefore uncorrected for 
the changes in PL. One is therefore left unsure whether the dependence of the 
CCO signal change on haematocrit would remain once the effect of changes in 
PL had been incorporated. Nevertheless large changes in haematocrit are 
extremely unlikely during the types of physiological challenges described in this 
thesis and within this context we feel the effect of haematocrit on our measured 
A[oxCCO] is negligible.
Evidence for crosstalk has also been sought in studies using human subjects. 
Skov et al used a four wavelength Radiometer spectrometer to measure 
changes in cerebral haemoglobin and oxCCO concentrations in children 
undergoing cardiac surgery[4]. They reported the possibility of crosstalk 
between the CCO and haemoglobin signals and concluded that NIRS 
measurement of the CCO redox state required further validation. An interesting 
series of papers has investigated the issue of crosstalk artefact within a 
paradigm of visual stimulation in the adult human. This group initially reported 
changes in CCO redox state in the occipital cortex during visual stimulation[18] 
and later used a Monte Carlo simulation to show that their initial results might 
simply represent crosstalk artefact[19]. They then modified their experimental 
paradigm in order to minimise global haemodynamic effects and subsequently 
reported that they were not able to model the measured A[oxCCO] as a 
crosstalk artefact and concluded that actual changes in CCO redox state were 
occurring during visual stimulation[7].
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The situation during functional activation paradigms is more complex than that 
found during hypoxaemia as A[oxCCO] would be expected to occur within 
discrete cortical regions and more work is clearly required to further elucidate 
this important issue. Findings may not be easily transferable between species 
as the variations in optical geometry will affect the light transfer and several of 
the in silico studies do not take account of the multi-layered structure of the 
human head and the varying concentration of CCO within these layers.
The data presented in this chapter provides some evidence that the A[oxCCO] 
we measure is not merely a crosstalk artefact. This analysis is clearly 
insufficient to definitively discount the issue of crosstalk and additional 
modelling and experimental studies are required to further investigate the use of 
the NIRS algorithms to detect changes in the CCO signal in multi-layered 
systems. We plan to address this issue using a combination of continuous wave 
and phase resolved spectroscopy together with knowledge of the CCO 
concentrations in the various cranial layers and their respective optical 
characteristics.
These findings increase confidence in the ability of the BBS system to detect 
real changes in A[oxCCO] and therefore support the use of this equipment to 
make clinical measurements of CCO redox changes.
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Chapter 7
Changes in cerebral cellular and mitochondrial redox state during 
normobaric hyperoxia in patients with traumatic brain injury
This chapter describes a study to investigate changes in cerebral metabolism 
during normobaric hyperoxia (NBH) in patients with TBI. TBI is associated with 
depressed aerobic metabolism and mitochondrial dysfunction and although 
NBH has been suggested as a treatment for TBI, human studies have produced 
equivocal results. This study utilises a wide range of invasive and non-invasive 
monitoring modalities including BBS, brain tissue oxygen tension (Pbr02) 
measurement and cerebral microdialysis to study the effects of NBH after TBI 
and to investigate changes in cellular and mitochondrial redox state, as 
measured by brain tissue lactate:pyruvate ratio (LPR) and change in [oxCCO] 
respectively.
7.1 Introduction
TBI describes a heterogenous set of injury mechanisms and pathologies, but 
there appear to be common metabolic pathways leading to depressed aerobic 
metabolism, reduced cellular ATP production, inability to maintain ionic 
homeostasis and ultimately cell death[1-4]. The exact aetiology of this cellular 
energy failure is poorly understood but both reduced substrate delivery and 
impaired mitochondrial substrate utilisation appear to be implicated. Efficient 
cellular ATP production requires oxygen availability within mitochondria, yet 
Alves et al demonstrated using a cerebral fluid percussion insult in the cat that 
TBI induces cerebral hypoxia despite unchanged arterial oxygen tension and 
MBP and so reduced ATP production after TBI may be in part related to 
mitochondrial hypoxia[3]. As discussed in section 2.3, it is well established that 
hypotension and hypoxaemia, which reduce cerebral oxygen delivery, are 
associated with poor functional outcome after TBI[5-10] and so, within the 
context of attempting to minimise secondary injury after TBI it appears vital to 
ensure adequate oxygen delivery to cerebral mitochondria, particularly in the 
early stages post TBI when reduced cerebral blood flow increases the risk of 
cerebral hypoxia[11].
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This concept appears straightforward, yet it is far from simple to assess or even 
to define ‘adequate mitochondrial oxygen delivery’. Values of in vivo 
mitochondrial oxygen tension either in health or disease are not yet established, 
but a delayed fluorescence technique for measuring mitochondrial oxygen 
tension in cell cultures has recently been described and this has the potential to 
make in vivo measurements[12]. It is possible to measure Pbr02 using 
commercially available invasive probes, yet although it has been demonstrated 
that reduced PbrCb is associated with poor outcome after TBI, the threshold for 
tissue ischaemia is not well established and concentrations between 0.7 and
2.7 kPa have been suggested[13-16]. It is unlikely that, even at the 
mitochondrial level, there will exist a well defined ischaemic threshold for 
oxygen tension as this will depend on factors such as the degrees of 
mitochondrial dysfunction and pharmacological sedation, both of which might 
decrease oxygen requirements. Given the potential for, and the detrimental 
effects of, hypoxia after TBI, a monitoring tool is needed which is able to assess 
the adequacy of mitochondrial oxygen tension in an individual and time specific 
manner. This might allow targeted treatment aimed at maintaining ATP 
production and avoiding cellular energy failure. This might prove beneficial after 
TBI.
Animal models assessing CCO activity using histopathological techniques 
indicate that CCO mediated oxidative metabolism is decreased after TBI and 
that this effect may last up to 10 days post injury[17]. We have shown in chapter 
5 that BBS can measure non-invasively changes in CCO redox state and that 
when PaC0 2  is stable these changes correlate with changes in cerebral oxygen 
delivery. BBS would therefore appear to be an ideal technique for assessing the 
reactivity of CCO redox state to changes in mitochondrial oxygen delivery in 
patients with TBI.
In light of the risk of cerebral hypoxia, hyperoxia has been investigated as a 
potential treatment strategy for increasing aerobic metabolism after TBI. In 
particular, hyperbaric hyperoxia (HBH) has shown beneficial effects in both 
animals and humans after TBI[18-20]. However chambers capable of delivering 
HBH to critically ill patients are expensive and availability is severely limited.
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Interest has therefore grown in the use of NBH which is extremely cheap and 
simple to administer. Studies investigating the use of NBH in adults after TBI 
have consistently shown increases in Pbr02 and reductions in microdialysis 
measured brain tissue lactate concentration^-23]. Interpretation of these 
findings is however controversial with some investigators concluding that the 
reduction in microdialysate lactate concentrations supports a beneficial role for 
NBH[21] while others suggest that the lack of changes in microdialysate LPR 
and glucose indicates that glucose oxidation might be impaired during NBH[22]. 
Cerebral microdialysis is a routine part of multimodality monitoring on the NCU 
and has been discussed in section 2.4.1. Raised microdialysate lactate 
concentration is associated with tissue hypoxemia and poor outcome after TBI. 
However it reflects not only the degree of anaerobic metabolism but also the 
global glycolytic rate [24]. Lactate:pyruvate ratio (LPR) is considered a superior 
marker of anaerobic metabolism and is a measure of cellular redox state[25]. It 
has the added advantage of being independent of in vivo catheter recovery and 
is the most widely monitored microdialysis variable after TBI. To date, NBH 
studies in humans after TBI have shown no changes in LPR and this has 
contributed to the controversy surrounding interpretation of the resulting data.
We hypothesise that NBH will induce oxidation in cerebral redox state in adult 
patients in the early period post TBI.
7.2 Methods
This study was approved by the Joint Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery and the Institute of 
Neurology and, as all patients were unconscious at the time of the study, written 
assent was obtained from their personal representatives. Inclusion criteria were 
a diagnosis of TBI requiring sedation and ventilation on the NCU. Exclusion 
criteria were the expectation of death or weaning of sedation within 24 hours of 
injury, a baseline Fi02 £60% or more than 48 hours elapsing between the time 
of injury and the start of the study.
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11 adult patients were enrolled into the study (10 male, 1 female). The median 
age was 42 years (range 17 to 68) and the median time between the injury and 
the start of the study was 25 hours (range 15-47).
7.2.2 Monitored Variables
Multimodality monitoring and protocolised ICP and CPP directed care was 
instigated. As part of routine care, invasive intracranial pressure (Microsensor, 
Codman, MA, USA), PbrC>2 (Licox PMO, Integra Neurosciences, NJ, USA) and 
cerebral microdialysis (CMA 70 or 71, CMA/Microdialysis, Solna, Sweden) 
catheters were inserted into the brain interstitium through a three divergent 
lumen skull bolt (Technicam Ltd, Newton Abbott, UK). Microdialysis catheter 
positioning followed the recommendations of the consensus meeting on 
microdialysis in neurointensive care[26] with catheters targeted to the 
pericontusional tissue in the case of focal lesions, or the right frontal lobe in the 
case of diffuse injury. The microdialysis catheters were perfused with Perfusion 
Fluid CNS (CMA/Microdialysis), at a rate of 0.3 pl/min. No data were collected 
in the first 4 hours after catheter placement to avoid insertion artefacts and 
catheter positioning was confirmed with subsequent radiological imaging. 
Microdialysate glucose, lactate and pyruvate concentrations were measured at 
the bedside using a CMA 600 analyser (CMA/Microdialysis).
For the purposes of this study, broadband spectrometer optodes were placed
3.5 cm apart in a black plastic holder, and fixed to the upper forehead in the 
midpupillary line ipsilateral to the invasive cerebral monitoring. The BBS 
instrumentation was identical to that described in section 5.2 and spectra were 
acquired at a frequency of 1 Hz. A peak intensity greater than 1500 photons 
was considered adequate and in one patient the sampling exposure time was 
increased in order to obtain this.
The source-detector optode pair for each channel of the NIRO 300 was placed 
in a black plastic holder with a source-detector separation of 5cm. One channel 
was fixed to the right hand side of the forehead and the other to the left hand 
side of the forehead in the midpupillary line with the channel laterality allocated 
randomly. Within each pair the source fibres were positioned medially and the
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detector optodes laterally in order to minimise the transmission of light from the 
channel 1 source to the channel 2 detector and vice versa. A bandage and a 
light absorbing cloth were placed over the optode holders to eliminate stray light 
and prevent optode movement. SRS and MBBL data was collected at 6 Hz.
VMCA ipsilateral to the NIRS optodes was measured using 2 MHz transcranial 
Doppler ultrasonography (Nicolet, UK), as a surrogate of cerebral blood 
flow[27]. The side of the brain containing the invasive monitoring and over 
which the BBS optodes and TCD probe were placed was that which showed the 
most evidence of cerebral injury on CT and is termed the ‘most injured 
hemisphere’: the side of the brain with the least evidence of injury is termed the 
‘least injured hemisphere’.
7.2.2 Study Protocol
All patients received local protocol-guided therapy, based on Joint Section of 
Neurotrauma and Critical Care of the American Association of Neurological 
Surgeons[28] and European Brain Injury Consortium guidelines[29]. After 30 
minutes of baseline data collection, the FiC>2 was increased to 60% for 60 
minutes and then to 100% for 60 minutes before being returned to baseline for 
a further 30 minutes. Cerebral microdialysate specimens were collected and 
analysed at intervals of 15 minutes and ABG analysis was performed at 
intervals of 30 minutes, commencing 15 minutes after the start of the baseline 
period. There is an inherent delay associated with cerebral microdialysis 
monitoring which relates to diffusion of metabolites into the extracellular space 
and across the catheter membrane, and the time taken to collect the 
microdialysate. Therefore, a final microdialysis sample was collected 75 
minutes after the FiC>2 was returned to baseline. A schematic of the study 
protocol is shown in figure 7.1.
7.2.3 Data Analysis
All monitored variables were collected to PC and synchronised. Absolute 
A[oxCCO], A[Hbdiff] and A[HbT] calculated from the BBS measured changes in 
light attenuation as described in section 5.2.4. While analysing the data it 
became apparent that small changes in optical pathlength were occurring
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during the study and changes in chromophore concentration measured using 
the BBS were therefore continuously corrected for optical pathlength calculated 
using second differential analysis of the 740 nm water feature[30]. Bilateral TOI 
and ACBV were calculated from the NIRO 300 data as described in section 
4.2.3. Summary data were produced for the four phases of the study: baseline, 
60%, 100% and return to baseline Fi02. For the initial and final baseline periods 
15 minute means for each variable were calculated, centred on the time of ABG 
sampling within that phase. For the 60% and 100% Fi02 phases, means of the 
data between the two ABG samples within that phase were calculated (figure 
7.1).
Statistical analysis was carried out using SAS software (v9.1, SAS Institute, 
USA) and p values <0.05 were considered significant. Group changes were 
compared with baseline using non-parametric ANOVA and post hoc pairwise 
comparisons. Correlations between variables were assessed using Spearman 
rank correlation analysis with Bonferoni corrected two-tailed tests of 
significance.
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Figure 7.1: Study and analysis protocol for study of TBI patients during NBH. 
ABG - arterial blood gas sampling, MD - microdialysate sampling, BL - baseline.
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7.3 Results
Patient demographics and details of presenting pathology are shown in table 
7.1. Computed tomography scans of the heads of the recruited patients are 
shown in figure 7.2.
Patient Age Sex Injury
Mechanism
Pathology Initial
GCS
Outcome Time
(hrs)
Treatment
1 42 M Assault EDH 7 Survived 25 Surgical
2 17 M RTA ASDH 3 Survived 27 Surgical
3 57 F RTA SAH 10 Died 15 Medical
4 61 M Fall Contusions 8 Died 24 Medical
5 45 M Fall ASDH/SAH 7 Died 47 Medical
6 22 M Assault ASDH 11 Survived 22 Surgical
7 68 M Fall ASDH/ICH 14 Survived 37 Surgical
8 44 M Fall Contusions 7 Died 25 Surgical
9 27 M Unknown EDH/SAH 8 Died 24 Surgical
10 20 M RTA EDH 7 Survived 25 Surgical
11 34 M Fall ASDH 4 Survived 43 Medical
Table 7.1: Demographic data and details of presenting pathology for patient group. 
Time- time from injury to start of NBH study. GCS-Glasgow Coma Score, EDH- 
extradural haematoma, ASDH-acute subdural haematoma, SAH-subarachnoid 
haemorrhage.
During the study on patient 3, movement of the NIRS optodes caused gross 
changes in light attenuation and during the study on patient 7 a power failure 
led to total loss of NIR data. These two patients were excluded from further 
analysis. Data from the remaining patients were analysed, but there was some 
data loss in some patients. Specifically Pbr02 monitoring was not possible in 
patient 10 due to inadvertent catheter removal prior to the study; SRS data 
collection failed in patients 6 and 10 due to software malfunction; BBS optode 
movement in patient 2 caused gross artefacts and subsequent data removal 
and microdialysis perfusate pump failure in the same patient prevented 
collection of the final microdialysate sample. Gross artefact was defined as 
measured changes in chromophore concentration in excess of total
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physiological concentrations or a linear trend in measured chromophore 
concentration changes throughout the study with no return towards baseline.
d
Patient 1
Patient 4
Patient 7
Patient 2
Patient 5
Patient 3
Patient 6
Patient 8 Patient 9
Patient 10 Patient 11
Figure 7.2: CT scans of patients recruited to study of NBH after TBI.
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Table 7.2 shows baseline values of measured variables. Table 7.3 shows 
variable values during the baseline and 100% Fi02 phases for individual 
patients. Table 7.4 shows group changes in monitored variable values from the 
initial baseline to the 60% and 100% Fi02and the final baseline phases.
Group changes for measured variables are shown in figures 7.3 and 7.4.
Fi02
(%)
Sa02
(%)
Pa02
(kPa)
Pbr02
(kPa)
PaC02
(kPa)
ICP
(mmHg)
CPP
(mmHg)
VMCA
(cm/s)
Median 28.5 99.0 14.00 1.57 4.46 16.6 66.1 40.8
Q1 25.9 97.7 11.90 1.22 4.40 10.2 64.6 38.8
Q3 34.0 99.1 14.80 2.90 4.52 24.0 68.4 46.0
A[Gluc]
(mmol/l)
MDfGluc]
(mmol/l)
MD[Lac]
(mmol/l)
MD LPR PL
(cm)
TOIinj
(%)
TOIuninj
(%)
Median 5.80 2.83 3.09 19.8 12.1 74.9 72.6
Q1 5.70 1.86 2.15 16.7 11.9 71.7 55.6
Q3 7.20 3.03 3.95 25.9 13.0 79.1 77.0
Table 7.2: Median and interquartiles for baseline values of measured variables in 
patients with TBI.
There was no difference in baseline TOI between the two cerebral hemispheres 
but changes in TOI measured over the most (ATOIinj) and least (ATOIuninj) 
injured cerebral hemispheres were significantly different from each other during 
both the 60% (ATOI 1.8% higher on the injured side p=0.02) and 100% Fi02 
phases (ATOI 1.1% higher on the more injured side p=0.02). There were no 
differences between the changes in CBV measured over the two hemispheres 
during any phase of the study.
Change in Pbr02 correlated with change in [oxCCO] (rs=0.57 p=0.005) and 
change in [oxCCO] correlated with change in LPR (rs=-0.53 p=0.006) but 
change in Pbr02 did not correlate with LPR (rs=-0.41 p= 0.06).
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Patient Epoch B rp02
(kPa)
MD[Lac]
(mmol/l)
MD LPR A[Hbdiff] 
(umol/l)
A[HbT]
(umol/l)
A[oxCCO]
(umol/l)
1 Baseline 0.95 3.95 16.0 0.00 0.00 0.00
100% 8.65 3.53 13.8 3.57 -0.76 0.39
2 Baseline 1.31 2.12 18.2
100% 7.27 2.15 17.2
4 Baseline 2.79 2.15 25.6 0.00 0.00 0.00
100% 9.94 2.02 24.5 5.69 -0.19 0.12
5 Baseline 1.84 5.49 25.9 0.00 0.00 0.00
100% 13.29 5.44 24.3 3.91 -3.83 0.13
6 Baseline 3.35 3.09 19.8 0.00 0.00 0.00
100% 4.70 2.17 18.1 6.83 -0.31 0.13
8 Baseline 1.00 6.28 28.6 0.00 0.00 0.00
100% 4.33 6.33 25.9 3.72 -5.92 0.28
9 Baseline 5.89 1.72 16.7 0.000 0.00 0.00
100% 30.56 1.32 16.0 14.62 5.60 3.06
10 Baseline 2.76 30.4 0.00 0.00 0.00
100% 2.22 23.3 12.51 -2.37 0.34
11 Baseline 1.34 3.63 15.5 0.00 0.00 0.00
100% 6.99 3.86 17.2 7.37 1.81 -2.37
Table 7.3: Variable values during the baseline and 100% Fi02 phases for individual 
patients. Note data loss for patients 2 and 10 relating to technical issues described in 
section 7.3.
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Epoch Fi02
(%)
ASa02
(%)
APa02
(kPa)
APbr02
(kPa)
APaC02
(kPa)
AICP
(mmHg)
ACPP
(mmHg)
60% 57.3 1.0 15.70 1.78 0.09 -0.4 1.6
§ t § §
100% 97.2 1.0 41.55 6.55 0.16 0.1 -1.3
§ § § §
Final 29.2 -0.7 -1.00 0.57 0.08 0.1 -2.3
Baseline § § *
Epoch AVmca
(%)
ATOIinj
(%)
ATOIuninj
(%)
ACBVinj
(ml/100g)
ACBVuninj
(ml/100g)
AA[Gluc]
(mmol/l)
APL
(cm)
60% 0.4 3.8 0.5 0 -0.01 0.15 0.1
t
100% 1.4 4.0 3.9 -0.03 -0.08 -0.10 0.3
§ § t
Final 3.5 2.4 0.9 0.04 -0.05 -1.3 0.2
Baseline t
Epoch AMD[Gluc]
(mmol/l)
AMD[Lac]
(mmol/l)
AMD LPR A[Hbdiff]
(pmol/l)
A[HbT]
(pmol/l)
A[oxCCO]
(pmol/l)
60% -0.08 -0.32 -1.5 2.13
S
-0.15 0.10
100% -0.09 -0.13 -1.5 6.45 -0.56 0.21
* * § t
Final -0.12 -0.34 -2.0 2.27 0.45 0.06
Baseline t t t
Table 7.4: Changes in variable values from baseline to 60% and 100% Fi02 p
patients with TBI during NBH ( *  p<0.05, f  p<0.01, t  p<0.001, § p<0.0001).
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Figure 7.3: Group median and interquartile range for measured variables for patients 
with TBI during NBH. In the plot of changes in gas tensions there were no significant 
changes in PaC02 ( *  p<0.05, t  p<0.01, t  p<0.001, § p<0.0001).
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Figure 7.4: Group median and interquartile range for measured variables for patients 
with TBI during NBH ( *  p<0.05, t  p<0.01, t  pO.001, § p<0.0001).
7.4 Discussion
We report combined microdialysis and broadband NIRS monitoring of changes 
in cerebral redox state in patients with TBI. Our results demonstrate oxidation in 
cerebral cellular and mitochondrial redox state during NBH in the first 48 hours 
post injury. The magnitude of the changes in [oxCCO] during NBH was greater 
in the TBI cohort (median 0.21 pmol/l) than the healthy volunteers (median 0.07 
pmol/l, section 5.3.2) and although this comparison is complex to interpret as 
the challenges were not matched in terms of methods of ventilation and the
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subjects pulmonary function, this finding is consistent with the significant 
regional ischemia that occurs in the acute phase post TBI[31] and suggests that 
the patients in this study were suffering a degree of mitochondrial hypoxia at 
baseline. The oxidation in cerebral redox state that we observed is likely to be 
associated with increased aerobic metabolism and NBH therefore has the 
potential to increase cell survival after TBI.
There are several mechanisms whereby NBH might improve brain cellular 
metabolism in patients with severe TBI. An increase in arterial oxygenation will 
improve oxygen delivery as measured by an increase in Pbr02. However, 
oxygen delivery is determined by both arterial oxygen content (Ca02) and CBF. 
CaC>2 is determined mainly by haemoglobin saturation and, if haemoglobin is 
already well saturated, the small contribution from the additional amount of 
dissolved oxygen during NBH is unlikely to have a significant impact on overall 
oxygen delivery. Alternatively, NBH might improve CMR02 by improving the 
brain’s ability to utilise the delivered oxygen. This might be because impaired 
mitochondria require a higher P02 to function or alternatively because an 
increased oxygen tension gradient is required to drive oxygen across 
oedematous tissue to reach the mitochondria[32]. Oxygen tension has both 
direct and indirect modulatory effects on oxidative metabolism and a variety of 
pathways may be implicated. Intriguingly, an increasing body of literature has 
demonstrated the ability of NO, which is implicated in the pathobiology of TBI, to 
inhibit oxygen binding to CCO, and hence its subsequent reduction, by 
competing for the oxygen binding site in a reversible manner[33]. Raised 
cerebral NO levels are present after TBI and might therefore contribute to 
mitochondrial dysfunction[1]. It is possible that elevated mitochondrial oxygen 
tension might antagonise the effects of NO and therefore favour the binding of 
oxygen and its subsequent reduction, but this mechanism remains hypothetical 
at present.
Pbr02 reflects the balance between tissue oxygen delivery and utilisation[3]. In 
agreement with several other investigators we found that Pbr02 increased 
during NBH, indicating increased cerebral oxygen availability[16,23,34]. 
A[Hbdiff] represents changes in the balance between arterial oxygen delivery
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and oxygen offloading to tissue in the context of stable CBF and CBV. As we 
observed no changes in VMCA or [HbT] during NBH, it can be assumed that 
cerebral haemodynamics were stable during the study period. The increase in 
A[Hbdiff] during NBH therefore suggests improvement in the balance between 
oxygen delivery and demand and this is further supported by the associated 
increase in PbrC>2 .
There were no significant changes in NIRO 300 measured CBV over either 
hemisphere, and no difference in CBV response between the two sides. TOI 
increased significantly in both hemispheres reflecting the increased oxygen 
delivery and the increase was greater in the in the most injured hemisphere 
during both the 60% and 100% Fi02 phases. There are several possible 
interpretations of this finding. VMCA in the more injured hemisphere was 
unchanged during NBH yet in the healthy volunteers we found a significant 
reduction in VMCA during hyperoxia (section 5.3.2). Significant intra-patient 
heterogeneity exists after TBI[31] and regional differences in the vascular 
response to hyperoxia might exist. If hyperoxic vasoconstriction occurred 
predominantly in the least injured hemisphere then the reduction in arterial 
blood volume in this hemisphere would translate to a less marked rise in TOI 
during NBH. Although CBV was unchanged, the altered cerebral compliance 
after TBI makes it difficult to predict the relative changes in arterial and venous 
volume and these may differ from those found in the healthy brain. Alternatively 
there might be differences in the baseline AVR between the two sides. A 
decreased baseline AVR in the most injured hemisphere would cause a 
relatively larger increase in TOI on this side as the change in saturation occurs 
predominantly in the venous circulation. However this theory is not supported by 
the finding of similar baseline TOI values recorded over the two hemispheres 
and we have previously shown that changes in AVR have a relatively small 
effect on changes in TOI (section 4.3.5). It is also important to consider 
differences in the optical characteristics of the two hemispheres. Several of the 
patients in this study had asymmetrical haemorrhage overlying or within the 
cerebral tissue and some were operated on prior to the NIR data collection. 
Although TOI does not require correction for total optical pathlength, differences 
in the optical characteristics between the two hemispheres might influencing the
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tissue interrogated by the NIR light and cause variation in partial optical 
pathlengths in the various cranial layers. These findings again underline the 
complexities in interpreting TOI data. Bilateral VMCA recording would allow 
further investigation of NBH induced changes in haemodynamics and modelling 
studies will be required to address the changes in tissue optical characteristics 
found after TBI.
The decrease in microdialysate lactate concentration that we observed is similar 
in direction and magnitude to that found by other workers and is likely to 
represent improvement in tissue hypoxia during NBH[21-23]. Microdialysate 
LPR is a marker of cellular redox state and reflects the NAD to reduced-NAD 
ratio, and the degree of aerobic metabolism[4]. In contrast to previous studies, 
we observed a significant reduction in microdialysate LPR during NBH, 
suggesting an increase in aerobic metabolism. The changes in microdialysate 
variables that we report are small and it is not possible to ascertain their clinical 
significance from these data. Nevertheless this pilot study protocol utilised a 
relatively short (2 hour) period of NBH and similar changes in microdialysate 
lactate concentration during NBH have been associated with improved outcome 
after TBI[21]. There was no change in arterial or microdialysate glucose 
concentrations during the study. However, in contrast to the arterial 
measurements, there was a trend toward reduced microdialysate glucose 
concentration during NBH and this might represent increased cerebral glucose 
utilisation.
We observed an increase in A[oxCCO] during NBH that returned to baseline by 
the end of the study. There was a positive correlation between A[oxCCO] and 
change in Pbr02 and a negative correlation between A[oxCCO] and change in 
LPR. These changes in cellular and mitochondrial redox state during NBH 
indicate an increase in electron transfer from CCO to oxygen, thus favouring 
increased flux through the mitochondrial electron transfer chain and increased 
aerobic metabolism. In combination with the A[Hbdiff], these data suggest that 
increased arterial and tissue oxygen delivery is driving an increase in oxygen
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utilisation and ATP production. However, simultaneous measurements of 
CMRO2 and ATP concentration are needed to confirm this hypothesis.
A[oxCCO] in the human brain has not previously been compared with other 
markers of cellular redox state. The correlation between non-invasive regional 
(NIRS), and invasive focal (cerebral MD), measures of changes in cerebral 
redox state suggest that the NIRS changes that we are recording are related to 
cellular metabolism. The time course of the microdialysate data appears to 
differ from that of the PbrC>2 and NIRS data. This may contribute to the 
correlation between change in PbrC>2 and change in LPR failing to reach 
significance after the Bonferoni correction and influence the strength of the 
relationship between changes in PbrC>2 and [oxCCO].
HBH has been shown to improve cerebral metabolism and outcome, but studies 
of NBH have produced variable results. In a fluid percussion injury model in 
rats, HBH alleviated injury-induced reduction in mitochondrial redox and 
increased cerebral oxygen consumption[19]. In a randomized controlled clinical 
trial, Rockswold et al found that HBH reduced mortality after TBI without 
increasing the number of patients with favourable outcome[20]. In a further 
study by the same group, HBH reduced CSF lactate concentrations and this 
effect lasted for six hours after the end of the treatment period[18]. However, 
CSF pyruvate was not measured in this study so LPR could not be calculated. 
In the clinical situation of TBI, NBH has been more widely investigated. Menzel 
et al reported reduced microdialysate lactate levels in TBI patients treated with 
NBH[23]. In a later study, the same group confirmed reduced microdialysate 
lactate concentrations but found no significant change in LPR during a 24 hour 
period of 100% FiC>2 commenced within the first 6 hours post injury, with 
patients acting as their own controls[21]. In this study NBH resulted in 
decreased mortality compared to historic controls. Magnoni et al also reported 
reduced microdialysate lactate and no significant changes in LPR after NBH in 
patents with TBI, but interestingly found no change in cerebral arterio-venous 
oxygen difference[22]. These findings were interpreted by the authors as 
indicating no change in oxidative glucose metabolism during NBH.
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Our study differs from others in several respects. Firstly we positioned our 
microdialysis catheters in the more affected cerebral hemisphere, and targeted 
the pericontusional brain tissue[26]. In the study by Tolias et al microdialysis 
catheters were placed in the least affected hemisphere[21] whereas in the study 
by Magnoni et al the catheter positioning is unclear[22]. Oxidative depression 
after TBI is primarily restricted to the ipsilateral cerebral cortex[17] and 
positioning of microdialysis catheters has a critical effect on metabolite 
microdialysate concentrations[35]. Secondly there are differences in the timing 
of the studies and the duration of NBH treatments. In particular, the study by 
Magnoni et al enrolled patients up to 79 hours post injury and studied them for 
several subsequent days[22]. The potential for cerebral hypoxia is most likely 
early after TBI[11] and there may be a critical time window for NBH treatment. 
In our patient group all studies commenced less than 48 hours post injury.
If hyperoxia improves mitochondrial function and cerebral aerobic metabolism, 
CMRO2 will increase. We did not measure CMRO2 so are unable to comment 
further on this issue in relation to our study. However, in a previous study 
investigating the impact of HBH (100% oxygen at 1.5 atm) on cerebral 
metabolism, there was a modest improvement in global CMRO2 in the 15% of 
patients with reduced CBF prior to treatment[18]. In contrast to findings in HBH, 
current evidence reporting the effect of NBH on CMRO2 after TBI is 
inconclusive. In their study, Magnoni et al reported a non-significant reduction in 
arterio-venous oxygen content difference during NBH[22], but interpretation of 
these findings is difficult because CBF was not measured and venous oxygen 
content was assessed using jugular bulb venous oximetry, which provides a 
global measure and may miss important regional effects. Conversely animal 
studies reveal increased CMRO2 in response to NBH after TBI[36]. More 
recently, Diringer et al examined the direct effect of NBH on cerebral 
metabolism, assessed using positron emission tomography, in five patients with 
severe TBI[37]. This study seems to indicate that there is no role for NBH after 
TBI. However, this study measured global CMRO2 and regional changes might 
have been missed. Nortje et al used similar methodology combined with 
cerebral microdialysis and also found no changes in global cerebral 
metabolism. However they demonstrated increased CMRO2 in areas of low
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baseline CMR02 and although these findings were not replicated in the tissue 
surrounding the microdialysis catheter they also found reductions in LPR during 
NBH[38]. These findings of regional improvements in cerebral metabolism are 
consistent with our own. It is also possible that NBH might improve outcome in 
severe TBI through mechanisms not reflected in a measurable increase in 
CMR02[39]. Further clinical research is therefore needed in larger numbers of 
patients to establish whether NBH is of therapeutic value after TBI.
In the normal brain, at least, hyperoxia is generally believed to cause 
vasoconstriction but we found no changes in VMCA, CBV or ICP during NBH in 
our study. Although there was a statistically significant reduction in CPP during 
the baseline return phase, we do not believe that this was clinically significant 
and, in any case, the lowest CPP lay within the range allowed by our 
management protocols. Simple explanations for the lack of evidence of 
cerebral vasoconstriction in our study are the placement of the microdialysis 
and NIRS monitors to target the more injured areas of brain, with our findings 
being consistent with impaired autoregulation within the regions of interest. 
Alternatively the slight increase in PaC02 that we recorded, which in isolation 
would tend to cause vasodilatation and increase in ICP, might have 
counteracted any effects of hyperoxic vasoconstriction. However, the absence 
of evidence of vasoconstriction in our study is also likely to be related to the 
complex response of the injured brain to NBH[3]. Tolias et al reported a 
reduction in ICP during NBH in patients with TBI[21] but Rockswold et al found 
that CBF and ICP were only decreased during NBH in those with elevated 
baseline CBF and that CBF increased during HBH in patients in whom CBF was 
reduced or normal prior to treatment[18]. Once again, when interpreting these 
data, it is important to bear in mind the significant metabolic heterogeneity that 
exists after TBI.
Microdialysis provides a hyperfocal measurement of brain tissue biochemistry 
but does not identify metabolic changes in tissue distant from the catheter. As 
the perfusate is not static there is insufficient time for equilibrium to occur 
across the membrane and the concentration of metabolites in the 
microdialysate therefore only represents a fraction of the true brain tissue
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concentration. This fraction is termed the relative recovery. Relative recovery 
has been calculated for the metabolites analyzed in our study and has been 
shown to be equivalent for the CMA 70 and 71 catheters used in this study[40]. 
As lactate and pyruvate have similar molecular weights, LPR is not affected by 
changes in relative recovery and this is one advantage of this measurement 
over other microdialysis variables. In common with other investigators we 
demonstrated a prolonged effect of NBH on microdialysate variables, lasting 
beyond the period of NBH. There is an inherent delay involved in microdialysis 
monitoring of cellular redox state and although we applied a timing correction to 
account for the time taken for perfusate to pass along the catheter tubing the 
metabolite concentrations measured represent an average over the time of 
sampling. A delay may also exist related to the diffusion distance between the 
cellular and extracellular spaces. However, in our study microdialysate lactate 
concentration and LPR were not significantly different from baseline values by 
75 minutes after the end of the hyperoxygenation period.
The clinical application of NIRS measurement of A[oxCCO] has been identified 
by studies correlating A[oxCCO] with post-operative neurological dysfunction in 
patients undergoing cardiac surgery[41] and during deep saturations associated 
with sleep apnea[42]. We show an oxidation in CCO during NBH and this 
implies that CCO is not fully oxidised in the resting state after TBI. Similarly 
oxidation in CCO above the resting state has been shown in healthy 
animals[43] and humans[44] in the recovery period following hypoxemia and in 
healthy humans during NBH (section 5.3.2).
NBH has potentially toxic effects on the lungs, eyes and central nervous system 
and, although the doses and duration of treatment required to produce these 
affects are not clearly defined and are likely to vary between individuals, oxygen 
toxicity is unlikely to occur when breathing 100% FiC^for less than 24 hours[3]. 
There is evidence to suggest increased free radical production when breathing 
air at high pressure (3 atmosphere) but none showing increased free radical 
levels at 1.5 atmosphere or less[19]. Whilst hyperoxygenation has the 
theoretical capacity to increase free radical production, it is also possible that by 
promoting electron flux through the electron transfer chain, it might prevent the
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formation of free radicals produced by build up of reducing equivalents. Oxygen 
toxicity is extremely unlikely following the regime applied during this study but 
further work is required to investigate the potential risks of longer periods of 
NBH after TBI.
This pilot study has several limitations. We studied only a small number of TBI 
patients and further data collection in a large cohort of patients is required to 
validate these findings. VMCA is a surrogate marker of CBF and relies on there 
being no significant changes in middle cerebral artery calibre during the study. 
Continuous bedside measurement of absolute CBF, in conjunction with 
measurements of arterial and venous oxygen content difference and calculation 
of CMRO2 , would aid further investigation of NBH. In this study patients acted 
as their own controls and it is possible that the changes that we observed might 
have been influenced by the natural course of TBI. However, we do not believe 
this is the case as all measured variables returned towards, or reached, 
baseline values by the end of the study. Furthermore, changes in cerebral 
metabolism unrelated to our interventions are likely to have been minimal as 
systemic variables were stable over the time course of this study. The 
significant disease heterogeneity that exists within the diagnosis of TBI makes it 
extremely difficult, if not impossible, to identify control cohorts adequately 
matched for disease type and severity within a dataset of the size that we 
present.
In summary we show oxidation in cerebral cellular and mitochondrial 
compartments during NBH in patients with TBI using two independent 
monitoring techniques. Cerebral microdialysis and NIRS monitoring provide 
complementary information which can further our understanding of TBI 
pathophysiology. It might also be possible to use these techniques to guide 
targeted treatment strategies. Our results suggest that NBH has the potential to 
improve outcome after TBI and further investigation is warranted.
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Chapter 8
Concluding remarks and future work
8.1 Summary
This thesis investigates the use of near infrared spectroscopy as a tool for 
monitoring the adult human brain. Initially, detailed studies are performed using 
healthy volunteers. Within this cohort the spectroscopic responses we measure 
are likely to be representative of global cerebral changes. We use spatially 
resolved spectroscopy to measure TOI over the frontal lobes during changes in 
cerebral oxygenation, blood flow and volume induced by isocapnoeic 
hypoxaemia and hyperoxia, and normoxic hyperventilation and hypercapnoea. 
TOI appears to be an attractive clinical measurement as it provides an absolute 
measure of tissue oxyhaemoglobin saturation presented in the accessible 
format of a percentage. However, wide variability in absolute TOI values within 
and between subjects exists. This variability may limit the use of absolute TOI 
as a clinical marker of the adequacy of cerebral oxygen delivery and may 
explain why TOI has not found wide clinical applicability thus far. Multiple 
regression techniques are used to show that TOI response is affected by 
changes in arterial oxyhaemoglobin saturation, end tidal carbon dioxide tension, 
cerebral blood volume and mean arterial blood pressure. However, the effect of 
changes in cerebral blood volume and mean blood pressure is minimal 
compared to the other two variables. The predominant effects of changes in end 
tidal carbon dioxide tension in the brain are changes in cerebral blood volume 
and flow. The regression technique we use controls for changes in cerebral 
blood volume and so we can conclude that changes in TOI are predominantly 
affected by changes in arterial oxyhaemoglobin saturation and cerebral blood 
flow: both of which are directly linked to cerebral oxygen delivery. We suggest 
that change in TOI may be clinically useful as a marker of changes in cerebral 
oxygen delivery.
Broadband spectroscopy is used to measure changes in [oxCCO] in the healthy 
brain. Few studies of this measurement in adult humans have been reported. 
We present changes in [oxCCO] during a series of physiological challenges and 
demonstrate induced increases and decreases in [oxCCO]. In agreement with
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several animal studies we conclude that cerebral CCO is not fully oxidised in 
the resting state. During hypoxaemia we show that changes in [oxCCO] 
correlate with estimated changes in cerebral oxygen delivery despite there 
being no correlation between estimated changes in cerebral oxygen delivery 
and changes in either [Hbdiff] or [HbT]. NBH induces increases in [oxCCO] and 
this demonstrates that NBH had potential as a therapeutic tool for inducing 
changes in mitochondrial redox state and thus the rate of aerobic metabolism.
We then analyse then measured CCO signal more closely by examining the 
BBS data from the volunteer hypoxaemia studies. NIRS measured changes in 
[oxCCO] have been viewed with scepticism by some within the biomedical 
optics community and one of the main debates concerns the ability of 
measurement algorithms to adequately separate the CCO and haemoglobin 
signals. We provide evidence that the CCO signal is not merely a crosstalk 
algorithm arising from changes in the haemoglobin signals and then show that 
the raw optical attenuation we measure during hypoxaemia cannot be fully 
accounted for by only analysing changes in [Hb02] and [HHb]. If these two 
chromophores alone are fitted to the optical data then the residual attenuation is 
not significantly different to that expected if changes in [oxCCO] are occurring. 
This suggests that real changes in CCO redox state are occurring during 
hypoxaemia.
Changes in [oxCCO] during normobaric hyperoxia in patients with TBI in the 
early hours post injury are then investigated. We demonstrate the feasibility of 
near infrared spectroscopic monitoring on the NCU. We compare non-invasive 
near infrared spectroscopic data with invasive cerebral monitoring tools. Using 
cerebral microdialysis and broadband spectroscopy we show oxidation in both 
cerebral cellular redox state (as measured by brain extracellullar fluid lactate 
pyruvate ratio) and cerebral mitochondrial redox state (as measured by 
changes in [oxCCO]), and present correlations between these two monitoring 
modalities. We conclude that normobaric hyperoxia, in the context of TBI, may 
increase aerobic metabolism and has the potential to improve patient outcome.
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8.2 Future Work
This thesis suggests that measurement of changes in [oxCCO] in the adult head 
has potential as a cerebral monitoring tool. Based in large part on the data 
presented here, our group has obtained a £400 000 grant from the ESPRC to 
further investigate this measurement. We are constructing a new state-of-the-art 
two channel spectrometer which combines broadband and phase modulated 
spectroscopy. This will offer several advantages over the existing 
instrumentation. It will allow continuous and absolute measurement of the tissue 
scatter and absorption coefficients. We will therefore be able to determine if 
changes in light scatter are occurring and so verify whether or not the 
assumptions within the modified Beer-Lambert law can be applied during the 
types of studies presented in this thesis. This combined phase and broadband 
system will also allow us to make measurements of absolute [HbCy, [HHb] and 
[oxCCO]. The prospect of making absolute measurements of [oxCCO] in 
patients with brain injury is particularly interesting. As previously noted, changes 
in [oxCCO] in animals correlate with MRS measured changes in ATP levels and 
it would be fascinating to compare absolute [oxCCO] with MRS measurements 
in brain injured patients. We plan to make bilateral measurements and examine 
differences in cerebral metabolism between the least and most injured cerebral 
hemispheres of patients with TBI.
We are also using a variety of techniques to address further the ability of our 
BBS algorithms to separate the CCO and haemoglobin signals. We are building 
multilayered phantoms with which to test the new spectroscopy system and to 
determine the sensitivity to changes in [oxCCO] occurring predominantly in the 
cerebral cortex. A parallel arm of work concerns the understanding of the CCO 
responses. We are developing computer based models in order to simulate 
CCO responses to cerebral physiology. The data presented here is crucial to 
this process and is vital for both model training and parameter setting.
The data presented here contribute to the current and ongoing debate 
surrounding the use of normobaric hyperoxia in patients with TBI. We add to the 
evolving body of literature suggesting that NBH may improve regional cerebral 
metabolism after TBI. This intervention is cheap and easily accessible and
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certainly merits further investigation in randomised trials. Prior to this, further 
work is required to identify optimal dosing strategy and treatment windows. The 
history of randomised controlled trials of interventions in TBI is littered with 
negative results and to maximise the chance of identifying beneficial 
interventions it is vital to examine surrogate markers in pilot studies before 
advancing to large expensive multi-centre trials. The use of broadband 
spectroscopy to measure changes in [oxCCO] concentration may prove to be 
an ideal surrogate marker and work is required to examine the relationship 
between these changes and outcome after TBI.
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